Pathophysiology and novel therapeutic approaches in autoimmune Addison's Disease by Gan, Earn Hui
 i 
 
 
 
Pathophysiology and Novel 
Therapeutic Approaches in 
Autoimmune Addison’s Disease 
 
 
Earn Hui Gan 
MB ChB, MRCP (UK) 
 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
 
Institute of Genetic Medicine, School of Medical Sciences,  
Newcastle University, UK 
 
September 2014 
 
 
  
 ii 
 
Declaration 
 
This thesis is based on my studies performed in the Institute of Genetic Medicine, 
Newcastle University from August 2010- August 2013. The contents of this thesis are 
original. . All the studies were performed solely by myself, apart from some of the 
immunoblotting and Elisa works, which the research assistant, Katie MacArthur, 
assisted me with. No part of this thesis has been submitted for the award of any other 
degree. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 iii 
 
 
Acknowledgements 
I would like to express my gratitude to everyone who has assisted me throughout the 
process of producing this thesis. Firstly, I would like to thank my supervisor Professor 
Simon Pearce for his teaching and encouragement, which has enhanced my training and 
experience throughout my studies. He has given me a good grounding in both clinical 
and laboratory aspects of research and has inspired me to be enthusiastic in medical 
sciences. I am also grateful to my co-supervisor, Dr Petros Perros, who has given me 
advice and encouragement to make this thesis possible. 
Enormous thanks also go to Dr Rachel Oldershaw, for her advice on 
immunophenotyping of mesenchymal stromal cells and supplying important reagents. I 
am thankful to Professor Robert Pickard, Professor Thomas Lennard and research nurse 
Wendy Robson who generously provided me with discarded adrenal tissue that was 
crucial to my research. 
I would like to thank all the patients who had kindly volunteered for this study, and am 
grateful to Dr Petros Perros, Dr Andy James, Dr Steve Ball and Dr Richard Quinton for 
allowing me to study their patients. 
I would also like to express my gratitude to my colleagues working in the Institute of 
Genetic Medicine for advice on aspects of the project and sharing some reagents. In 
particular Katie MacArthur and Dr Anna Mitchell, who have taught me many of the 
techniques used in this work and supported me during the most difficult of times.  
My project could not have been carried out without the financial support from the 
Medical Research Council (MRC) who funded the translational stem cell study. Many 
research development opportunities including funding for conferences were also 
generously provided by the Society for Endocrinology. 
Finally, I would like to thank my parents and family for their endless love and support. 
In particularly my husband, Nicholas, for always being there whenever I need him.  
  
 iv 
 
Abstract 
 
Autoimmune Addison’s disease (AAD) is a debilitating condition and affected patients 
rely on lifelong steroid replacement. Despite treatment, many patients have increased 
morbidity and mortality. The disease’s rarity has precluded large scale genomic or 
cellular studies in humans, resulting in an incomplete picture of the pathophysiology of 
AAD. This thesis details my research on the pathophysiology and novel therapeutic 
approaches in AAD. 
I performed two candidate gene studies on susceptibility alleles that have been 
implicated in other autoimmune diseases to explore potential causal pathways of these 
genetic determinants in AAD. The common variant 307*Ser allele of CD226 gene was 
found to contribute to AAD susceptibility as part of autoimmune polyendocrinopathy 
type 2. Two genetic variants from a panel of rare and functionally defective variants in 
the sialic acid acetylesterase (SIAE) gene were identified but they were not significantly 
associated with AAD. 
I explored new therapeutic approaches in AAD using a therapeutic regimen of 
parenteral ACTH1-24. This study demonstrated the presence of residual adrenal function 
in patients with established AAD, which was remediable to ACTH1-24 therapy. Clinical 
remission was induced in 2 of 13 study participants. However, some patients developed 
cutaneous reaction following ACTH1-24 injection, with one failing to sustain clinical 
remission. I proceeded to investigate the potential immunologic effects induced by 
ACTH therapy using ELISA and immunoblotting methods. Auto-reactivity against 
ACTH1-24 and ACTH 1-39 was detected, which could account for the side effects and 
treatment resistance observed. 
Finally, I attempted to characterise adrenocortical progenitor cells through cell cultures, 
immunocytochemistry and flow cytometry. A mesenchymal stem cell-like (MSC) 
population was isolated from human adrenals for the first time. My studies have 
advanced knowledge relevant to regenerative medicine approaches to adrenal failure, 
and the finding of residual adrenal function in some Addison’s disease patient opens an 
important therapeutic window for this condition. 
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Chapter 1. Introduction 
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1.1 Background to Addison’s disease  
Addison’s disease is a chronic condition caused by failure of the adrenal gland to produce 
the essential adrenocortical hormones, cortisol and aldosterone. These hormones are 
essential to maintaining homeostasis as well as the physiology and metabolism of multiple 
organs. It was first described in 1849 by Dr Thomas Addison, who discovered the 
pathological changes in the ‘suprarenal capsule’ (adrenal gland) during autopsies performed 
on patients who presented with a common cluster of symptoms: pigmentation, hypotension 
and lassitude (Addison 1855). Of the 11 autopsies described by him, at least six of them 
were due to tuberculous adrenalitis. However, he was intrigued by one of the patients who 
had adrenal fibrosis of unknown origin, characterised by inflammation of the adrenal gland 
with tissue contraction and atrophy. This was likely to be the first description of 
autoimmune adrenalitis. In line with Addison’s autopsy results, tuberculosis infection was 
the most common cause of primary adrenal failure in the Western world, with 70% of 
adrenal glands examined during autopsy in 1930 found to be infected (Guttman 1930). 
However, autoimmune adrenalitis has now taken the lead and accounts for more than 80% 
of the cases in the Caucasian European population following the introduction of effective 
anti-tuberculosis therapy (Betterle et al. 2002, Arlt & Allolio 2003).  
On the other hand, adrenal destruction can be attributed to other causes such as HIV (human 
immunodeficiency virus) or CMV (cytomegalovirus) infections, infiltrative diseases, adrenal 
haemorrhage or malignancy. Genetic disorders such as DAX1 gene (dosage-sensitive sex 
reversal-adrenal hypoplasia congenita critical region on the X chromosome gene 1) or 
steroidogenic factor 1(SF1) mutation, congenital adrenal hyperplasia, familial 
adrenocorticotropic hormone (ACTH) resistance syndromes and adrenoleucodystrophy 
(which is caused by a defect in the very long chain fatty acid transporter gene), are among 
 3 
 
the rarer causes of primary adrenal insufficiency. A detailed discussion of the various causes 
of primary adrenal failure is depicted in table 1.1.  As all the works on this thesis are based 
on autoimmune adrenalitis, the rest of the discussion will be focusing on autoimmune 
Addison’s disease. 
 
1.2 Autoimmune Addison’s Disease (AAD) 
Autoimmune Addison’s disease (AAD) is a relatively rare endocrine condition with a 
prevalence of 110-140 cases per million people in the western world (Willis & Vince 1997, 
Laureti et al. 1999,  Erichsen et al. 2009) , making it 30 times less frequent than type 1 
diabetes and 200 fold rarer than autoimmune thyroid disease. However, in common with 
several other autoimmune disorders, the incidence of AAD has been rising, with about 8500 
people in the UK suffering from AAD and around 200 newly diagnosed people each year 
(Lovas & Husebye 2002, Arlt & Allolio 2003). The common age of onset is between 30-50 
years old and it is more prevalent in females (female to male ratio of 1.5-3.5:1) (Kong & 
Jeffcoate 1994, Willis & Vince 1997,  Laureti et al. 1999,  Lovas & Husebye 2002). 
AAD is an organ-specific autoimmune condition, caused by selective immune-destruction of 
the steroid producing cells in the adrenal cortex, leading to a deficiency of the essential 
steroid hormones cortisol and aldosterone.   It is an inevitably fatal disease in the absence of 
treatment and affected patients have to be kept on lifelong steroid replacement for survival. 
This condition displays a wide spectrum of clinical manifestation, ranging from non-specific 
complaints of lethargy or dizziness to severe symptoms like hypoglycaemia, hypotension or 
even death in untreated cases. 
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Table 1.1.Causes of primary adrenal insufficiency 
Aetiologies of 
primary adrenal 
failure 
 Pathological conditions 
Adrenal 
destruction 
Autoimmune adrenalitis (autoimmune Addison’s disease) 
Infections (tuberculosis, fungal, viral eg CMV, HIV.) 
Infiltration by sarcoidosis, amyloidosis and haemochromatosis 
Haemorrhage (e.g Waterhouse-Friderichsen syndrome) 
Malignancy (metastatic disease) 
Adrenoleucodystrophy 
Adrenal thrombosis from systemic lupus erythematosus (SLE), 
trauma, antiphospolipid syndrome, panarteritis nodosa 
 
Adrenal 
dysgenesis or 
hypoplasia  
Genetic defects: Congenital adrenal hypoplasia (DAX1; SF1 
mutation); Allgrove’s syndrome; Familial glucocorticoid 
deficiency type:  Mutations on ACTH receptor (MC2R); 
melanocortin 2 receptor accessory protein (MRAP)( Metherell et 
al. 2005), steroidogenic acute regulatory protein 
(STAR)( Metherell et al. 2009), nicotinamide nucleotide 
transhydrogenase (NNT) (Meimaridou et al.2012) and 
minichromosome maintenance–deficient 4 (MCM4) ( Hugher et 
al.2012) genes. 
 
Impaired 
steroidogenesis 
Congenital adrenal hyperplasia 
 
 
Drugs Ketoconazole, rifampicin, etomidate, cyproterone acetate and 
adrenolytic agents such as mitotane, aminoglutetimide, trilostane 
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Additionally, patients who suffer from this condition could remain undiagnosed with a 
prolonged course of subclinical disease, until intervening events spark off an acute adrenal 
crisis. It is commonly associated with autoimmune thyroid disease (~70%) and/ or type 1 
diabetes (~20%), constituting the type 2 polyendocrinopathy syndrome (APS2) (Betterle et 
al. 2004, Owen & Cheetham 2009).  Cross-sectional studies revealed that around 50% of 
patients with AAD have other autoimmune conditions (Nerup J 1974, Myhre et al. 2002,  
Falorni et al. 2004). 
 
1.3 Presentation and natural history of AAD  
As previously mentioned, the symptoms of primary adrenal insufficiency are mostly non-
specific, causing it to be labelled as the ‘master of disguise’ in medical textbook. Patients 
with AAD commonly present with weakness, ill-defined fatigue, postural dizziness, weight 
loss and anorexia. These symptoms are non-specific and occur insidiously, making it 
challenging for physicians to make the right diagnosis, and many patients have thus been 
misdiagnosed with depression or anorexia nervosa. Nevertheless, skin or buccal 
pigmentation secondary to compensatory ACTH excess and salt craving are among the 
specific features not to be missed in AAD. Their presence in conjunction with other non-
specific complaints is highly suggestive of primary adrenal insufficiency.  
The clinical diagnosis of AAD is commonly preceded by a prolonged stage of subclinical 
adrenal hypofunction, although a small number of patients progress more rapidly and 
present with adrenal crisis at disease onset (Myhre et al. 2002). The finding of serum 21-
hydroxylase autoantibody is the hallmark of AAD. It is seen in 20-80% of patients in cross-
sectional studies, in comparison with <0.5% in the general population (Chen et al. 1996, 
Falorni et al.1997, Myhre et al. 2002).  For those patients with normal adrenal function, the 
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presence of 21-hydrolylase antibody indicates a cumulative risk of ∼20% of developing 
overt Addison’s disease (Coco et al. 2006). 
Based on the observed natural history of patients with positive adrenal autoantibodies, 
Bettele et al proposed the presence of 4 clinical stages in AAD, delineating the progressive 
deterioration in adrenal function (table 1.2). The clinical stages are characterised by the 
initial rise in plasma renin activity (PRA) and ACTH level prior to impaired cortisol 
response upon ACTH stimulation. This is followed by the manifestation of overt adrenal 
insufficiency at the final stage, commonly associated with pigmentation and fatigue 
(Betterle et al. 1988). Baker et al. recently suggested that borderline elevation in ACTH 
level (11-20 pmol/L) is a good predictor of progression to overt disease in preclinical AAD 
stage (Baker et al.2012). In addition to the biochemistry abnormalities described, it is not 
uncommon to find hyponatramia, hyperkalaemia, metabolic acidosis, hypoglycaemia, 
aneamia, lymphocytosis and mild eosinophilia among patients with untreated adrenal 
insufficiency.  
Similar to many other autoimmune endocrine disorders, the presence of autoantibodies 
precedes the clinical manifestation of the disease. A few studies have followed up patients 
with positive adrenal antibodies. However, it is worth noting that the study numbers were 
relatively small due to the rarity of AAD and most of them did not segregate the type 1 
autoimmune polyendocrinopathy syndrome (APS1) cohort from APS2/isolated AAD during 
analysis. Betterle et al. followed 17 subjects with positive adrenal autoantibodies (AA) and 
noted the presence of AA at as early as stage 0 (table 1.2), during the preclinical stage of 
AAD. As high as 41% (7/17) of them progressed to clinically overt disease after a mean 
follow up period of 3.2 years (range 6 months to 10 years) (Betterle et al. 1988). He also 
found that AA titre persisted but fluctuated throughout the preclinical stage, with some 
people demonstrating gradual decline in AA titres after the onset of the disease. In fact, two 
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patients had negative AA after a mean period of 35 months. De Bellis et al. followed 20 
patients with positive AA and 11 of them remained persistently positive for AA with 2/11 
(18%) developed clinically overt AD (De Bellis et al. 1993). A case series also reported 
spontaneous remission in 6 patients with positive adrenal antibodies, who were at either 
clinical stage 0 or 1. The disappearance of adrenal antibodies was accompanied by 
spontaneous recovery of plasma renin level, 5 years after follow-up (De Bellis A et al 1991). 
A larger study then followed 100 AA-positive and 63 AA-negative patients without AAD 
for a maximum of 21 years (mean 6.0 yr, median 4.8). It was shown that 31% of 
asymptomatic individuals with positive AA become symptomatic between 3 months and 11 
years (Coco et al. 2006). In addition, 1% of the first-degree relatives of patients with AAD 
have anti-21hydroxylase antibodies and about 15% of them would have developed overt 
AAD over an observational time of 6 years (Coco et al. 2006). Thus, not all patients with 
positive AA progressed to clinically overt adrenal failure; indeed some of them will never 
develop AAD. Furthermore, a small number of people with positive AA even reverted back 
to an autoantibody-negative state.  
These highlighted the highly variable individual response towards adrenal autoantibodies. In 
keeping with AAD, observational studies showed that some first-degree relatives of patients 
with type 1 diabetes who had anti-islet cell antibodies never develop diabetes (Spencer et al. 
1984). The disappearance of anti-thyroid antibodies has also been reported in some patients 
with autoimmune thyroiditis (Tunbridge et al. 1981). Nevertheless, the presence of 21-
hydroxylase antibody in an individual remains significant as the cumulative risk of 
developing overt adrenal insufficiency remains high at 20% (Coco et al. 2006). Hence, a few 
risk factors have been identified predicting the development of overt adrenal insufficiency 
among asymptomatic patients with positive AA. These include higher 21-hydroxylase 
autoantibody index (Laureti et al. 1998), younger age (Betterle et al. 1997), HLA haplotypes, 
 8 
 
particularly DRB1*0404-DQ8 and DRB1*0301-DQ2 (Betterle et al. 1988, Yu L et al. 1999), 
male gender and biochemical evidence of adrenal dysfunction upon discovery of adrenal 
antibody (Coco et al. 2006).    
Although some works have been done to investigate the preclinical/clinical stages of AAD, 
the natural history of AAD, particularly those relevant to the post-diagnosis stage, has not 
been studied in detail. AAD has generally been assumed to be a chronic irreversible 
condition in which patients will rely on exogenous steroid replacement for life after 
diagnosis. This disorder has also been assumed to be a monophasic condition, whereby 
immune-mediated destruction of adrenal gland will inevitably lead to permanent adrenal 
failure. However, the presence of ‘remitting-relapsing’ phases or complete remission 
following a single episode of clinical manifestation in other organ-specific immune disorder 
i.e multiple sclerosis, autoimmune thyroid diseases highlights the fact that current 
assumptions on the natural history of AAD could be faulty. Indeed, there are three 
individuals reported in the literature with spontaneous recovery from established 
autoimmune Addison’s disease (Smans & Zelissen 2008 , Chakera  & Vaidya 2012, Baxter 
et al.2013). There is certainly a knowledge gap in the natural history of established AAD, 
which is worth exploring as this could potentially revolutionise patient management in AAD. 
 
1.4 Health burden of AAD 
AAD is a debilitating condition and carries a significant health burden to the developed 
world. Although steroid replacement therapy saves the lives of those affected by AAD and 
makes them feel significantly better than prior to diagnosis, but for most of them, their 
quality of life is not fully restored. The long term outcome is also compromised by many 
potential complications associated with chronic steroid treatment, particularly osteoporosis 
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and type 2 diabetes.  It is not uncommon to hear AAD patients complaining of weariness, 
fatigue, reduced stamina and poor ability to maintain work performance despite optimal 
steroid therapy. This has resulted in some patients having to utilise more sick leave, unable 
to carry out full-time jobs or even end up with redundancy.  
According to a Norwegian study using the SF36 health assessment (n=79), general health 
and vitality perception were significantly impaired among all AAD patients irrespective of 
gender and age of diagnosis (Lovas & Husebye 2002). Role-physical and physical 
functioning was reduced among affected females, which are strongly associated with the 
likelihood of receiving working disability benefits and higher fatigue scores. Furthermore, 
they discovered that Norwegian men treated for AAD (mean age 39 years) had general 
health equal to men older than 70 years in the general population, whereas affected women 
have a general health perception on par with Norwegian patients suffering from mild 
rheumatoid arthritis and American patients with congestive heart failure. A high proportion 
of patients (41%) aged between 40-67 years were also found to receive working disability 
benefits despite steroid replacement.   
On the other hand, chronic exogenous steroid replacement has been associated with risk of 
osteoporosis and type 2 diabetes mellitus. Pharmacological doses of glucocorticoids are 
known to increase osteoporosis and fracture risk, especially in trabecular bone (Reid 1997). 
This is due to the inhibition of calcium absorption, reduction in bone formation and 
increased bone resorption. Furthermore, it has been shown that the conventional 
glucocorticoid therapy doses used in AAD are higher than the endogenous cortisol 
concentration produced by the adrenal gland (Esteban et al. 1991). This could potentially 
exaggerate the adverse bone effect among AAD patients. In a large population-based cohort 
study from Sweden comprising 4007 patients with AAD, a 45% excess risk of hip fracture 
independent of age at AD diagnosis, sex or duration of diagnosis was found. The relative 
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Table 1.2. Clinical stages of autoimmune Addison’s disease 
 (Adapted from Betterle et al.1988 & 2002, Baker et al.2012) 
Clinical 
stages 
Biochemical and clinical presentation 
PRA Aldosterone ACTH-
stimulated 
cortisol 
ACTH Basal 
cortisol 
Clinically overt 
Addison’s disease 
0 Normal Normal Normal Normal Normal None 
1 High Normal/low Normal Normal Normal None 
2 High Normal/low Low Normal Normal None 
3 High Normal/low Low High Normal None 
4 High Low Low High Low Yes 
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risk of hip fracture was highest in the year before and the first year after disease diagnosis 
(HR 4.1; 95% CI: 2.9- 5.8). The risk of hip fracture declined thereafter but remained 
significant for more than 5 years after diagnosis (HR=1.3, 95% CI, 1.1-1.6) (Bjornsdottir et 
al. 2011).  
Although the life expectancy of AAD patients has been considered normal once the disease 
is diagnosed and steroid replacement therapy is started. The analyses from large population-
based studies showed increased mortality among them. Data from the Swedish National 
Hospital Registry, comprising 1675 patients with a 14-year study period, demonstrated 
increased all-cause mortality with a risk ratio of 2.19 for men and 2.86 for women 
(Bergthorsdottir et al. 2006). The rise in mortality is predominantly ascribed to infectious 
disease, malignancy and cardiovascular disease (Bergthorsdottir et al. 2006). Similar 
findings were uncovered by another Swedish study, showing more than a 2-fold increased 
mortality risk among patients with autoimmune primary adrenal failure (SMR 2.5; 95% CI: 
2.3-2.7). Nevertheless, the increased malignancy risk was only observed among APS1 
patients when tumours observed during the first year of follow-up were excluded (Bensing 
et al. 2008). In line with these studies, analyses from the Norwegian group also highlighted 
the risk of premature death among young AAD patients before the age of 40, commonly due 
to acute adrenal crisis, infection or sudden death, despite conventional glucocorticoid 
replacement (Erichsen et al. 2009a).  
In addition to the complications discussed above, patients have to prepare for the ever-
present risk of an unexpected adrenal crisis, which is inevitably fatal without prompt 
medical intervention. A survey from Germany involving 254 patients with primary adrenal 
insufficiency, reported an incidence rate of 6.6 crises per 100 patient years. Around 46.9% 
(108/254) of patients reported at least one adrenal crisis since their diagnosis (Harner et al. 
2010). In another survey carried out by the UK Addison’s Disease Self-Help Group, 47% of 
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the participants reported adrenal crises requiring hospital admission since their diagnosis. Of 
them, 10% had had four or more occasions of hospital admission with adrenal crisis (White 
& Arlt 2009). The main precipitating factors for adrenal crisis include gastrointestinal 
infection and fever, stressful events such as surgery, pregnancy and change of temperature 
or heat during travel.  Despite the extensive observational studies on adrenal crisis, no 
modifiable risk factors have yet been identified that could effectively prevent this event. 
Indeed, Hahner et al showed that adrenal crisis was not affected by glucocorticoid dosage, 
age at diagnosis, body mass index, educational status or DHEA treatment (Hahner et 
al.2010). Adrenal crisis has certainly increased health costs from hospital stays or even 
intensive care admission. Although the lack of epidemiological data from UK and European 
countries makes it hard to estimate the health cost of AAD, data from north America, the 
National Adrenal Disease Foundation in 2011 reported the annual cost to a patient suffering 
from AAD amounts to USD23,230 per patient per year, summed up to $11.6 billion to treat 
the five to six million patients living with AAD. (http://www.aarda.org/pdf/cbad.pdf)  The 
data published included the costs for daily steroid replacement and cost of physician and 
specialist consultation prior to the diagnosis of AAD being made. In general, AAD results in 
many years of intensive healthcare consumption and reduced workforce capacity as the 
average age of diagnosis is 39 years, which could significantly impact the country’s 
economy and health service.   
 
1.5 Normal development of adrenal gland 
The adrenal gland is composed of two functionally discrete tissues derived from two 
embryologically distinct origins. The adrenal cortex is formed from cells of intermediate 
mesoderm and the inner medulla is derived from neural crest cells of the neuroectoderm 
origin (Evelyn 1927).  Following organogenesis, the adrenal cortex differentiates into 3 
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distinct zones. Zona glomerulosa, the outermost layer cells arranged in rounded clusters 
surrounding glomeruli, produce mineralocorticoids that regulate serum sodium 
concentration and blood volume. The middle zone comprises cells that form the zona 
fasciculata that synthesises and secretes glucocorticoids, the stress-response hormones.  
Zona reticularis, residing in the innermost region of the adrenal cortex, is responsible for the 
production of sex steroid precursors (Keegan & Hammer 2002). 
During the 4
th
 week of human gestation, adrenogonadal primodium (AGP) is formed from 
the proliferation of mesoderm-derived cells of the coelomic epithelia and underlying 
mesonephros (mesonephric mesenchymal cells) and resides in between the urogenital ridge 
and the dorsal mesentery (Luo et al. 1994, Hatano et al. 1996), defined by expression of 
nuclear receptor NR5A1 (Steroidogenic factor 1, SF1). The bipotential AGP separates into 
the gonadal primordia and adrenal primordial (fetal adrenal cortex) at the 8
th
 week of the 
embryonic days, under the influence of Wilm’s tumour 1and Cited2-mediated upregulation 
of SF1 expression (Keegan & Hammer 2002). Once separated from the AGP, SF1 
expression is maintained via the recruitment of the homeobox protein PKNOX1 (Prep1), 
homeobox gene 9b (Hox) and pre B-cell leukemia transcription factor (Pbx1) to a fetal 
adrenal-specific SF1 enhanceer (FAdE) (Zubair et al. 2006). This FAdE-dependant 
expression of SF1 is then maintained in the fetal adrenal cortex through autoregulation of 
SF1 expression. Proliferation of fetal adrenal cells was believed to be under the influence of 
ACTH derived from fetal pituitary (Mesiano & Jaffe 1997). 
Following the formation of the fetal adrenal cortex, the neural crest derived chromaffin 
progenitor cells will migrate through the cortex to form the medulla, and the mesenchymal 
encapsulation of the fetal adrenal cortex ensues (figure 1.1). The initiation of the 
development of the adult definitive cortex will take place in week 8 or 9 of gestation, which 
becomes evident between the capsular cells and fetal adrenal cells (Uotila1940, Mesiano & 
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Jaffe 1997). The fetal adrenal cortex regresses rapidly after birth through apoptosis and 
expansion of the adult cortex. Two layers of differentiated zones in the adult adrenal cortex 
–zona glomerulosa and zona fasciculata can be distinguished at birth. The zona reticularis 
becomes evident 3 years after birth and is completed at puberty (Hui et al. 2009). 
1.6 Adrenal steroidogenesis 
Adrenal steroidogenesis is controlled by a complex orchestration of the hypothalamic-
pituitary-adrenal axis and the paracrine signalling of the adrenocortical stem cells and 
adrenocytes. The pulsatile secretion of ACTH from the pituitary gland is the key regulator of 
adrenal steroidogenesis. Upon ACTH stimulation, the steroidogenic acute regulatory 
proteins (StAR) shift cholesterol from the outer mitochondria membrane (OMM) to the 
inner mitochondria membrane (IMM), making them available for rapid steroidogenesis 
according to the zonal-specific expression of steroidogenic enzymes (Monna et al.2003). 
The cholesterol side change cleavage reaction is the initial rate limiting step in steroids 
biosynthesis, involving the cytochrome P450 side chain cleavage enzyme (P-450scc) which 
resides at the inner mitochondrial membrane (Churchill et al. 1978), that converts the 
cholesterol side chain to pregnenolone. The pregnenolone produced then travels to the 
endoplasmic reticulum, where it undergoes further transformation according to the distinct 
steroidogenic enzymes in each adrenal zonation (figure 1.2). 
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Figure 1.1. Adrenal gland organogenesis 
(Reproduced from Wood and Hammer 2011) 
 
Model of adrenal gland formation from the adrenogonadal primordium to the zonation of the 
definitive cortex.  
(Note colours of the respective cell types: adrenogonadal primordium, purple; fetal adrenal 
cells, red; gonadal cells, blue; neural crest/medullary cells, yellow; mesenchymal/capsular 
cells, green; definitive cortex, black; fully differentiated and zonated definitive cells, gray.) 
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Figure 1.2. Biosynthesis of steroids in adrenal and gonads 
(Reproduced from Payne AH & Hales DB 2004) 
 
Figure 1.2 depicts the major biosynthesis pathway of steroid hormones in adrenal 
cortex and gonads. Individual enzymes are highlighted in circle whereas the final 
steroid hormone products are in capital letters. The rate limiting step in 
steroidogenesis is the conversion of cholesterol to pregnenolone by the cholesterol 
side-chain cleavage enzyme (CYP11A), taking place in both adrenal cortex and 
gonads.  Each step of the steroidogenesis pathway is regulated by a specific enzyme. 
Each zone of the adrenal cortex has distinct enzyme activity leading to the final 
production of aldosterone, cortisol and adrenal androgens.  Pregnenolone is first 
converted to either progesterone or 17α-hydroxypregnenolone , by 3-β-
hydroxysteroid dehydrogenase (3β HSD) and steroid 17α-hydroxylase (CYP17) 
respectively. These intermediate precursors are converted to 11-deoxycorticosterone 
and 11-deoxycortisol by steroid 21α-hydroxylase (CYP21), an enzyme unique to the 
adrenal cortex. This is followed by the conversion to aldosterone and cortisol by 
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aldosterone synthase (CYP11B2) and steroid 11β-hydroxylase (CYP11B1), 
respectively. Adrenal androgens (dehydroepiandrosterone and androstenedione) are 
formed from the hydroxylation of 17α-hydroxypregnenolone  and 17α-
hydroxyprogesterone. The presence of 17 β-hydroxysteroid dehydroxysteroid 
(17HSD) and the aromatase complex (CYP19) in the gonads allow formation of 
testosterone and estradiol. 
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1.7 Current concept on the pathogenesis of AAD  
Since the discovery of Addison’s disease in 1849, various studies comprised of animal 
models and post-mortem examinations have been undertaken to unravel its underlying 
mechanism. Although we learned that aberrant immune response toward steroid producing 
cells in the adrenal cortex results in AAD, the exact mechanism that triggers adrenal 
autoimmunity remains enigmatic. I will discuss the current understanding of the 
pathogenesis of AAD from histopathology, immunopathology and genetics perspective. 
 
1.7.1 Histopathology 
A lot of valuable histology information was obtained from post-mortem examinations 
performed when AAD was still a fatal condition. AAD had been labelled as a disease of 
‘inflammatory contracted suprarenals’ back in 1930. In a post-mortem examination of a 
patient who died of adrenal insufficiency, Saphir & Binswanger noticed that the adrenal 
glands were hypoplastic, with only remnants of cortical tissue remaining. The remnants 
were represented by yellow streaks or dots, with a thin capsule enclosing only the reddish 
grey medulla (Saphir & Binswanger 1930). Histology studies performed in later years 
concluded that autoimmune adrenalitis is characterised by widespread diffuse infiltration of 
monoculear cells comprising lymphocytes, plasma cells and macrophages (Carperter et al. 
1964, Irvine et al. 1967 & 1968). In addition, the affected adrenal cortex lost the normal 3-
zonal architecture, with adrenocortical cells demonstrating necrosis and pleomorphism. 
Interestingly, islands of hyperplastic adrenocortical cells or regenerating nodules were 
observed in the midst of mononuclear cell infiltration (Guttman 1930). These residual 
adrenal nodules eventually became overwhelmed by the inflammatory process; the cortex 
would then be replaced entirely by fibrous tissue (Jackson et al. 1988). The slow 
inflammatory process within the adrenal cortex characterised by continuous destruction and 
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self-regeneration is in keeping with the insidious onset of AAD. It has also been suggested 
that this disease will only become clinically apparent when 90% of the functioning 
adrenocortical cells have been destroyed (Rosenthal et al. 1978).   
Despite these early histology data, the exact sequence of the pathogenesis of autoimmune 
adrenalitis in human remains elusive. A similar immune form of Addison's disease occurs in 
several breeds of domestic dog (Klein & Peterson 2010). The adrenal inflammation in 
canine was found to be associated with cortical atrophy and lymphoplasmacytic adrenalitis. 
However, zona glomerulosa was partially spared (Frank et al. 2013). Various studies have 
tried to induce autoimmune adrenalitis in several animal species, including guinea pigs, 
rabbits, mice and rats, by injection of autologous or heterologous adrenal homogenates 
mixed with various adjuvants, as well as transferring spleen or lymph node cells from 
actively immunised rats or mice into their naive companion (Barnett et al. 1963, Colover & 
Glynn 1958, Steiner et al. 1960, Fujii et al. 1992). Although these models managed to 
produce lymphocytic infiltration in the adrenal gland, none of them demonstrated diffuse 
atrophy of the adrenal cortex, or regeneration nodules that were seen in humans.  Hence, 
animal models are of limited relevance to human disease.  
 
1.7.2  Immunology 
The role of adaptive immunity in AAD has been highlighted since 1960s, when Nerup and 
colleagues demonstrated that circulating T lymphocytes from patients with autoimmune 
adrenalitis were reactive towards fetal adrenal extracts or to a mitochondrial fraction from 
adrenals (Nerup J et al. 1969 & 1970). However, the mechanistic profile of the 
immunopathogenesis of AAD has yet been fully unravelled, mainly due to the limitations of 
obtaining fresh adrenal samples from patients with active autoimmune adrenalitis and poor 
animal models.   
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Both humoral and cell-mediated immune responses are believed to contribute to disease 
pathogenesis.  The presence of adrenal autoantibodies is among the potential factors that 
trigger an immune response towards adrenocortical cells. These steroid-producing cell 
antibodies have been found to target 21-hydroxylase, 17 hydroxylase and side-chain 
cleavage enzymes (Bednarek et al. 1992, Krohn et al. 1992, Winqvist et al. 1993). These 
autoantibodies were found to bind to subcellular fractions of adrenocytes enriched for 
microsomal enzymes and mitochondria (Ludwig et al. 1976, Nerup et al. 1970, Bright et al. 
1990). In contrast to 21-hydroxylase autoantibodies, which are only found in the adrenal 
cortex, autoantibodies against 17α-hydroxylase and cholesterol side-cleavage enzymes were 
also found to bind to the ovary, placenta and testis, contributing to autoimmune premature 
ovary failure (Sotsiou et al. 1980, Anderson et al. 1968). Interestingly, although these 3 
steroid-producing enzymes are closely related and their amino acid sequence is partially 
homogenous, they are independent molecular targets of autoantibodies in AAD (Peterson et 
al. 1997, Uibo et al. 1994). 
Among the identified adrenal autoantibodies, 21-hydroxylase (21-OH) enzymes are the 
dominant antigens in either isolated Addison’s disease or AAD in the context of APS2 
(Erichsen et al. 2009, Soderbergh et al. 2004). This autoantibody may persist in patients 
years after the diagnosis (Dawoodji et al. 2014). The 21-hydroxylase enzyme is an 
intracellular enzyme localised in the endoplasmic reticulum and comes from the family of 
p450 cytochrome. It consists of 496 amino acids with a calculated molecular weight of 
56kDa (Furmaniak et al. 1988). The enzyme activities are dependent on NADPH, a 
flavoprotein, P450 reductase. It converts 17α-hydroxyprogesterone into 11-deoxycortisol, 
and also converts progesterone into 11-deoxycorticosterone. The central and the C-terminal 
region of 21-hydroxylase enzymes (amino acid 241-494) were thought to be important for 
autoimmunity (Song et al. 1994; Wedlock et al. 1993). A mutation within this region 
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(Pro453-->Ser) has resulted in partial loss of autoantibody binding, suggesting that Pro453 
has a key role in forming an autoantigenic epitope on 21-hydroxylase (Asawa et al.1994).  
On the other hand, AAD is likely due to a T-cell mediated immune response.  AAD and 
APS 2 have been associated with DR3-DQ2 and DR4-DQ8 HLA haplotypes, which are 
known to predispose to other T cell-mediated autoimmune diseases such as type 1 diabetes 
(Myhre et al. 2002; Gombos et al.2007). The class II major histocompatibility complex 
(MHC class II) molecules are also found to be highly expressed in the adrenocortical cells of 
AAD patients as compared to the normal healthy population. This suggests extensive 
exposure of the adrenal cortex to interferon-γ (IFN-γ), secreted by activated CD4+ and 
CD8+ T lymphocytes, which then perpetuate further lymphocytic proliferation and immune 
response towards the adrenal cortex (Skoskiewicz et al. 1985, Todd et al.1985).  In addition, 
defects in T cell functions had been described in APS2. Impairment of activation-induced 
cell death with persistence of autoreactive T cells were reported among AAD patients who 
had compromised CD4+CD25+ regulatory T cell and caspase 3 functions  (Kriegel et al. 
2004, Vendrame et al. 2006).  Recent studies had demonstrated that T cell response are 
clustered to a few immunodominant 21-OH epitopes, such as HLA-B8–restricted epitope 
21-OH431–438  (Rottembourg et al. 2010) and  HLA-A2–restricted dominant epitope at 
position 21-OH342–350. (Dawoodji  et al. 2014). However, there is still limited information 
with respect to 21-OH specific T cell response in AAD. A more comprehensive epitopte 
mapping on 21-OH are required to inform the role of T cell mediated immune response in 
AAD.  
Despite the clear association between adrenal autoantibodies and AAD, the exact triggers 
and reasons for adrenalitis being perpetuated remain enigmatic. Although in-vitro studies 
showed a marked dose-dependent inhibition of 21-hydroxylase enzyme activity with sera 
from patients with positive 21-hydroxylase autoantibodies (Furmaniak et al.1994), there is 
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no evidence that the same effects take place in vivo. In fact, a study has shown that the 
serum steroid profile of pre-clinical AAD patients with positive 21-hydroxylase antibodies 
remained unchanged, in which an increase in 17α-hydroxyprogesterone levels would be 
expected from reduced 21-hydroxylase enzyme activity (Boscaro et al.1996). Besides, these 
autoantibodies which have been shown to cross placenta and are present in neonatal blood, 
did not result in transient or permanent neonatal hypoadrenalism (Winqvist et al.1996). This 
autoantibody is clearly different from those seen in autoimmune thyroid disease, whereby 
the presence of thyroid stimulating hormone receptor antibodies that cross the placenta has 
been shown to lead to neonatal hypothyroidism or hyperthyroidism (Weber et al.1998). 
Nevertheless, this clinical discrepancy is thought to be reasonable as 21-hydroxylase 
enzyme is located in the smooth endoplasmic reticulum which could preclude its direct 
interaction with circulating autoantibodies (Mitchell & Pearce 2012). Nevertheless, some 
studies have suggested their more plausible role in mediating direct adrenocortical cell 
destruction (Khoury et al.1981; Bright & Singh 1990). The 21- hydroxylase autoantibodies 
are IgG1 isotype and target carboxyl terminal of this enzyme. This means that they have the 
potential to destroy adrenal cells through cellular cytotoxicity by perpetuating complement 
or antibody-dependant processes directed at membrane or intracellular antigen (Gattoni et al. 
2006). Furthermore, the auto-reactive B cells might also act as antigen-presenting cells, 
which in turn enhances the generation of T cell mediated autoimmune destruction process. 
Indeed, it has been shown that the level of 21-hydroxyase autoantibodies correlates with the 
degree of adrenal destruction/ failure at diagnosis (Laureti et al. 1998).  Their presence in 
asymptomatic healthy controls can also predict the risk of progression to clinical disease (Yu 
L et al. 1999; Falorni et al. 1997). 
Apart from the well described adaptive immunity, studies in the last few decades have 
started to shed light on the potential role of innate immunity in AAD. The adrenal gland is a 
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highly vascular and dynamic organ. It constantly interacts with immune systems through 
various mediators such as resident macrophages, lymphocytes and dendritic cells which are 
present in the adrenal glands (Bornstein & Chrousos 1999; Marx et al. 2000). Although the 
exact roles of these immune cells have yet to be confirmed, it has been suggested that they 
are involved in the regulation of steroid hormone production by means of cytokines and 
chemokines secretion (Marx et al. 1998). For instance, Toll-like receptors (TLR), a group of 
receptors which are essential for the innate immune system, are expressed in adrenocortical 
cells under normal conditions. The stimulation of TLR ligand induces strong inflammatory 
response, leading to the secretion of various chemokines, including TNF-α and interleukin-6 
(IL-6) (Kanczkowski et al. 2009). This response is found to be important in regulating stress 
responses upon infection or bacteraemia but its role in adrenal autoimmunity remains 
unclear (Bornstein et al. 2006). Additionally, steroid-producing cells could produce 
cytokines and chemokine, such as IL-1, IL-6, IL-8, IL-18 and TNF-α, which have a key role 
in the immune-endocrine cross talk to regulate steroidogenesis (Bornstein et al. 2004, 
Rotondi et al. 2007a). A specific chemokine implicated in AAD and several other 
autoimmune endocrine disorders is the CXC Chemokine Ligand 10 (CXCL10, also known 
as interferon-inducible protein 10, IP10) (Rotondi et al. 2007b). They were found to be 
elevated in the serum of AAD patients and are produced by adrenal cells following 
cytokines TNFα and interferon (IFN)-γ exposure during viral infection (Rotandi et al. 2005). 
In-vitro studies suggest that toll-like receptor 3, nuclear factor κB (NFκB) and signal 
transducer and activator of transcription-1 (STAT1) could induce CXCL10 expression in the 
adrenocortical cell line (Bratland E et al 2013), suggesting the combination of environment 
(viral), endogenous and innate immunity in the pathogenesis of AAD. 
It is clear from the discussion above that the full mechanistic picture of immunopathogenesis 
remains obscured although parts of them have slowly been revealed. Nevertheless, two 
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potential models for the immunopathogenesis in AAD have been developed which will be 
discussed below. 
 
Hypotheses of the immunopathogenesis of AAD 
Hypothetical model 1 
Bratland & Husebye has delineated a detailed model on the potential pathogenesis of AAD 
(Bratland & Husebye 2011). They suggested that viral infection or intense stress that 
induced apoptosis of adrenocotical cells could possibly lead to excessive recruitment of 
dendritic cells that take up elements released by the apoptotic cells, including genomic DNA 
and steroid-producing enzymes such as 21 hydroxylase enzymes. If there is a breakdown in 
central tolerance or a lower set point of clonal selection, Th1 cells might be activated to 
perpetuate a series of antigen-presenting T cell process. This will include interferon –γ 
induced B cell expansion, memory B cell and autoantibody production. Additionally, 
interferon-γ secreted by Th1-CD4+ cells will also lead to activation and expansion of auto-
reactive cytotoxic lymphocyte and macrophages, leading to cellular destruction. The 
autoantibodies generated by B cells that bind to the target antigen in adrenal cells will also 
result in complementary or antibody-dependant cytotoxic process. In addition, the 
generation of various chemokines will also induce cell death through radical molecule 
production (figure 1.3). 
 
Hypothetical model 2. 
Mitchell & Pearce suggested another model based on the breakdown of glucocorticoid-
induced immune privilege. It was suggested that the local steroidogenesis suppresses adrenal 
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antigen presentation within the adrenal cortex in normal situation (Mitchell & Pearce 2012). 
However, if immune tolerance to adrenal antigen is lost, antigen presentation will be 
enhanced followed by inflammatory infiltration in the adrenal cortex (stage 1 disease). 
Adrenal cells will then be damaged by the inflammatory process results in reduced local 
glucocorticoid production (stage 2 disease). This will then promote further adrenal antigen 
presentation, inflammatory cell recruitment and adrenal cell destruction. Adrenal cortex will 
eventually destroy and steroidogenesis ceases, correspond to the overt clinical phase of 
AAD (figure 1.4). 
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Figure 1.3. A highly simplified schematic overview of possible events leading to 
autoimmune adrenalitis and adrenocortical insufficiency 
(Reproduced from Braland & Husebye 2011) 
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Figure 1.4. A hypothetical model of the events leading the overt autoimmune Addison’s 
disease 
(reproduced from Mitchell & Pearce 2012) 
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1.7.3 Genetics of AAD 
In common with other autoimmune disorders, AAD is believed to have a complex genetic 
basis, with
 
a risk to first-degree relatives of about 2% (Mitchell & Pearce 2012). AAD with 
APS2 or isolated AAD is to be distinguished from those in conjunction with APS1, which is 
a monogenic condition, inherited in a Mendelian fashion owing to AIRE gene mutation. Data 
incorporating AAD probands from the UK and Norway has revealed a sibling recurrence 
risk ratio (the risk of disease in a sibling of an individual with the disease compared to the 
population prevalence of the disease) of between 160 and 210 (Mitchell & Pearce, 2012). 
This is significantly higher than the sibling recurrence risk ratio in autoimmune thyroid 
disease and type 1 diabetes, which are approximately 10 and 15 respectively (Risch 1987, 
Vaidya et al. 2002).  
The rarity of AAD has precluded large-scale genetic analysis and the genomic studies 
carried out thus far are based on candidate gene association and case-control design 
conducted in small cohorts of patients. The number of known risk genes for AAD has 
increased steadily in the past years and have a dominant influence on various immunological 
pathways, both the adaptive and innate immune systems. In common with other autoimmune 
endocrinopathy, the MHC locus on chromosome 6p21 harbouring the class II HLA alleles is 
strongly associated with AAD. Several studies involving both eastern and western 
populations have confirmed the risk alleles as HLA-DRB1*03-DQA1*0501-DQB1*0201 
(DR3/DQ2) and DRB1*0404-DQA1*0301-DQB1*0302 (DR4/DQ8) haplotypes, with a risk 
ratio of 36.7 (Erichsen et al. 2009,Gombos et al. 2007, Maclaren and Riley 1986, Myhre et 
al. 2002, Yu et al. 1999). In contrast, HLA-DRB1*01-DQA1*01-DQB1*0501 (DQ5) is 
associated with protection against AAD (Myhre et al. 2002). On the other hand, the presence 
of a highly conserved extended haplotype DR3 and HLA-B8 has been shown to confer the 
highest risk of progression to AAD in patients with adrenal autoantibodies (Baker et al. 
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2010).  This study showed that 97% of the multiplex individuals (86 AAD patients from 68 
families;12 multiplex and 56 simplex) had both HLA-DR3 and HLA-B8 vs. 60% of simplex 
AD patients (P = 9.72 × 10
-4
) and 13% of general population controls (P = 3.00 × 10
-
19
).  The DR3-B8 haplotype of AD patients were less often associated with HLA-A1 
compared with controls (47% vs.81%; P = 7.00 × 10
-5
). 
HLA proteins are expressed on the surface of antigen-presenting cells and display both self 
and non-self-peptides to T lymphocytes during immune surveillance. The strong association 
between various class II HLA alleles and AAD suggested that alteration in the MHC class II 
protein renders the peptide epitope on the steroid 21 hydroxylase to be presented more 
effectively to the autoreactive T cells, in the presence of certain at risk groups. For instance, 
DRB1*0404 was more commonly found in AAD patients, compared to DRB1*0401. The 
protein encoded by HLA-DRB1*0404 differs from the one encoded by HLA-DRB1*0401 in 
only two amino acid residues (Gregersen et al 1987; Hammer et al. 1995). The lysine 
residue, which was found at position 71 of the DR β-chain of DR0401, was replaced by 
arginine in DR 0404 alleles. This significantly affected the peptide binding capabilities of 
the HLA molecules. Indeed, a significant association was found between carriers of the 
DRB1*0404- DQ8 haplotype and cellular immune response against a subgroup of peptide 
found in 21 hydroxylase enzymes among AAD patients (Bratland & Husebye 2011). 
Nevertheless, only 15-20% of patients are carriers of DRB1*0404, hence other at risk alleles 
should have significant roles in AAD as well (Erichsen et al. 2009).  
Although many other risk alleles identified within the MHC region reflect only the effect of 
neighbouring genes in linkage disequilibrium, the A5.1/A5.1 genotype of the MHC class I 
chain-related gene A (MICA) seems to be independently associated with progression to 
clinical adrenal insufficiency. It gives a ratio of 18.0 and absolute risk of 1 per 1131 for 
AAD (Gambelunghe et al. 1999). MICA is considered to confer independent risk to AAD as 
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the strength of the association was greater than might be expected from linkage 
disequilibrium with the HLA-DR3/DR4 haplotype alone (Park et al. 2002, Triolo et al. 
2009). Polymorphisms of the MICA gene are based on the number of triplicate GCT repeats 
in exon 5. The translated protein interacts with the NKG2D receptor, which is important for 
thymic maturation of T cells (Hue et al. 2003). However, the debate of whether MICA as an 
independent risk gene remains unsettled, as its role in autoimmunity was challenged in a 
large-scale genotype analysis in type 1 diabetes (Field et al. 2008).  
In addition to the MHC class II alleles, CTLA4, PTPN2, 
 
PDL1, FCRL3, 
 
NLRP1, CLEC16A
 
, 
CIITA, CYP27B1, STAT4 and GATA 3 polymorphisms have been identified as contributing 
to AAD susceptibility (Pani et al. 2002, Skinningsrud, et al. 2008, Mitchell et al.2009, 
Roycroft et al. 2009, Jennings et al. 2009, Magitta et al. 2009, Brozzetti et al. 2010, Zurawek 
et al. 2010, Mitchell et al.2014) (Figure 1-5). These genes are involved in either adaptive or 
innate immunity and their alteration could lead to the breakdown of immune-tolerance. 
Cytotoxic T lymphocyte antigen 4 (CTLA4) gene on chromosome 2q33 encodes a 
costimulatory molecule expressed on the surface of activated T lymphocyte (Brunet et al. 
1987). It competes with the co-stimulatory molecule CD28 for interaction with B7/B7.1 and 
thus down-regulate T cell activation (Husebye & Lovas 2009). Polymorphism of CTLA4 has 
been implicated in numerous autoimmune diseases, including Graves’s disease, coeliac 
disease, rheumatoid arthritis and type 1 diabetes (Yanagawa et al. 1995, Nistico et al. 1996, 
Djilali-Saiah et al.1998, Vaidya et al. 2004). In AAD, a positive association has been shown 
in polymorphism of an A or G single nucleotide polymorphism in exon 1, AR repeat in the 
3’untranslated region of exon 3 and A or G alleles of the JO30 SNP downstream of this gene. 
These polymorphisms are thought to have reduced the amount of soluble CTLA4 and hence 
increased T cell activation by enabling CD28 to access more of its ligand (Blomhoff et al. 
2004).  
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The other immune genes that are involved in the modulation of T cell receptor signalling are 
protein tyrosine phosphatase non-receptor type 22 (PTPN22) and CD274 genes. PTPN22 is 
located on chromosome 1p13 and encodes a negative regulator of T cell signalling, the 
lymphoid tyrosine phosphatase (LYP). The PTPN22 polymorphism 1858 C>T results in 
Arg620Trp substitution and has been implicated in AAD, as well as type 1 diabetes, 
rheumatoid arthritis and Graves’ disease (Begovich et al. 2004, Velaga et al. 2004, Kahles et 
al. 2005, Skinningsrud et al. 2008, Roycroft et al. 2009). The increased risk can be explained 
by the loss-of-function effect of 1858T-allele, leading to unstable LYP that is more 
susceptible to degradation and results in the survival of autoreactive T cells during thymic 
selection (Zhang et al. 2011). On the other hand, the variants of CD274 gene on 
chromosome 9p24 which encodes programmed cell death ligand 1(PDL1) has also been 
associated with AAD and other autoimmune conditions ( Brown et al. 2003, Hayashi et al. 
2008, Mitchell et al. 2009) This gene is responsible for regulating T-cell associated ligands 
with co-stimulatory roles.  
Recently, the signal transducer and activator of transcription 4 (STAT4) and GATA3 
polymorphisms have been implicated in AAD (Mitchell et al.2014). These susceptibility 
genes were previously found to be associated with rheumatoid arthritis (Remmers et al. 2007, 
Eyre et al. 2012). STAT 4 is a transcription factor known to have a role in CD4
+
 cell fate, 
with respect to TH1 responses generation and TH17 cell differentiation.  GATA3 on the other 
hand has been shown to have a role in the homeostasis and regulation of CD8+ T-
lymphocytes (Tai et al. 2013). Therefore, their polymorphism could contribute to primary T 
cell dysregulation in AAD (Mitchell et al. 2014). 
Apart from T lymphocytes, B lymphocytes can also act as antigen-presenting cells and 
express cell-surface antigens that regulate T cell response. For instance, FCRL3 is one of the 
Fc-receptor-like family members, serving as B cell surface receptors of the immunoglobulin 
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receptor superfamily. They are encoded by the FCRL gene located in chromosome 1q21 and 
were expressed predominantly on B lymphocytes, as well as on natural killer cells and 
regulatory T cells. A polymorphism of FCRL3 with the T allele in the FCRL3 promoter 
(FCLR3_3*T) has been associated with AAD in the UK cohort as well as several other 
autoimmune conditions (Capon et al. 2001,  Kyogoku  et al. 2002,  Kochi et al. 2005, Owen 
et al. 2007). Intriguingly, the same variant was found to be protective for multiple sclerosis 
in the Spanish cohort, reflecting the complexity of genetics in autoimmunity across different 
populations (Matesanz et al. 2008). 
Although polymorphisms in genes involved in adaptive immune system have been the focus 
of genomic study in AAD, an increasing number of loci related to innate immunity have 
been identified as conferring risk to AAD. The NOD-like receptors (NLRs), one of the 
cytoplasmic pattern-recognition receptors, is thought to trigger an adaptive immune response 
and activate pro-inflammatory cytokines upon sensing microbial products. NLR 
polymorphism might result in the failure of differentiating self from non-self antigens and 
result in autoimmunity. Indeed, polymorphisms in various NLR genes have been implicated 
in type1 diabetes and vitiligo (Jin et al. 2007, Magitta et al. 2009). The Leu155His 
polymorphysim in NLRP1was also found to be associated with AAD (Magitta et al. 2009, 
Zurawek et al. 2010). However, the exact functional consequence of this genetic variant has 
yet to be demonstrated.  
On the other hand, a Norwegian study found that polymorphysims in CLEC16A and CIITA 
are significantly associated with AAD. These genes can be found in chromosome 16p13 but 
they are not in linkage disequilibrium, suggesting their independent risks in AAD 
(Skinningsrud et al. 2008). CIITA is also known as MHC class II transactivator (MHC2TA) 
and encodes the master control of MHC II expression. The variation in this gene might lead 
to alteration in tissue selectivity of MHC II expression and increase AAD susceptibility 
 33 
 
(Ghaderi et al. 2006).  CLEC16A is a C-type like lectin gene and the intronic polymorphism 
has been implicated in AAD. Although the function of the protein encoded remains 
unknown, it is expressed in antigen-presenting cells and has a C-type leptin-binding domain, 
suggesting its potential role as a cell-surface receptor (Hakomarson et al. 2007, Mitchell 
&Pearce 2012). 
The initiation of adrenal autoimmunity in AAD ascribes to a complex interplay between 
genetics, environment and endogenous factors. There are limited studies on the 
environmental influence, although the immunomodulatory role of vitamin D or sun exposure 
in autoimmune conditions has raised considerable interest. A variation in the CYP27B1 gene 
in chromosome 12q13 (1260 C>A) which encodes 1-α hydroxylase, an enzyme that 
hydroxylase 25-hydroxyvitamin D3, has been shown to increase the risk of AAD in both 
German and UK cohorts, as well as Graves’ disease, Hashimoto thyroiditis and type 1 
diabetes (Lopez et al. 2004, Jennings et al. 2005, Bailey et al. 2007).  
Although AAD has a strong genetic contribution and an increasing number of risk alleles 
have being identified in the last few decades, most of them have only a modest effect on 
disease susceptibility. In fact, MHC is the only single known locus confirmed to make a 
major contribution to an individual’s genetic susceptibility to AAD. The majority of the 
genetic components of AAD remain undefined. Hence further genomic studies are required 
to unravel the exact aetiologies and pathogenesis of AAD. 
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Figure 1.5. Schematic representation of candidate-gene loci that confer susceptibility to 
AAD 
(Reproduced from Mitchell & Pearce 2012)  
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1.8 Current therapeutic approaches in AAD 
The synthesis of 11-deoxycortisone in 1937 and eventually cortisone and fludrocortisone in 
1946 and 1950 has transformed AAD from a lethal condition to a chronic but manageable 
disease. The treatment for primary adrenal failure has been virtually unchanged since then, 
and patients with AAD have a lifelong dependency on daily steroid replacement with the 
ever-present risk of adrenal crisis. The common glucocorticoid replacement regimen is 
hydrocortisone (15-20mg) or cortisone acetate (20-30mg) taken twice or three times daily. 
The use of synthetic glucocorticoids such as prednisolone which is deemed to give a more 
stable glucocorticoid effect throughout the day has also been advocated. However, their 
variable pharmacodynamics effects (Diederich et al. 2002) and potential long term 
undesirable metabolic effects have rendered them less favourable as the first line of 
treatment. The synthetic mineralocorticoid, fludrocortisone, is usually taken once daily at 
the dose of 50-200mcg, guided by blood pressure, electrolytes and plasma renin level. 
Therefore, for most AAD patients, daily steroid replacement is adequate to control 
symptoms but is not a perfect solution to restore them to full health and normal life-
expectancy. Cessation of this medication or inappropriate dose adjustment during 
intercurrent illness could result in hospital admission or death. Hence, efforts to explore 
different therapeutic approaches to improve the outlook and health in AAD patients have 
emerged in the recent decades.  
Traditionally, only glucocorticoid and mineralocorticoid are replenished during adrenal 
failure. The clinical relevance of adrenal androgens deficiency in AAD patients has 
nonetheless become a hot topic of debate in recent years. The adrenal cortex produces high 
amounts of dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEAS), estimated to 
be 4-14mg and 20-25mg respectively on a daily basis (Longcope 1986, Baulieu & Robel 
1996). These adrenal androgens are regarded as the inactive precursor steroids, which are 
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then converted to testosterone and estrogen in peripheral tissues. It has been estimated that 
approximately 30-50% of androgens in men and a high proportion of androgens in post-
menopausal women are contributed by adrenal androgens (Labrie et al. 2003). Nevertheless, 
the clinical significance of DHEA(S) deficiency in patients with adrenal insufficiency 
remains unclear. Several studies using oral DHEA replacement therapy in Addison’s disease 
or secondary adrenal insufficiency have been conducted, but the benefits in sexuality or 
subjective health status were not consistent (Arlt W et al.1999, Hunt et al. 2000, Gebre-
Medhin et al. 2000, Johannsson et al. 2002,  Lovas et al. 2003, Dhatariya et al. 2005,  Bilger 
et al. 2005, Nair et al. 2006, Christiansen et al. 2007). The latest and largest DHEA trial 
(n=106) showed beneficial effects on bone by reversing ongoing loss of bone mineral 
density at the femoral neck, without significant improvement in quality of life (Gurnell et al. 
2008). Hence, although adrenal androgen replacement with DHEA 20-50mg has been 
advocated in AAD, the evidence remains weak and inconsistent. 
On the other hand, it is well known that the secretion and metabolism of endogenous 
glucocorticoid is highly complex. The normal cortisol secretion is characterized by pulsatile 
ultradian and diurnal rhythm. The cortisol level peaks in the early morning, within 1 hour 
prior to awakening, and falls progressively during the day to reach a nadir in the evening 
(Kerrigan et al. 1993).  Automated frequent blood sampling of serum cortisol had also 
revealed a pulsatile ultradian rhythm throughout a 24-hour cycle, in which the amplitude 
generally decreases during the diurnal trough (Veldhuis et al. 1990, Chrousos 1998). This 
ultradian rhythm may have the theoretical implication on the generation of tissue-specific 
signals. The 2 glucocorticoid receptors, mineralocorticoid (MR) and glucocorticoid (GR) 
receptors have different ligand affinities, and the pulsatility may have a particular effect on 
the occupancy of the lowered-affinity GR receptor (Young et al. 2004). Furthermore, 
metabolic abnormalities and increased cardiovascular risk have been implicated in 
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conditions that disrupt the normal circadian rhythm, such as depression and insomnia (Plat 
et al. 1999, Spiegel et al. 1999). Hence, the lack of the physiological rhythm in the 
conventional replacement regimes could explain partly the increased mortality and 
cardiovascular risk among AAD patients. Cortisol day curves have indeed shown that the 
conventional twice daily hydrocortisone replacement therapy resulted in a supra-
physiological rise of cortisol concentration upon steroid ingestion followed by a rapid fall in 
serum levels in 4-6 hours, resulting in a sub-physiological level at pre-dose (Trainer et al. 
1993).  
Hence, continuous hydrocortisone infusion regimen that can mimic and reestablish the 
normal circadian rhythm of cortisol was developed (Lovas & Husebye 2007). Oksnes et al. 
showed that continuous subcutaneous hydrocortisone infusion using proprietary insulin 
pump was well-tolerated by patients and the circadian pattern of ACTH and cortisol level 
was re-established (Oksnes et al. 2014).  However, contrasting results with respect to 
subjective health status were demonstrated by two randomized trials involving small patient 
cohorts (n= 33 and 10, respectively) (Oksnes et al. 2014, Gagliardi  et al. 2014). 
On the other hand, a novel modified-release hydrocortisone formulation and a combined 
immediate/delayed release hydrocortisone have also been introduced (Debono et al. 2009, 
Johannsson et al. 2009 & 2012, Verma et al. 2010). The modified-release hydrocortisone 
formulation (Chronocort) allows delayed and sustained release of hydrocortisone to replicate 
normal physiological cortisol levels under unstressed conditions (Verma et al. 2010). The 
once-daily dual-release hydrocortisone tablet (Duocort), on the other hand, is made up of an 
immediate-release coating together with an extended-release core. This formulation has been 
shown to mimic the physiological diurnal rhythm of cortisol better, by providing a sustained 
serum cortisol profile 0-4 hours after the morning dose (Johannsson et al. 2009).  A 20% 
reduction in the late afternoon and 24 hour cortisol exposure was also demonstrated 
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(Johannsson et al. 2009).  Although these novel hydrocortisone formulations have been 
shown to improve quality of life and biometabolic parameters, the trials involved have either 
been carried out on highly selected patient groups or were lacking randomized trials with 
prednisolone (Verma et al. 2010, Johannsson et al. 2012). 
The novel therapeutic approaches discussed thus far have been based on steroid replacement 
therapy which, realistically, will not be able to mimic the physiological circadian rhythm of 
serum cortisol profile completely. Hence, re-establishment of endogenous adrenal 
steroidogenesis will be the ultimate curative approach in AAD. This treatment approach has 
recently been attempted by Pearce and colleagues using B lymphocyte-depleting anti CD20 
antibodies (Pearce et al. 2011). One out of six patients demonstrated steady improvements in 
serum cortisol and aldosterone secretion, and eventually discontinued steroid replacement 
therapy for 12 months. This study suggested that the natural history of AAD is modifiable 
and disease-modifying drugs targeted at the immune response could lead to a cure. This is in 
line with type 1 diabetes mellitus and Graves’opthalmopathy, in which immunomodulatory 
drugs administered early on in natural history have shown some success (Pescovitz et 
al.2014, Salvi 2014). An interesting observation from this study was the rapid decline in the 
serum cortisol level following commencement of exogenous steroid treatment within one 
month of diagnosis. On average, there was a reduction in serum cortisol level of more than 
50% in 3 weeks (Pearce et al. 2012). It was suggested that the removal of trophic influence 
of ACTH following exogenous steroid could partly lead to the rapid decrease in adrenal 
steroid biosynthesis. This phenomenon demonstrates the plasticity of the adrenal cortex. I 
believe that a good understanding of this concept is the key to unlocking the next step 
towards regenerative medicine in Addison’s disease.  
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1.9 Adrenal plasticity  
The adrenal cortex is one of the most plastic tissues in the human body. For more than 60 
years, it has been known that bilateral subcapsular enucleation in a rodent resulted in the 
regeneration of adrenal mass within 4-6 weeks (Ingle & Higgins 1938, Greep & Deane 
1949).  Steroidogenic function was detected as early as day-8 following enucleation, while 
full steroidogenic capacity could continue developing for up to 6 weeks (Ingle & Higgins 
1938, Ennen et al. 2005). A similar picture was also depicted when the adrenal cortical 
tissue with capsule attached were auto-transplanted to a flank muscle pocket in a rodent 
model undergoing bilateral adrenalectomy (Schaberg 1955, Saxe & Connors 1985, 
Beuschlein et al 2002). Interestingly, administration of exogenous glucocorticoids to the 
rodent model following adrenal enucleation inhibited the regrowth of adrenal glands and 
suppressed steroidogenesis (Ingle & Higgins 1938). This suggests that both adrenal size and 
steroidogenic frunction are primarily regulated by ACTH secreted from the pituitary gland.  
In humans, ACTH exhibits diurnal pulsatile secretary pattern. The ACTH secretion starts 
during sleep and is characterised by a series of plasma peaks for 8-10 hours, followed by a 
trough level in the afternoon and evening (Veldhuis et al. 1990, Horrocks et al. 1990). Both 
the adrenal size and steroidogenic function are strongly regulated by this daily pulsatile 
ACTH secretion. During chronic exogenous glucocorticoid therapy, ACTH secretion is 
suppressed leading to adrenal atrophy, and functional adrenal failure ensues if exogenous 
steroids are rapidly withdrawn. Conversely, adrenal gland hyperplasia is seen during 
Cushing’s disease following excessive pituitary ACTH secretion. These lines of evidence 
suggest that adrenocortical tissue is highly plastic and ACTH is the main regulator of 
adrenal cell mass and steroidogenesis. The adrenal plasticity is likely owing to the presence 
of adrenocortical progenitor or stem cells, which continuously repopulate the adrenal cortex 
in an ACTH-responsive fashion. With this in mind, understanding the characteristics and 
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behaviour of adrenocortical stem cells is crucial to enabling us to extrapolate the 
regenerative potential of cortical adrenocytes as a potential therapeutic approach in adrenal 
failure.  
 
1.10 Adrenocortical stem/progenitor cells 
The widely accepted model generated from rodent studies suggests that adrenocortical stem 
cells (ACSCs) are located in or adjacent to the adrenal capsule, which is also known as the 
blastema layer. They have the ability to proliferate and differentiate into various 
steroidogenic lineages upon stimulation of their trophic peptide hormone (ACTH1-39) 
(Pignatelli et al.2002, Kim & Hammer 2007,). However, the identity or molecular phenotype 
of the adult ACSCs remains uncharacterised in both rodents and man, largely due to the lack 
of specific markers that define this unique group of cells.   
In fact, the 3 separate zonal organisations of adrenal cortex were initially thought to have 
separated histogenesis but pulse chase studies using bromodeoxyuridine (BrdU) and 
thymidine-H
3 
suggest otherwise. These experiments exhibited gradual dilution of signals, 
with the strongest signals detected at the peripheral followed by an increasingly centripetal 
localisation over time (Ford and Young 1963, Zajicek et al. 1986). A transgenic mice model, 
utilising beta-galactosidase reporters under the control of a steroidogenic promoter, also 
revealed variegated expression of reporter genes in cord-like radial stripe pattern 
(Iannaccone et al. 2003). This radial clonality of adrenocytes, which originates from the 
capsular progenitors and extends radially from the periphery to the corticomedullary 
junction, had a transit-time of about 104 days in the rat (Zajicek et al. 1986). Furthermore, a 
histology study using proliferating cell nuclear antigen (PCNA) markers showed that most 
adrenocortical cells with mitotic DNA were populated at the peripherals of the adrenal 
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cortex and not the capsule (Mitani et al. 1999, Schulte et al. 2007).
 
The evidence suggests 
that the adrenocortical cells originating from the ACSCs proliferate and undergo centripetal 
displacement with a continuous, zone-specific differentiation programme and eventually 
undergo apoptosis at the corticomedullary junction (Mitani et al. 1999, Pignatelli et al. 2002, 
Kim & Hammer 2007). The daughter cells will first take on the aldosterone-secreting 
phenotype while in transit through the outermost layer, the zona glomerulosa, followed by 
cortisol and adrenal androgen secretion when migrating through zone fasciculata and 
reticularis respectively. 
 
In recent years, genetic lineage tracing studies of the various morphogenic signalling 
pathways and transcription factors in mice have consolidated the evidence supporting the 
presence of stem/progenitor cells in the capsule or subcapsular region. The details of this 
phenomenon will be discussed below.  
 
1.11 The origin of adrenocortical stem/progenitor cells 
Although the adrenal capsule has been ascertained to be the stem cell niche for adult 
progenitor/stem cells, the source and phenotypic characteristics of ACSCs have yet to be 
fully defined. As previously discussed, the fetal adrenal enhancer (FAdE) is responsible for 
SF1 expression in the fetal adrenal cortex during embryogenesis, which is then maintained 
by SF1 itself through feed-forward autoregulation (Zubair et al. 2006). Further studies 
showed that FAdE was abrogated at E14.5 in mice, followed by the regression of the fetal 
cortex (Zubair et al. 2006). Lineage tracing studies in mice using an inducible Cre transgene 
under the control of FAdE showed that all SF1 positive adult adrenocortical cells were 
derived from the fetal adrenal zone. ( Zubair et al. 2008). Nevertheless, the nature of the 
definitive SF1 enhancer that activates SF1 transcription in adult adrenal remains elusive, and 
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there is still a knowledge gap in terms of the molecular and cellular mechanism that 
coordinates this transition from fetal to the definitive adult adrenal cortex.  
The second potential source of ACSCs was unravelled following the discovery of sonic 
hedgehog (SHH) signalling pathway. This morphogenic signalling pathway has been found 
to be essential for adrenal gland development and maintenance (King et al. 2009, Ching & 
Vilain 2009, Huang et al 2010,). SHH co-localises with SF1 at the subcapsular region of the 
adrenal cortex. They are not found in the rest of the adrenal cortex that expresses both SF1 
and differentiated steroidogenic markers such as CYP11B1 and CYP11B2 (King et al. 2009). 
Interestingly, further lineage tracing studies revealed that SHH expressing cells at the 
subcapsular region give rise to the differentiated adrenocortical cells (King et al. 2009). In 
addition, a lineage tracing study carried out by Kim et al. showed that the descendants of the 
downstream activator of the SHH pathway, GLI1, which is only found in the adrenal capsule 
and does not express SF1, gives rise to GLI1 negative, SF1 or CYP11B1/ CYP11A1 
positive adrenal cells. Consistent with the finding of Kim et al., Huang et al. demonstrated 
centripetal detection of lacZ activity in the adrenal cortex of mice, after a long period of 
Gli1-Cre activation, in an inducible Gli1-Cre transgene crossed with a lacZ reporter (Huang 
et al. 2010). 
Hence, it appears that there are 2 potential adrenocortical stem/progenitor cell groups: 1. 
ACSCs originating from the fetal adrenal cortex; 2. GLI1-positive SF1-negative adrenal 
cells and SHH-positive, SF1-positive cells from the capsule/subcapsular region, all of which 
give rise to SF1-positive, differentiated adrenocortical cells. One could also hypothesize that 
GLI1-postive SF1-negative cells are adrenocortical stem cells which give rise to the 
intermediate, SHH-positive, SF1-positive progenitor cell group, and these cells act as 
transient amplifying progenitor cells that differentiate into SF1 positive adrenocortical cells, 
but further studies are required to prove this hypothesis. 
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Wood and Hammer then proposed a two-lineage unifying model combining these potential 
sources of adrenocortical stem/progenitor cells (figure 1.6). The model involves a primary 
lineage established from SF1 positive, coelomic epithelium which is delaminated into the 
mesenchyme which forms the fetal adrenal cortex. The secondary lineage derived from SF1 
negative mesenchymal cells resides at the capsule giving rise to SF1 positive adult 
adrenocortical cells (Wood & Hammer 2011). The SF1 positive fetal adrenal-derived 
primary cell lineage, which is independant of SHH signalling, may initiate SHH expression 
(via an unknown mechanism) and induce GLI1 expression among nearby SF1 negative 
mesenchymal cells, converting them into SF1 negative, GLI1 positive cells that serve as an 
intermediate between SF1 expressing cells originating from the fetal adrenal cortex and 
SF1-positive adult adrenal cells directed by definitive SF1 enhancer. Although  genetic 
studies have shown that capsular cells are capable of giving rise to differentiated adrenal 
cortical cells (King et al. 2009, Ching and Vilain 2009, Huang et al. 2010), no studies have 
shown that these cells are derived from fetal adrenal cell thus far. Hence, the mechanistic 
and molecular basis for the definitive transition between all these cells remains elusive. 
Nevertheless, it has recently been revealed that the steroidogenic Leydig cells of the testes 
are derived from both coelomic epithelium and mesonephric mesehcyme (DeFalco et al 
2011), suggesting the same might hold true for adrenal steroidogenic cells. 
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Figure 1.6. Unifying Model of Adrenocortical Stem/Progenitor Cells 
(Reproduced from Wood & Hammer 2011) 
 
Model 1. Definitive adrenal cells arise from fetal adrenal cells. Model 2. Definitive adrenal cells arise from capsular stem/progenitor cells or 
subcapsular stem/progenitor cells. Model 3.Proposed unifying model of adrenal stem cells in which fetal adrenal cells give rise to a transition cell in 
the capsule which in turn gives rise to the definitive adrenal cells.(Colours of respective zones: capsular cell, green; fetal zone, red; capsular 
stem/progenitor cell, blue; subcapsular/progenitor cell, black; definitive zone, gray) 
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1.12  Adrenocortical stem cell niche and mediators for stem cell 
maintenance, proliferation and differentiation 
I will next discuss the details of the sonic hedgehog morphogenic signalling pathways 
(SHH) and endocrine transcription factors (eg. SF1, DAX1) involved in the development 
and maintenance of adrenocortical stem cells. Major interest has been drawn to the 
molecular biology of adrenocortical stem cells in the recent years, largely due to their 
implication in the development of adrenocortical tumours. Most of these studies were 
carried out in murine models and have given sound evidence suggesting their essential 
roles in adrenocortical growth and differentiation, as well as the regulation of 
adrenocortical stem cells.  
 
1.12.1 Steroidogenic factor-1(SF1)  
Steroidogenic factor-1(SF1) or Ad4BP (Ad4 binding protein) is an orphan nuclear 
receptor paramount in transcriptional regulation of various genes encoding the ACTH-
activated steroidogenic enzymes (i.e cytochrome P450 side-chain cleavage enzyme, 
17α-hydroxylase , 3β-hydroxysteroid dehydrogenase ,21-hydroxylase , 11β-
hydroxylase), as well as several additional genes involved in the steroid biosynthetic 
pathway, such as the melanocortin 2 receptor (MC2R) and the steroidogenic acute 
regulatory (STAR) protein  (Luo et al. 1994, Parker & Schimmer 1994, Zhang et al. 
1995) . It plays a pivotal role in adrenocortical proliferation and differentiation. Adrenal 
agenesis was demonstrated in homozygous Sf1 knocked-out mice which died shortly 
after death from adrenal insufficiency; whereas mice heterozygous for Sf1 were viable 
with small adrenal glands (Bland et al. 2000& 2004). Similarly, no homozygous loss of 
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function mutation in SF1 have been reported in human to date, likely due to the fact that 
complete loss of SF1 is not compatible with life (Ferraz-de-Souza et al. 2011). 
SF1 is expressed in various steroidogenic tissues including the adrenal cortex, ovarian 
theca and granulosa cells, as well as testicular Leydig cells (Hammer & Ingraham 1999). 
All cortical adrenocytes express SF1 but the adrenal capsule is devoid of its expression 
(Morohashi & Omura 1996).  Upon ACTH stimulation, SF1 is actively recruited to the 
promoters of a variety of steroidogenic enzyme genes (Winnay et al. 2006). A cyclical 
occupancy of SF1 on MC2R gene promoter was also exhibited, which coincides with 
the phosphorylation of SF1 and leads to the recruitment of co-activator proteins 
resulting in transcriptional activation (Winnay & Hammer 2006). 
Interestingly, SF1 has been shown to serve as both a transcriptional activator and 
repressor of ACTH-dependant target genes, which is well depicted in its action on pre-
B-cell transcription factor 1 (PBX1) and DAX1 transcription factor. PBX1 is a direct 
target of SF1 and acts as the downstream activator of SF1-dependant steroidogenesis 
(Lichtenauer et al. 2007). DAX1 is another common target gene for SF1 and the gene 
product was found to serve as a repressor of SF1-dependant transactivation, leading to 
the inhibition of steroidogenesis in the subcapsular region of adrenal cortex (Lalli et al. 
2003). 
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1.12.2 DAX1( dosage-sensitive sex reversal, adrenal hypoplasia congenital 
critical region, on the chromosome X, gene 1) transcription factor 
DAX1 is an orphan transcriptional factor specifically enriched in the subcapsular region 
of the adrenal cortex (Swain et al. 1998, Babu et al. 2002). It appears to be necessary for 
the maintenance of ACSCs in the undifferentiated state with proliferative capacity, via 
functional repression of SF1 (Ito et al. 1997,  Niakan & McCabe 2005, Niakan et al. 
2006). DAX1-deficient patients usually exhibit adrenal hypoplasia resulting in adrenal 
insufficiency (Zanaria et al. 1994, Phelan & McCabe 2001). The widely accepted model 
suggests a synergistic glucocorticoid receptor (GR)/SF1-dependant induction of DAX1 
expression, which in turn leads to the repression of SF1-mediated steroidogenesis (Lalli 
& Sassone-Corsi 2003). However, the binding of ACTH to MC2R stimulates adenylyl 
cyclase and induces cAMP production which then unblocks both GR and SF1 from 
DAX1 promoters. This will then shut off DAX1 transcription and initiate adrenal 
steroidogenesis (Kim A et al. 2009). Hence, as DAX1 is only present in the subcapsular 
region (potential stem cell niche), steroidogenesis is inhibited among the 
undifferentiated progenitor cells and the ‘stem-ness’ of ACSCs is maintained. 
Additionally, DAX1 is vital in the fate decision (adrenal vs gonad) and differentiation 
process of fetal adrenal cells through regulation of GATA 6 transcription (Tremblay & 
Viger 2001, Jimenez et al. 2003).  This is clinically evident from the autopsy of patients 
with adrenal hypoplasia congenital (AHC- caused by hypofunctional mutations of 
DAX1), in which the adrenal glands fail to establish an adult ACSC population and 
broadly show the histological appearance of the fetal adrenal gland (MacMohon et al. 
1957). Interestingly, young  Dax1 knockout mice initially exhibited a hyperfunction 
adrenal state consistent with the loss of  Dax1-dependant inhibition of steroidogenesis 
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(Schey et al. 2011) but was followed by attenuation of steroidogenic capacity when they 
aged, with profound loss of the subcapsular region and concomittent adrenal dysplasia 
were observed (Yu et al. 1998, Scheys et al. 2011). This model is in keeping with a 
number of patients with DAX1 mutations demonstrating enhancement of steroidogenic 
function state prior to the development of adrenal failure (Lin et al. 2006, El-Khairi et al. 
2011). 
 
1.12.3 The sonic hedgehog signalling pathway 
The sonic hedgehog (SHH) signalling pathway, which was first discovered following a 
mutational screen in Drosophilia, was found to be vital in the regulation of embryonic 
development and adult stem cell maintenance (Ingham & McMahon 2001, McMahon et 
al. 2003, Xie & Abbruzzese 2003, Gupta et al. 2010, Ingham et al. 2011). SHH is a 
secreted signalling protein that acts upon target cells by binding to a twelve pass 
transmembrane binding protein, the Patched1 (Ptch1) membrane receptor (Allen et al. 
2011, Izzi et al. 2011). In the absence of the SHH protein, Ptch1 inhibits the 
accumulation of the seven pass transmembrane protein, the Smoothened (Smo). When 
the SHH ligand binds to the cell surface receptor Ptch1, it relieves the Ptch1-mediated 
repression of the Smo protein, leading to downstream activation and expression of the 
GLI family transcription factors (Ingham and McMahon 2001, Bai et al. 2004). 
SHH colocalises with SF1 within the cortical cells in the subcapsular region, but fully 
differentiated adrenocytes in the rest of the adrenal cortex are devoid of SHH expression 
(Ching and Vilain 2009, King et al. 2009). When genetic lineage analysis was 
performed in mice using constitutive Cre expressed from the Shh locus in combination 
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with conditional floxed reporter, it was shown that the Shh expressing cells give rise to 
cells in the differentiated steroidogenic adrenal cortex, but not capsule or medulla (King 
et al 2009). This signifies its role in the proliferation and maintenance of the adrenal 
cortex but not adrenal differentiation (Ching and Vilain 2009, Huang et al. 2010, King 
et al. 2009).   On the other hand, conditional deletion of Shh in steroidogenic 
adrenocortical cells (under the Sf1 promoter) demonstrated marked adrenal hypoplasia, 
with the adrenal gland being 5-10 times smaller than the wild type with normal-size 
medulla (Ching & Vilain 2009, king et al 2009, Huang et al. 2010). Despite the clear 
size reduction with a thin capsule, the adrenal gland managed to maintain proper zonal 
organisation and steroidogenic cell differentiation (Ching & Vilain 2009, King et al. 
2009, Huang et al. 2010).  These observations suggest that the SHH pathway does not 
influence the initiation of adrenal differentiation but is essential for the optimal growth 
of the adrenal capsule, to maintain the pluripotency of adrenocortical stem cells. 
Nevertheless, it remains undetermined if this proliferative ability of capsular cells is due 
to the direct effect of SHH as a capsular cell mitogen or a secondary signal that acts on 
the capsule mesenchyme. Interestingly, the Shh mutant mice suffered from adrenal 
insufficiency when they aged despite having normal glucocorticoid levels when they 
were young (Huang et al. 2010). Hence, it remains a possibility that humans with 
impaired SHH signalling might suffer from adrenal insufficiency, particularly when 
they grow older or when elevated steroid production is required during stress (Laufer et 
al. 2012). 
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Summary  
The regulation of adrenocortical stem/progenitor population is predicted to be a 
dynamic process involving both activation and inhibition pathways, combining the 
exquisite orchestration of paracrine and endocrine signals to achieve an integrated 
homeostatic mechanism for organ maintenance. Although genetic lineage tracing 
studies performed on rodent models have started to shed light on this field, there is still 
a significant knowledge gap on the regulation of ACSC proliferation and differentiation 
in humans. More work is required to define this unique group of cells. 
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Figure 1.7 A schematic overview of the signalling pathways involved in the 
regulation of adrenocortical stem/progenitor cells 
 
Figure 1.7 depicts the signaling pathways involved in the maintenance and 
differentiation of adrenocortical stem/progenitor cells. DAX1 inhibits the activation of 
SF1-mediated steroidogenesis and maintain the cells in an undifferentiated state. ACTH 
induces the clearance of GR from the DAX1 promoter, resulting in transcriptional 
silencing of the DAX1 gene and initiation of SF1-mediated steroidogenesis. DAX1 also 
participates in tissue fate decisions through dynamic regulation of GATA4/GATA6 
transcription factors in adrenals and gonads. SHH is secreted from the subcapsular cell 
to activate SHH signaling in the capsule by binding to the Ptch1 transmembrane 
receptor, leading to downstream activation and expression of the GLI family 
transcription factors. 
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Table 1.3. Potential molecules involves in ACSC maintenance and development 
Molecule Expression Proposed function Clinical disease 
DAX1 Subcapsular -Activated by Wnt signalling 
and glucocorticoids 
-Potential mediator of 
undifferentiated state in 
ACSC 
-Inhibits SF1-mediated 
steroidogenesis 
X-linked cytomegalic 
adrenal hypoplasia 
congenita 
SHH Subcapsular/
peripheral 
cortex 
-Required for adrenal 
development and 
differentiation of SHH(+)/ 
SF1(+) cells into 
differentiated SF1(+) 
adrenocortical cell types 
None/unknown 
GLI1 Capsule -Potential ACSC [SF1 (-)/ 
GLI(+) capsular cell] gives 
rise to underlying cortex 
-GLI(+)/SF1(−) cells 
differentiate into all other 
SF1(+) adrenocortical 
lineages during fetal 
development 
None/unknown 
Wnt 
ligands & 
β-catenin 
(Effector 
of Wnt 
signalling) 
 
 
Subcapsular 
region and 
fetal cortex 
-Contributes to multipotency 
of undifferentiated cells 
(ACSC) 
-Initiation of adrenal 
tumorigenesis 
Nuclear accumulation 
and mutation in 
adrenocortical 
adenoma/carcinoma 
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Molecule Expression Proposed function Clinical disease 
SF1 Cortex -Transcription of 
steroidogenic enzymes 
Induction of adrenal cell fate 
(in progenitor cells?) 
Adrenal hypoplasia, 
upregulated in 
childhood and adult 
adrenocortical 
carcinoma 
Inhibin-α Subcapsular -Prevents TGF II-dependent 
initiation of transcription 
-Gatekeeper of adrenal cell 
fate  
Adrenocortical tumour 
in children, 
ovarian/testicular 
germline tumour 
Pod1 Capsule -Inhibition of SF1 
transcription in the adrenal 
capsule (potential ACSCs) 
None/unknown 
ACTH Endocrine 
signals 
-Steroidogenesis 
differentiation  
-SF1 transactivation 
-SF1 phosphorylation 
Familial glucocorticoid 
deficiency (ACTH 
receptor mutation) 
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Aims of the thesis 
It is clear from my overview that there is still a substantial gap in our understanding of 
the pathophysiology of AAD and human ACSC biology, which needs to be addressed in 
order to advance this field further. This could be achieved by direct examination of 
patients with active diseases through either clinical or genetics studies, as well as 
cellular studies using human adrenal tissues. This approach can overcome the 
limitations encountered in rodent models due to the substantial differences between 
rodent and human adrenal. The suboptimal health status among AAD patients also calls 
for a better therapeutic approach. The general aim of this studentship is to explore the 
pathophysiology of AAD and to pursue alternative treatment options using a 
regenerative medicine approach to augment adrenal steroidogenesis, with the ultimate 
aim of improving the health and long-term outlook of AAD patients.  
Study aims: 
 To explore the potential causal pathway of common and rare genetic 
determinants in AAD, that has been implicated by susceptibility in other 
autoimmune conditions. 
 To pursue new treatment options in AAD via re-establishment of adrenocortical 
steroidogenesis using a therapeutic regimen of parenteral ACTH1-24.  
 To study the natural history and latency of endogenous ACSC revival, 
tolerability and potential side effects of the new treatment.  
 To elucidate the cellular phenotypic markers of human adrenocortical stem cells 
(ACSC). 
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Chapter 2. Genetics of 
Autoimmune Addison’s disease 
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2.1 Background 
In keeping with many autoimmune conditions, AAD has a strong genetic predisposition. 
Detailed understanding of the various genetic determinants in AAD could potentially 
uncover causal pathways that have been implicated in this rare but debilitating disease. 
Recent genome-wide studies in the commoner autoimmune conditions have identified 
novel disease-susceptibility alleles at an unprecedented rate. However, the contribution 
of these alleles to AAD has yet to be fully elucidated. Furthermore, most of the 
susceptibility alleles identified thus far was found to have a modest disease effect. 
Therefore, there are potentially many more unexplored genetic variants implicated in 
AAD. 
The non-synonymous polymorphism in exon 7 of the gene encoding the lymphocyte 
cell-surface CD226 (DNAM1) receptor, Gly307Ser (rs763361), has recently been 
identified as conferring risk to type 1 diabetes, Graves’ disease, multiple sclerosis, 
systemic lupus erythematosus (SLE), systemic sclerosis and rheumatoid arthritis (Hafler 
et al. 2009, Maiti et al. 2010, Han et al. 2010 Dieudé et al. 2010, Alcina et al.2010), and 
has yet to be investigated in AAD. The variant involves the serine-encoding allele of a 
polymorphism in the intracellular tail of the cell-surface CD226 molecule (CD226 
307*Ser) (Todd et al. 2007).
 
CD226 is also known as the DNAX-accessory molecule-1 
(DNAM-1), and is widely expressed in cells of haematopoetic origin including CD4
+ 
and CD8
+
 T lymphocytes,  natural killer (NK) cells, platelets, subset of B cells and 
natural killer T lymphocytes, where it plays the role of a costimulatory molecule 
(Shibuya et al. 1996).
 
It is possible that the 307*Ser variant alters splicing of the CD226 
transcript (Todd et al. 2007, Hafler et al. 2009), or that the change in residue itself 
affects downstream signalling.  The addition of Ser307 to the adjacent serine-threonine 
phosphorylation sites Ser302, Ser305 and Thr306, which are present in the cytoplasmic 
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tail of the CD226 molecule, might have an effect on the protein level and lead to 
increased signalling for the activation of T and NK cells (Lofgren et al. 2010).
  
CD226 
307*Ser is a common genetic variant and the minor allele frequency (MAF) established 
in the UK 1958 birth cohort controls was 0.47 (Hafler et al. 2009). 
On the other hand, a panel of rare and functionally defective genetic variants in the 
sialic acid acetylesterase (SIAE) gene were identified as being strongly associated with 
many autoimmune conditions, including Crohn’s disease, type1 diabetes, SLE, 
Sjogren’s syndrome, juvenile idiopathic arthritis, multiple sclerosis, mixed connective 
tissue disease, rheumatoid arthritis and ulcerative colitis (Odds ratio>8) (Surolia et al. 
2010).  This study originally described 19 rare variants of SIAE gene of which 11 were 
catalytically defective. A subsequent larger study (n=66,924) of more prevalent 
autoimmune and inflammatory disorders, including type 1 diabetes, coeliac disease, 
Crohn’s disease and autoimmune thyroid disease failed to replicate this finding (Hunt et 
at. 2011). Nevertheless, SIAE represents one of the very first associations of rare 
genomic variants with common autoimmune disorders. Interestingly, loss-of-function 
rare variants in the TREX1 (the major mammalian 3'-5' exonuclease) and CYP27B1 
(vitamin D 1α-hydroxylase) genes have also been described in SLE and MS patients 
respectively, suggesting that in contrast to the common disease-common variant 
hypothesis, there may be a greater role for rare genetic variants in the susceptibility to 
less prevalent autoimmune diseases (Namjou et al. 2011, Ramagopala et al. 2011). 
Sialic acid acetylesterase (SIAE) is a negative regulator of B lymphocyte signalling. It 
removes acetyl moieties from the 9-OH position of sialic acid, allows sialic acid on B 
cell glycoproteins to interact with CD22 (B cell inhibitory receptor) and results in 
attenuation of B-cell receptor (BCR) signalling (Cariappa et al. 2009). Enhanced BCR 
signalling with spontaneous anti-chromatin antibodies production had been 
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demonstrated in SIAE mutant mice on a C57Bl/6 background, suggesting that defects in 
SIAE function conferred by SIAE variants might contribute to human autoimmunity 
(Pillai et al. 2009). Although genome-wide studies have not demonstrated any 
association or linkage with SNPs at the SIAE locus in patients with autoimmunity, this 
might not be expected under a multiple rare variant model (common disease/ rare 
variant). Nevertheless, autoimmune Addison’s disease is rarer than all of the previously 
studied disorders and hence rare variants might have a significant contribution to its 
pathogenesis. 
With this in mind, I have examined the role of the CD226 307*Ser variant (rs763361) 
and rare SIAE variants on the susceptibility to AAD. 
 
2.2 Subjects and Methods  
2.2.1 Subjects 
Autoimmune Addison’s disease subjects 
The diagnosis of AAD was confirmed by either a low basal cortisol with a high 
adrenocorticotropic hormone (ACTH) level, or a subnormal response to the ACTH1-24 
stimulation test (short synacthen test, using 250 mcg of parenteral synthetic ACTH1-24).  
Patients with autoimmune polyendocrinopathy syndrome type 1 (APS1), primary 
adrenal failure owing to infiltrative or infective causes or secondary adrenal failure were 
excluded. Caucasian subjects with AAD were recruited between 1996 and 2012 through 
outpatient endocrinology services in the North East of England, and through the UK 
Addison’s disease self-help group.  In the CD226 association study, I investigated 326 
Caucasian subjects with AAD and the details of the subgroup of AAD are depicted in 
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table 2.1. On the other hand, 378 Caucasian subjects with AAD were studied in the 
SIAE association study. 
Healthy control subjects  
Healthy controls were used to determine the background population of allele 
frequencies. They were healthy local Caucasian controls with no clinical features or 
family history of autoimmune diseases. However the autoantibody status was not 
known and was not tested. Hence, the presence of subclinical autoimmune conditions 
could not be completely excluded. 311 and 387 healthy local Caucasian controls were 
used for comparison in the association study for CD226 and SIAE candidate genes 
respectively. These studies were carried out with the approval of the Leeds (East) 
Research Ethics Committee (Ref 05/Q1206/144). 
 
2.2.2 Methods 
2.2.3 Polymerase chain reaction (PCR) and gel electrophoresis 
Polymerase chain reaction (PCR) was used to amplify a region of deoxyribonucleic acid 
(DNA) around a single nucleotide polymorphism (SNP) or a specific nucleotide region 
of interest for sequencing.  This was achieved through a measurable Taq DNA 
polymerase which could add nucleotides to pre-existing 3’-OH groups of a primer pair 
designed for specific DNA template strands.  
I followed the generic rules when designing primers for PCR reactions. In general, the 
primers were 20-25 bp long with > 50% GC content. Repetitive sequences or runs of 
bases were avoided and the primer pairs were balanced for annealing temperature. 
Primer pairs were also examined to avoid the presence of hairpin loops or risk of 
annealing to each other. Finally each primer was assessed to ensure they were suitable 
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for a unique part of the genome using the BLAST (Basic Local Alignment Search Tool) 
programme. The final products were between 200-500bp.  
The PCR reaction mixture and conditions were according to the recommended 
manufacturer’s protocol, as detailed in table 2.2. Three water blanks were included in 
every PCR set-up to ensure that there would be no contamination. The PCR would be 
discarded if the water blank was positive. The PCR reaction conditions were optimized 
by adjusting the annealing temperature, magnesium concentration or the duration for 
annealing and extension steps. PCR was performed on the Tetrad 2 thermal cycler and 
the cycling parameters for each experiment are detailed in the following section. 
The PCR products were then checked by electrophoresis (120v) on a 2% agarose gel.  
5µl of sample was loaded with 1µl of DNA loading dye (Thermoscientific) in each well 
and 5µl DNA marker (100bp size ladder) was run in the first lane.  Gels were stained 
with SafeView
TM 
(Newlife BioChemEx, Bethesda) and visualized under UV light. 
 
2.2.4 CD226 genotyping:  
I used a TaqMan allelic discrimination assay to genotype the CD226 variants, 
Gly307Ser (rs763361) for disease susceptibility in AAD. TaqMan genotyping technique 
involves 2 allele-specific minor grove binder (MGB) probes containing distinct 
fluorescent dyes and a PCR primer pair to enable detection of a specific SNP target as it 
accumulates during PCR cycles. The probes also contained a non-fluorescent quencher 
and a MGB which allows for shorter probe sequences to be designed. The possible 
genotypes for rs763361 were CC,CT and TT. Two primer (forward and reverse) and 
probe pairs were used in each reaction to genotype the two possible variants at the SNP 
site. The probes and primers were provided by Taqman SNP genotyping assay (Applied 
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Biosystems; assay ID:C_1464836_20). The principle of Taqman allele discrimination is 
depicted in figure 2.1. I used the genomic DNA previously extracted from the venous 
blood of each subjects in my supervisor’s laboratory.  PCR was performed to multiply 
the DNA sequence of interest with CD226 variants and the parameters for the PCR 
mixture and reactions are outlined in table 2.2 & 2.3. Allelic discrimination plate read 
and analysis was carried out using the 7900 HT Fast Real-Time PCR system and SDS 
2.3 software. Ten percent of all samples were re-genotyped blind to ensure fidelity of 
genotyping (>99%).  
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Table 2.1 The number of isolated AAD vs AAD patients with associated 
autoimmune conditions in CD226 candidate gene studyThe number of isolated 
AAD vs AAD patients with associated autoimmune conditions in CD226 candidate 
gene study 
CD226 association study (n=326) 
Isolated AAD                                       44% (143) 
APS2                                                    56% (183) 
 Autoimmune hypothyroidism (106) 
 Graves’disease (30) 
 Premature ovarian failure (30) 
 Type 1 diabetes (17) 
 Pernicious anaemia (14) 
 Rheumatoid arthritis (8) 
 Vitiligo (8) 
 Coeliac disease (7) 
 Alopecia (2) 
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2.2.5 SIAE genotyping 
I carried out the genotyping of SIAE rare variants using Sequenom iPLEX for single 
nucleotide polymorphisms (SNPs). The results were verified by either restriction 
enzyme digestion (RFLP) or direct DNA sequencing where appropriate. 
 
2.2.6 Primer extension-MALDI-TOF genotyping (SEQUENOM-iPLEX) 
In contrast to the Taqman genotyping method, Sequenom employs a label-free primer 
extension reaction to produce allele specific oligonucleotides with distinct masses. The 
mass differences allow allele discrimination for each of the SNPs to be multiplexed in 
one single assay, leading to high-throughput genotyping. The high-throughput detection 
capacity is due to the speed and accuracy of Matrix-Assisted Laser 
Desorption/Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry. It is based on 
the principles that the time of flight of each molecule travelling through the vacuum is 
proportional to the molecule size and the analysis is done in real-time when the 
molecules hit the detector.  The allele discrimination in the iPLEX assay is conferred by 
primer extension with a high-fidelity polymerase enzyme across the SNP site, with 
universal reaction conditions for all SNPs.  This results in allele-specific differences in 
mass among the extended products.  
Assay design:  I studied 9 germline variants within the SIAE gene (chromosome 11), 
which are among the 11 rare and 1 common non-synonymous SIAE variants 
demonstrated by Surolia et al. to be functionally defective in esterase activity or enzyme 
secretion (table 2.4). These rare SNPs comprise 21 of the 24 cases (88%) of functionally 
defective rare SIAE variants reported by Surolia et al. The SNPs selected include 
C196F, T312M, C226F, F404S, R230W, R479C, W48X, Y349C and M89V. These 
SNPs were genotyped in Caucasian individuals with AAD and healthy controls in the 
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UK. The location of these 9 SNPs was identified from ENSEMBL (chromosome 11: 
124.503009-124.565.603).  The DNA sequence (300-400bp) incorporating the SNP of 
interest were imported into the MassARRAY assay design software 
(www.MySequenom.com). The programme multiplexed suitable SNPs together and 
determined a single base extension primer for each SNP. PCR primers are designed in a 
region of approximately 100 base pairs around the SNP of interest and an extension 
primer is designed immediately adjacent to the SNP. There were 9 out of 14 SNPs in 
SIAE rare variants found to be suitable for a single multiplex sequenom assay design. 
The primer sets were purchased from Metabion international AG. The details of the 
primers of the 9 SNPs assayed are outlined in table 2.5.  
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Table 2.2 PCR reaction mixture for CD226 genotyping (rs763361) 
Components (final volume 5 µl/well) Volume/well (µl) 
Genomic DNA (20ng) 1.5 
Taqman Universal Mastermix (No AmpErase UNG) 2.5 
Taqman SNP Genotyping Assay 20x 0.25 
Sterile water 0.75 
 
 
 
Table 2.3 PCR thermal cycling condition for CD226 genotyping (rs763361) 
Thermal cycling step Conditions 
1. AmpliTaq gold enzyme activation Hold at 95 oC (10 minutes)  
2. DNA denaturation 92oC (15s) 
3. Primer annealling/polymerase 
extension 
60
 o
C (1 minutes) 
Cycles (2-3) 40 times 
 
.  
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Figure 2.1 Taqman allelic discrimination assay 
Taqman allelic discrimination assay was used in genotyping CD226 polymorphism. 
This is achieved by the selective annealing of allele specific oligonucleotide (MGB-
labelled) probes upon specific targeted SNP. One probe that perfectly matched to the 
wild-type sequence variant labelled with VIC and the second probe matched to the 
mutant (SNP) sequence variant labelled with 6-carboxyfluorescein (FAM). The probe 
for allele A was labeled with FAM™ dye; the probe for allele G was labeled with VIC® 
dye. These TaqMan® probe and primer sets uniquely align with the genome to provide 
unmatched specificity for the allele of interest. 
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Table 2.4 The 12 functionally defective SIAE variants reported and the number of 
cases found (%) by Surolia et al. (Surolia et al.2010) 
Amino acid change Sequence change Frequency (%) n=1571 
W48X 143 G>A 0.0636  
M89V 265 A>G 0.076 
C196F 517G>T 0.191 
G212R* 634G>A 0.0636 
C226G 796T>G 0.0636 
R230W 688C>T 0.0636 
Q309P* 926A>C 0.0636 
T312M 935C>T 0.1273 
Y349C 1046A>G 0.0636 
R393H* 1178G>A 0.0636 
F404S 1211T>C 0.2546 
R479C 1435C>T 0.0636 
 
*SNPs not selected in my study 
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Table 2.5 Details of the primers for SIAE single nucleotide polymorphism (SNPs) genotyped by Sequenom iPLEX assay. 
This was a 14-plex assay, with the remaining 5 SNPs consisting of other genes of interest being studied by other members of the research group. The 
multiplex was designed using the sequenom iPLEX assay design software programme. 
 
SP ID Primer 1 Primer 2 Extension primer Amplicon 
length(bp) 
W48X ACGTTGGATGTGATATGGTGCTGCAGAAGG 
 
ACGTTGGATGTCACTGTGGCTCCAGGTGTA 
 
TGCTGGGGCAGTGATAT 
 
91 
 
M89V 
 
ACGTTGGATGTCACTCTGATACGTGGATGG 
 
ACGTTGGATGCCAAAGTCTGTTGTGCCATC 
 
TACGTGGATGGTGGTACTGGATCCT 
 
100 
 
C196F 
 
ACGTTGGATGCAGAAAACTTAGGCCATGGA 
 
ACGTTGGATGGTGTCATAAAGGTGACGTCC 
 
CAAGTACATGTCAGCAGTGT 
 
96 
 
C226G 
 
ACGTTGGATGGGTACCATACTACCCCTTTC 
 
ACGTTGGATGTCCCAGTAAGCACTCTGTTC 
 
CTACCCCTTTCAGAGTCATATTGC 
 
100 
 
R230W 
 
ACGTTGGATGTTGTTTAGGGACCCCACAGG 
 
ACGTTGGATGACACCCATTGAAGCCTGGTC 
 
CCACAGGCTTTCAGTGACC 
 
80 
 
T312M 
 
ACGTTGGATGGGACAAGTCCAAATGGGAAG 
 
ACGTTGGATGATCGAAGACTGGCGTGAAAC 
 
agtcaAAATGGGAAGAAACGCTCC 
 
96 
 
Y349C 
 
ACGTTGGATGCTCAGACGATGGATTTCCCC 
 
ACGTTGGATGTATTGGGCATCTTTGGGTTG 
 
CATCAAACAGCAGACTTCGGCT 
 
100 
 
F404S 
 
ACGTTGGATGTGCTCTGGCTTATGGTGAGA 
 
ACGTTGGATGTGTGAGCCAAGAGTTCTATC 
 
ATGGTGAGAAGAATTTGACCT 
 
94 
 
R479C 
 
ACGTTGGATGTTCTTGTCATGGCACTGTGG 
 
ACGTTGGATGGGGACACTGCTTATATTCAC 
 
GCACTGTGGTTGCTCTC 
 
93 
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Sequenom PCR and primer extension reaction:  
PCR was performed to amplify the target DNA prior to extension primer binding. A 
uniplex PCR for each set of primer pairs from a multiplex design was initially 
performed to ensure a satisfactory product of the correct size.  PCR was performed in a 
10-μl reaction volume using a QIAGEN (Crawley, UK) PCR kit, with the 
concentrations per reaction as outlined in table 2.6. PCR was then performed by initial 
denaturation for 15 min at 95
o
C, followed by 45 cycles of denaturation at 95
 o
C for 20 
sec, annealing at 56
 o
C for 30 sec, and extension at 72
 o
C for 1 min, followed by a final 
extension at 72
 o
C for 3 min. The PCR products were then checked by running on a 2% 
gel as previously discussed to visualise PCR product bands and to ensure that there was 
no contamination. Multiplex PCR was carried out following successful uniplex assay 
for each SNPs. 5 µl of each PCR product was then loaded into a 384 well plate. 
Amplified products were genotyped using Sequenom iPLEX chemistry for MALDI-
TOF characterization of primer extension products, at the Sequenom MassARRAY 
facility located at the Institute of Genetic Medicine (Newcastle University, UK). Ten to 
fifteen percent of all samples were re-genotyped blind for each assay to ensure fidelity 
of genotyping (>99% for each SNP). The data was analysed by the MassARRAY reader 
mass spectrometer. A read-out as shown in figure 2.2 was obtained for each sample of 
the multiplex. 
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Table 2.6 Example of the PCR mixture for Sequenom genotyping 
Number of sample 1 52 Final 
concentration 
Sterile water 4.70 244.4 - 
10x buffer 1.25 65 1.25x 
Magnesium chloride (25mM) 0.65 33.8 1.63mM 
dNTPs (6.25mM each- total 
25mM) 
0.2 10.4 0.5mM(total) 
Primer mix (0.5 µM each-
forward/reverse primers) 
2 104.0 0.1 µM 
Hot Star Taq (5U/µl) 0.2 10.4 1 unit 
Total (µl) 9 468  
DNA  1  20ng/µl 
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A 
 
B 
 
Figure 2.2 Representative of results obtained from a Sequenom assay for one 
sample. 
This figure demonstrates the individual graphs for M89V(A) and T312M (B) 
genotyping. The coloured dotted lines indicate the expected position of peak if a 
particular allele is present.  (A) showed a heterozygote (M89A) which gives a peak at 
both points with a GA call. (B) showed only one peak at the expected position for 
normal variant homozygote, a CC call for T312M. 
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Figure 2.3 The basic principle of Sequenom IPLEX genotyping 
Following PCR amplification, the addition of Shrimp Alkaline Phosphatase (SAP) 
deactivates the remaining non-incorporated nucleotides in the reaction. Following a 
brief incubation, the primer extension mixture is added and the assays are terminated 
after a single base extension, by incorporating mass-modified terminators that allow 
mass separation of the SBE products.  
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2.2.7 Restriction Enzyme Digestion (RFLP) 
Restriction Fragment Length Polymorphism (RFLP) is a difference in homologous 
DNA sequences that can be detected by the presence of fragments of different lengths 
after digestion of the DNA samples with specific restriction enzyme. I used this 
genotyping technique to verify Y349C results obtained from Sequenom genotyping, 
which showed a significant percentage of rare variants among AAD patient (0.26%). 
In a typical case, the PCR products are digested with appropriate restriction 
endonuclease (RE), with the aid of Webcutter 2.0. Restriction enzymes that recognize 
and cut the sequence restrictions at the specific polymorphism/mutated point are 
selected. It was essential for the restriction site to be formed by one allele of the SNP 
but not on the other, so that there would be a difference in the length of PCR product 
between the wild type and the mutated PCR products.  However, Webcutter failed to 
identify any suitable RE for the SNP in Y349C, so I resorted to designing a 
“mismatched” primer for the rare variant 349C as suggested by SNP cutter 
(http://bioapp.psych.uic.edu/SNP_cutter.htm), a tool for SNP PCR-RFLP assay design. 
The SNP Cutter is a web-based application that batches and automates assay design for 
SNP genotyping using PCR-RFLP. When the SNP does not affect any restriction 
sequences, a "mismatched PCR-RFLP" can be used by introducing an artificial 
restriction enzyme site. This is achieved using a primer containing additional 
mismatched bases adjacent to the SNP site. The introduced mismatch can construct a 
restriction site in one of the allele sequences with the SNP site, as shown in table 2.7. 
Following PCR reaction, the PCR products were subjected to RE digestion. RE 
digestion was formed in 10µl digestion mixture containing 3µl of PCR product, 1µl of 
RE (PvuII) , 1µl NE buffer(1x)  and  5µl sterile water. The digestion mixture was 
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incubated at 37
o
C for 1 hour. The RE digestion products were then visualized by 
electrophoresis on a 2% agarose gel under UV light. 
 
2.2.8 Direct DNA sequencing  
The appropriate PCR primers for direct DNA sequencing of Y349C SNP was designed 
using the Primer 3 programme (table 2.8). The PCR product (20µl) was first run on a 3% 
agarose gel to ensure that it was the appropriately-sized PCR product. The DNA band 
was excised from the gel using a sterile scalpel under UV light and placed in a clean 
microcentrifuge tube. The size of the gel was minimised by removing extra agarose.  
The DNA was then purified and extracted using QIAquick gel extraction kit. 
Each sample was weighed and 3 volumes of buffer QG were added to 1 volume of gel 
(100mg/volume). The samples were incubated at 50
o
C for 10 minutes and each 
microcentrifuge tube was vortexed every 2-3 minutes during incubation until the gel 
slice had completely dissolved. The melted gel should be yellow in colour to indicate 
the correct pH (pH<7.5) to ensure good absorption of DNA to the QIAquick membrane.  
The yield of DNA fragment was then enhanced by adding 1 gel volume of isopropanol. 
The samples were then transferred to a QIAquick spin column with a collection tube 
and centrifuge for 1 minute to bind DNA. The flow-through was discarded and 0.5 ml 
of buffer QG was added to the spin column and centrifuge for another minute to remove 
all traces of agarose. The DNA was then washed with buffer PE, by incubating buffer 
PE with the DNA for 2-5 minutes before centrifugation. Once the flow-through was 
discarded, an additional centrifugation step at 10,000 x g for 1 minute was carried out. 
The QIAquick column was put in a clean microcentrifuge tube and 50ul of buffer EB  
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Table 2.7 demonstrates the oligonucleotide sequence and annealing temperature 
(Tm) used for the amplication of SNP sequence in Y349C. 
The restriction enzyme used to confirm the base changes (A to G) identified through 
Sequenom assay was PvuII. The DNA base with low case indicates the mismatched 
base adjacent to the SNP site whereas the nucleotide sequence highlighted in bold and 
italic text indicates the SNP site. The underlined DNA bases indicate the forward and 
reverse primers 
Forward primer 
(mismatch primer) 
GCATCAAACAGCAGACTTCaGCT 
 
Tm 63 
Reverse primer TTTATCTCGAGGGTGGATGC 
Tm 60 
Restriction 
Enzymes: 
PvuII 
Recognition 
sequence (forced 
restriction site) 
CAGCTG 
Fragment size wild type (A): 125 bp 
rare variant (G): 101 bp & 24 bp 
 
Base change A/G 
Allele sequences 
(SIAE_Y349C) 
 
TCCGTTGGCATCAAACAGCAGACTTCaGCT[A/G]TGTCCCC
AACCCAAAGATGCCCAATACTTTCATGGCTGTAGCTATG
GATCTCTGTGATAGAGACTCGCCTTTTGGCAGCATCCAC
CCTCGAGATAAAC 
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 (10mM Tris-Cl, pH 8.5) was added to the centre of the QIAquick membrane to elute 
DNA, and centrifuge for another minute at 10,000 x g. The DNA was then collected and 
the concentration was determined using Nanodrop spectrophotometer. The DNA was 
sent off to Eurofins MWG Operon’s DNA sequencing service with the recommended 
DNA and primer concentration. 
 
2.2.9 Statistical analysis  
2.2.9.1 Case-control association analysis 
Case control studies of SNPs were analysed using Fisher’s exact and Chi-squared tests, 
by means of 2x2 and 2x3 contingency tables respectively. Genotypes were checked for 
Hardy-Weinberg equilibrium (threshold P >0.05). Hardy–Weinberg equilibrium is the 
basic principle of population genetics to provide a baseline for measuring genetic 
change. It assumes that both allele and genotype frequencies in a population remain 
constant, a state known as the Hardy–Weinberg equilibrium, unless specific disturbing 
influences are introduced such as mutation, migration or natural selection. Deviation 
from this equilibrium in a control population indicates potential problems with the 
population structure or genotyping. The Hardy–Weinberg equation was calculated using 
SHEsis software (Shi & He 2005). Odds ratios (OR) are used to compare the relative 
odds of the occurrence of rare alleles/genotypes.  The 95% confidence interval (CI) is 
used to estimate the precision of the OR. A large CI indicates a low level of precision of 
the OR, whereas a small CI indicates a higher precision of the OR (Szumilas 2010). 
2.2.9.2 Power calculation 
The power to detect a relevant minor allelic OR for the SNP in a case control 
association study is based on the cohort size used and control allele frequency seen. I 
 77 
 
calculate the study power according to pooled case and/or control allele frequencies 
from studies previously published, using a one-sided significance level of 0.05 (α = 0.05) 
in a binomial model (Casagrande & Pike 1978). Power calculation was performed 
retrospectively using CaTS software (Skol et al. 2006). For CD226 variant association 
study, the study has 70% power to detect effects in the combined AAD cohorts, (α = 
0.05), with reference to the minor allele frequency established in the UK 1958 birth 
cohort controls (Hafler et al. 2009), by assuming the effect size (OR for allelic 
association) of 1.3.  For the SIAE variant association study,  a power estimation using 
the pooled case and control allele frequencies found by Surolia et al. (2.6% and 0.3%, 
respectively), showed that the study number used had 78% power to detect a similar 
sized effect (α=0.05). 
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Table 2.8 demonstrated the oligonucleotide sequence and annealing temperature 
(Tm) used for the direct sequencing of SNP in Y349C 
The underlined DNA base indicated the forward and reverse primer pairs where as 
nucleotide sequence highlighted in bold and small text indicate the SNP site. 
Forward primer      CATGGGATGAGAGGGACTGT 
Tm: 59.9
o
C 
GC%  55 
Reverse primer      CCCCAGCATACGTGACTCTT 
Tm: 60.1
o
C 
GC%  55 
Product size 467 bp 
Base change A/G 
Allele sequences 
(SIAE_Y349C) 
 
CATGGGATGAGAGGGACTGTTGCAGCTGTCTTTGGAGA
GACACTGCCACAACAGTAAGAAGCTCAGTAAATACGTG
TTGAATGAGCATTTAAATGCAATGAGAGAAGCAGAAGC
AGAGTCTGCCAGTGAAAAAGACTCCAGTGTGGGATTCT
GATACAATAAAATTAGCAATGTCTCTGCTTTCTAGTTAT
CTTCAGATTTGTCTAAGAAGAGCTCAGACGATGGATTTC
CCCAGATCCGTTGGCATCAAACAGCAGACTTCGGCTa/gT
GTCCCCAACCCAAAGATGCCCAATACTTTCATGGCTGTA
GCTATGGATCTCTGTGATAGAGACTCGCCTTTTGGCAGG
TATGATTGCTTCTTGGGCTTTGCATGAACAGTGTATGTTC
TTTGTAGTCTTTCACTCTGATGTTCACCGGTGAGGGGCA
ATTAGACTGAGGATTGGCACTTAAGAGTCACGTATGCTG
GGGTGTGCT 
 
 
 
 
 
 
 
 
 79 
 
2.3 Results 
2.3.1 CD226 (rs763361) association analysis 
Genotyping for rs763361 was carried out in 326 patients with AAD and 311 healthy 
controls. All genotypes were in Hardy-Weinberg equilibrium (p>0.05). The T allele of 
rs763361, encoding the CD226 307*Ser variant, was found in 289/622 (46.5%) of 
healthy control alleles. This finding is nearly identical to that reported in the UK 1958 
birth cohort controls of 47% (Hafler et al. 2009).
 
 In contrast, the T allele was found in 
329/652 (50.5%) of AAD alleles, compared to 46.5% of healthy controls; p=0.161, NS 
(table 2.8). 
Considering that CD226 307*Ser has been associated with many other autoimmune 
conditions, I re-analysed the AAD cohort according to whether the patient had isolated 
AAD or additional coexisting autoimmune conditions, namely autoimmune 
polyendocrinopathy type 2; APS2.  In the subjects with APS2, the rs763361 T allele 
was found in 197/366 (53.8%) of alleles, vs 46.5% of control alleles; p=0.030, Odds 
ratio 1.34 (5-95% CI 1.04-1.74). Individuals with isolated AAD showed no association 
at rs763361, with the T allele frequency being 132/286 (46.2%) compared to 46.5% in 
control alleles; p=0.94, NS. 
 
2.3.2 SIAE rare variants association studies 
Genotypes for the 9 SIAE SNPs were obtained for 378 patients with AAD and 387 
healthy controls.  Among the 761 subjects, I did not find any rare allele for the SIAE 
germline variants encoding W48X, C226G, R230W, Y349C, F404S and R479C (table 
2.9). One AAD patient was a heterozygous carrier of the codon 312*M (T312M) variant, 
but all controls were found to have the wild-type allele. A single heterozygous carrier of 
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the SIAE 196*F (C196F) allele was found amongst both the case and control cohorts. 
Similar to previously published study (Surolia et al. 2010), the common variant of SIAE, 
codon 89*V allele was present heterozygously in 12.1% and 12.0% of the patient and 
control cohorts, respectively. However, no codon 89*V homozygotes were found 
amongst control patients, whereas 2 AAD patients were 89*V homozygotes (p=0.242).  
All AAD patients who are either heterozygous carriers of the rare codon 312*M 
(T312M) and 196*F (C196F) variants, or the homozygous carriers of the codon 
89*V(M89V), had other associated autoimmune diseases in the spectrum of type-2 
autoimmune polyendocrinopathy syndrome (APS2). Among them, 3 had pernicious 
anaemia, 2 autoimmune hypothyroidism and 1 premature ovarian failure (table 2.10). 
In summary, taking into account all 9 alleles examined, 4/378 (1.06%) AAD patients 
and 1/387 (0.25%) healthy controls inherited SIAE genotypes that would be expected to 
lead to functionally detrimental consequences; odds ratio of 4.13 (95% confidence 
interval 0.44- 97.45; two-tailed p-value 0.212. NS). 
Verification of SIAE_Y349C results 
Following genotyping with Sequenom –iPLEX chemistry, the rare allele for the SIAE 
germline variant encoding Y349C was strongly positive among patients with AAD, 
with an odds ratio of 5.35(1.1-35.5) and  p- value of 0.019. Four patients were found to 
be homozygous carriers of the codon 349*C and 2 were heterozygous carriers. However, 
considering that allele 349*C is a rare allele and should have a MAF of <0.1, the rare 
349*C polymorphism found in the AAD cohort is not in Hardy-Weinberg equilibrium. 
Hence , I repeated the genotyping using an alternative technique to verify the results: 
restriction enzyme digestion (RFLP) and direct DNA sequencing. However, both 
methods consistently showed the absence of the rare 349*C allele (figure 2.5 & figure 
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2.6) and refuted the positive association between Y349C and AAD demonstrated by 
Sequenom-iPlex method. I repeated the genotyping of Y349C with the Sequenom 
method, using all positive samples previously shown and a few random negative 
samples. A completely different result was obtained showing 3 heterozygous 349*C 
carriers from previously negative samples.  
I explored the reasons for the false positive and inconsistent Y349C genotyping result 
obtained from Sequenom iPLEX. When I re-examined the primer design and the 
extensor primer seemed to have strong self- complementarity: 
CATCAAACAGCAGACTTCGGCT.  The primer design tool indeed inserted a sign 
signified strong hairpin warning (PWARN-H).  Hence, the Y349C results from 
Sequenom genotyping were disregarded in view of poor primer design. 
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Table 2.9 Genotype and allele data for CD226 Gly307Ser (rs763361) 
Rs763361 Genotypes P value Alleles 
P 
value 
Odds 
ratio 
  CC(%) TC(%) TT(%) 
 
(genotype) C(%) T(%)  (allele) 
(5-95% 
CI) 
All AAD 
82 
(25.2) 
159 
(48.8) 
85 
(26.1) 0.36 
323 
(49.5) 
329 
(50.5) 0.16 
1.17 
(0.94-
1.46) 
APS2 
41 
(22.4) 
87 
(47.5) 
55 
(30.1) 0.08 
169 
(46.2) 
197 
(53.8) 0.03 
1.34 
(1.04-
1.74) 
Isolated 
AD 
41 
(28.7) 
72 
(50.3) 
30 
(21.0) 0.97 
154 
(53.8) 
132 
(46.2) 0.94 
0.99 
(0.75-
1.31) 
Control 
90 
(28.9) 
153 
(49.2) 
68 
(21.9)   
333 
(53.5) 
289 
(46.5)     
 
Genotype and allele data for CD226 Gly307Ser (rs763361) in the UK AAD cohort, 
together with case-control analyses of the genotypes and alleles.   Probability values (P) 
are shown, with significant results highlighted in bold.   
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Figure 2.4. A representative allelic discrimination plot for CD226 (rs763361 ) 
genotyping using Taqman genotyping assay. 
There is a clear separation between the signals derived from allele X (C variant) or 
allele Y (T variant). Allele T of rs763361, encoding the CD226 307*Ser variant is 
shown in blue whereas the commoner C allele is shown in red. Lime green represents a 
mixture of the two alleles. 
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Table 2.10 Genotypes for SIAE variants in autoimmune disease cases and controls 
 Autoimmune Addison’s 
disease 
UK healthy controls 
Amino 
acid 
change 
Genotype 
(*) 
Rare 
allele/genotype 
frequency 
Genotype 
(*) 
Rare allele 
frequency 
p value 
W48X 0/0/370 0 0/0/373 0 - 
M89V 2/42/303 0.0058
†
 0/43/315 0 0.242 
C196F 0/1/374 0.0013 0/1/383 0.0013 - 
C226G 0/0/371 0 0/0/383 0 - 
R230W 0/0/375 0 0/0/386 0 - 
T312M 0/1/372 0.0013 0/0/385 0 0.492 
Y349C 0/0/360 0 0/0/381 0 - 
F404S 0/0/372 0 0/0/382 0 - 
R479C 0/0/358 0 0/0/362 0 - 
 
*Data presented as numbers of rare homozygote/heterozygote/common homozygote 
genotypes 
†Homozygous 89*V genotype  
 
 
 
 
 85 
 
 
Table 2.11 Clinical details of AAD patients with rare SIAE variants 
SIAE variants  Age at onset of 
AAD (yr) 
Associated autoimmune conditions 
M89V 
(homozygous) 
29 Pernicious anaemia 
M89V 
(homozygous) 
60 Pernicious anaemia, autoimmune 
hypothyroidism, premature ovarian 
failure 
C196F 83 Autoimmune hypothyroidism 
T312M 59 Pernicious anaemia 
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Figure 2.5 RFLP result for Y349C polymorphism 
The Y349C polymorphism was re-genotyped by PCR and digestion with the restriction 
enzyme PvuII. In the presence of 349*C allele, the enzyme will cut the 125 bp PCR 
product into 101 and 24 bp fragments. 100 bp DNA ladder was used.  Land A-F showed 
single bands at around 125 bp, suggesting the absence of rare 349*C allele. 
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Figure 2.6 Direct sequencing of Y349C variant using reverse primer.  
DNA sequence chromatograms (antisense strand) showing the T allel (A allel in the 
sense sequence) at position 378, at the Y349C variant 
 
 
 
 
 
 
 
 
Normal T variant (antisense strand) 
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2.4 Discussion 
Autoimmune Addison’disease  is a non-Mendelian polygenic disease and numerous loci 
might underlie this disorder.  Although most of the susceptibility alleles identified had 
modest disease effects, with Odds ratios ranging from 1.1 to 2.0 (Mitchell & Pearce 
2012), the magnitude of their contributory risk could be significant as they appear quite 
frequently in the population.  However, the genetic analysis of this rare condition has 
lagged behind that of other autoimmune diseases, largely due to the rarity of this 
condition, making it difficult to assemble a large patient cohort without international 
collaboration. The relatively small numbers of families with multiple affected AAD 
individuals also preclude linkage analysis which has good power. Hence, I carried out 
these candidate gene studies as part of my supervisor’s team continuous effort to 
uncover more susceptibility loci for AAD in order to understand the disease 
pathogenesis better. 
The 307*Ser allele of CD226 is a presumed aetiological variant that contributes to the 
susceptibility of numerous autoimmune conditions. A meta-analysis of 7876 cases and 
8558 controls from 7 published studies established this CD226 variant as contributing to 
the aetiology of multiple autoimmune diseases, including type 1 diabetes and 
Graves’disease (Qiu et al.2013). In this study, I examined its role in AAD for the first 
time. While considering all patients with AAD, there was no association at CD226. 
However, when the subgroup with APS2 were analysed, there was modest evidence of 
association (p=0.030).  
The association of this CD226 variant with APS2, but not in isolated AAD, is likely to 
suggest that the associated autoimmune conditions that define APS2 have the same 
genetic susceptibility as when found in isolation, such as autoimmune thyroid disease 
and type 1 diabetes (Hafler et al. 2009). Interestingly, the majority of our APS2 patients 
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actually have autoimmune hypothyroidism (AH) as the most frequent co-existing 
autoimmune disease (in 60% of our APS2 cohort), suggesting a probable association 
between AH and 307*Ser at CD226. This is in contrast with the study of Hafler et al. 
which demonstrated no association between this CD226 variant and a large cohort of 
Hashimoto’s thyroiditis patients (Hafler et al. 2009).  
I learned from the previous studies that the susceptibility genes contributing to AAD 
aetiology, including MHC, PTPN22, CTLA4, CLEC16A, CIITA, and PDL1 have 
predominantly a role in immune system functioning, particularly related to modulation 
of T cell receptor signalling, such as in PTPN22 , or at the cell-surface with a 
costimulatory role eg. CTLA4 and PDL1. Similarly, MHC, CIITA have roles in 
subserving antigen presentation to the T cell receptor, forming components in the 
afferent limb of the adaptive immune response. Thus, CD226, as a costimulatory T 
lymphocyte molecule was an excellent candidate as a contributor to many autoimmune 
diseases including AAD. 
This is the first study demonstrating the role of CD226 variation in autoimmune 
Addison’s disease. It showed that the 307*Ser allele contributes to APS2 susceptibility, 
but its effects in isolated AAD have yet to be confirmed. However, the main weakness 
of this study is the small cohort size, due to the rarity of this disease. In fact, the 
effective size of the association between CD226 variant in several other autoimmune 
conditions at CD226 307*Ser has been weak, with odds ratios for the allelic 
associations typically being between 1.1 and 1.3. Thus, given the relatively small 
collection of AAD patients, this study may have been underpowered to detect an effect, 
particularly if the actual contribution to AAD susceptibility is at the lower end of this 
range. Given the current cohort sizes, this study would have had 70% power to detect an 
effect of odds ratio 1.3 (at the 0.05 level), thus it is possible that the results of our study 
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for all-ADD (both isolated AAD and APS2) give a false-negative.  Nevertheless, it is 
equally possible that there is simply no contribution of CD226 307*Ser to AAD 
susceptibility, given the almost identical allele frequencies between isolated AAD 
patients and healthy controls (46.2% vs 46.5%). Further studies with larger patient 
cohorts are required to solve this question. 
While genome wide association studies have identified many common genetic variants 
that are linked to autoimmune disease, they would probably lack the power to detect 
rare variants that could be implicated in the disease. Rare variants are arbitrarily defined 
as having a frequency below 1% in the population (Cohen et al. 2004).  It has not been 
the focus of genetic studies in autoimmune diseases, largely due to the requirement for 
labour-intensive deep sequencing and functional testing for each rare variant.  I 
explored the hypothesis that rare SIAE variants would be associated with AAD, one of 
the uncommon autoimmune conditions via candidate gene approach. I demonstrated the 
presence of 2 codon 89*V homozygotes, two heterozygous carried of the 312*M and 
196* F alleles, respectively in the AAD cohort. This is in keeping with the Surolia et al 
study, where they indicated T312M and C196M to be the most frequent rare variants 
found (frequency>0.1%; n= 1571), as shown in table 2.4. Nevertheless, these 
associations were not significantly different from healthy control genotypes. Thus, our 
findings extend the negative study of Hunt et al. who showed no differences for nine of 
the SIAE gene rare variants (including M89V but not T312M) in cohorts of the 
commoner autoimmune and inflammatory conditions, such as type 1 diabetes, atopic 
eczema, celiac disease, Graves’ disease, and Hashimoto thyroiditis (Hunt et al. 2011). 
However, this large cohort of nearly 67,000 subjects did not include patients with the 
rarer condition of AAD. It is also noteworthy that the association analysis was 
calculated using the statistical method generally used for common genetic variants, 
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which might not be accurate and powerful in multiple rare variant model (Cooper & 
Shendure 2011). 
While our study had good power to replicate findings of a similar magnitude to those 
previously seen in other autoimmune conditions (OR 8.6) (Surolia et al. 2010), our 
analysis has been underpowered to detect a more subtle genetic effect, such as is more 
frequently seen for commoner autoimmune disease susceptibility alleles. In fact, the 
same research team who pioneered works related to SIAE rare variants in autoimmune 
diseases has recently replicated their study and reported that the M89V common variant 
was erroneously considered to be catalytically defective (Chellappa et al. 2013). 
Following exclusion of M89V from the analysis, there was still a strong but relatively 
weaker association between the confirmed catalytically defective rare variants and 
various autoimmune diseases (OR of 3.51). Hence, we cannot exclude that a future 
analysis of an enlarged AAD cohort or a family-based genetic association study may 
cast further light on this question. However, the parameters for declaring significance in 
studies of rare genetic variants are currently not well defined, given the low frequency 
of rare variants (Cooper & Shendure 2011). More importantly, the key attribute of 
reproducibility has not been fulfilled for SIAE variants in autoimmune diseases to date.
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Chapter 3.  Re-establishment of 
adrenocortical steroidogenesis in 
autoimmune Addison’s disease 
with parenteral ACTH1-24 therapy 
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3.1 Background 
Adrenocorticotropic hormone (ACTH1-39) is the master regulator of adrenal 
proliferation and steroidogenesis. ACTH secretion exhibits diurnal variation and starts 
during sleep, at around 03.00 hours with a series of peaks of approximately 40 minutes 
periodicity, for 8-10 hours (Veldhuis et al.1990, Horrocks et al.1990). The circulating 
ACTH levels reach their nadir in the afternoon and evening in healthy people. This 
diurnal and pulsatile pattern of ACTH secretion is essential to maintaining normal 
adrenal cell mass and steroidogenic function.  
Disruption to ACTH circulating levels and secretion patterns are implicated in many 
clinical conditions. Excessive ACTH secretion from the pituitary gland in Cushing’s 
disease leads to adrenal gland hyperplasia and unwarranted glucocorticoid production. 
In a complementary fashion, ACTH is suppressed during chronic exogenous steroid 
therapy (i.e.long term oral prednisolone treatment) leading to adrenal atrophy and 
functional adrenal failure. Independent lines of evidence from animal studies also 
support the essential roles of ACTH. Mice homozygously deleted for the pro-
opiomelanocortin gene (Pomc, containing the ACTH peptide) have small adrenals and 
reduced steroid production (Coll et al. 2004, Karpac et al. 2008). Interestingly, daily 
synthetic ACTH1-24 (synacthen) injections for 10 days of these Pomc-/- mice was shown 
to result in the regeneration of the adrenal mass, as well as the steroidogenic function 
(Coll et al.2004).   
As previously mentioned in chapter 1, adrenocortical tissue is highly plastic owing to 
the presence of adrenocortical progenitor or stem cells (ACSCs), which continuously 
repopulate the adrenal cortex in an ACTH-responsive fashion. In autoimmune 
Addison’s disease (AAD), an autoimmune response targeted at the key steroidogenic 
enzymes, mainly 21-hydroxylase, results in the impairment of adrenal steroidogenesis. 
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This is associated with a mixed T and B cell infiltrate leading to destruction of 
differentiated adrenocortical cells. However, various studies using 
immunocytochemistry techniques have suggested that the adrenocortical progenitor 
cells do not express the steroidogenic enzymes, which are the primary target of the 
autoimmune process. Hence, the ACSCs are likely to be spared from the immune attack. 
The clinical diagnosis of AAD is commonly preceded by a ‘pre-clinical’ stage in which 
elevated ACTH is noted without adrenal hypofunction. A case report has shown that 
AAD can take up to 9 years to present (Torrejón et al. 2007). During the ‘preclinical 
AAD’ phase, the fall in circulating corticosteroid levels from immune-mediated 
steroidogenic failure is compensated by an increase  in pituitary ACTH secretion, 
leading to increased ACTH-driven ACSC proliferation and differentiation, with 
compensatory adrenocortical regeneration (Betterle et al. 2002). Once the individual has 
been diagnosed with AAD, administration of exogenous steroid will lead to an 
iatrogenic suppression of ACTH with subsequent inhibition of ACTH-driven ACSC 
proliferation and differentiation. This results in a rapid shift of the balance towards 
adrenal destruction and steroidogenic failure. In view that ACSC is likely to be spared 
from the autoimmune attack, this group of cells might stay dormant following the 
suppression of their trophic hormone, the pituitary ACTH. Nonetheless, spontaneous 
recovery of adrenal function had been reported following a period of established AAD. 
A spontaneous partial adrenal recovery was reported in three men who suffered from 
AAD between 7 and 37 years (Smans & Zelissen 2008, Chakera & Vaidya 2012, Baxter 
et al. 2013). A full remission was also recorded in patients who had subclinical adrenal 
insufficiency with positive adrenal antibodies (Betterle et al. 2002).These published 
case reports unequivocally suggest that permanent destruction of ACSC or adrenal 
function is not universal in AAD. With this in mind, appropriate manipulation of ACSC 
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in vivo might have the potential to lead to adrenal regeneration in man, especially when 
the adrenocortical stem cells could be preserved in treated AAD patients.  
The aim of this study is to investigate if a therapeutic regimen of parenteral 
subcutaneous tetracosactide (ACTH1-24) therapy can revive adrenocortical stem cell 
function and allow re-establishment of adrenocortical steroidogenesis.  
 
3.2 Methods 
3.2.1 Study participants 
Thirteen patients between the ages of 16 and 65 years who had autoimmune Addison’s 
disease (AAD) for more than 1 year were recruited either from the endocrine clinics of 
the Newcastle upon Tyne NHS hospitals (n=12), or self-referred following an ethics 
committee agreed advert in the national Addison’s disease self-help group (ADSHG) 
quarterly newsletter (n=1). A full list of eligibility criteria are depicted in table 3.1. We 
identified 16 patients for possible inclusion in the study. Three did not meet the 
inclusion criteria, with 2 not having autoimmune primary adrenal failure (two with 
pituitary disease), and 1 with asthma. The study was registered as NCT01371526 at 
clinicaltrials.gov. Ethical approval was granted by the Northeast Research Ethics 
Committee (reference 10/H0903/14). 
 
3.2.2 Study design and treatment regimen 
The study is an open-label trial of synthetic ACTH analogue (ACTH1-24; tetracosactrin- 
‘Synacthen’) to stimulate adrenocortical function in adults with established AAD. 
Participants were recruited between September 2010 and April 2012. Written informed 
consent was obtained during the screening visit and participants underwent a seven-day 
run-in phase of the study, including a baseline assessment to confirm their eligibility 
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and 2 education sessions to learn how to self-administer subcutaneous synacthen. A 
refresher course on the indications for emergency parenteral glucocorticoid therapy was 
also given. The study ran for two parts, with each part lasting for 10 weeks (table 3.2). 
During part I of the study, participants self-administered 1mg depot synacthen 
(Synacthen® depot ampoule 1mg/ml; Alliance Pharma plc, Wiltshire UK) 
subcutaneously on alternate days. According to the product information sheet, the 
plasma concentrations of ACTH are maintained between 200 to 300pg/ml for 12 hours 
following 1 mg of intramuscular depot synacthen injection. The serum cortisol levels 
increase in a parallel fashion and the highest values are recorded during the first 8 to 12 
hours after the injection. The increased cortisol levels are maintained for up to 24 hours 
and return to basal levels after around 36-48 hours. Hence, this will achieve a 24 to 36-
hour sustained peak of ACTH with the aim of stimulating ACSCs back into active 
proliferation.  
Patients were reviewed at 7 days and then 2 weekly during phase 1 for assessment of 
tolerability and wellbeing. Formal re-testing of adrenal function occurred at 5 and 10 
weeks. If there was improvement in serum cortisol levels, participants would be 
maintained on the same regimen. However, if there was no improvement in adrenal 
function at 10 weeks, participants would be invited to take part in phase II of the study. 
In phase II, participants were randomly allocated to either continuous 24h subcutaneous 
infusion of synacthen (10µg/hr), or 12h synacthen with 30 minute 10µg boluses each hr, 
from midnight to midday. Intravenous bolus doses of synacthen above 5 µg are known 
to provide a close to maximal adrenal cortisol response (Dickstein et al. 1991).  
The randomisation was executed by a research nurse using sequentially opened, pre-
ordered sealed envelopes that contained randomly generated allocations, which was 
then verified by another research nurse. Allocation concealment was maintained 
throughout the study.  I programmed the Infusion pumps (OmniPoD; Ypsomed UK) at 
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the start of the phase II study and participants replenished the reservoir with synacthen 
every third day.  
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Table  3.1 Full eligibility criteriaFull eligibility criteria 
 
Inclusion criteria 
 Aged between 16 and 65 years  
 Established adrenocortical failure, as judged by a basal cortisol of less than 
100nmol/l or peak ACTH-stimulated cortisol response of less than 300nmol/l 
that was established a minimum of 12 months previously and persists at run-in 
assessments 
 Confirmation of primary origin of adrenal failure (basal ACTH level >55ng/L) 
 Normal or atrophic adrenals on cross-sectional imaging (if performed): 
compatible with autoimmune Addison’s disease 
 If female, willing to take secure contraceptive measures for the duration of the 
study, and for 3 months following the last synacthen dose.  
 Willingness to travel to Newcastle CRF for study 
 Willingness to attend education sessions about indications for parenteral 
glucocorticoid administration and technique of administration 
Exclusion criteria 
 Significant cardio-respiratory, chronic renal or non-autoimmune liver disease; 
malignancy 
 Asthma, current infectious disease, recent live vaccination, acute psychosis, 
peptic ulcer disease 
 Pregnancy, breastfeeding or plan for pregnancy within 9 months 
 Known non-autoimmune cause for adrenal failure (haemorrhage, 
adrenoleukodystrophy etc.) 
 Known hypersensitivity or allergy to Synacthen (ACTH1-24) 
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Figure 3.1 Study flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
3.2.3 Objective outcome measures and assessments 
Following baseline testing, outcome measurements were made at weeks 5, 10, 15 and 
20. All of these assessments were made after 36-42 hrs of withdrawal from regular 
steroid replacement therapy during which participants were admitted to the Clinical 
Research Facility. These measurements included baseline aldosterone, cortisol, 
dehydroepiandrosterone sulphate (DHEAS), 17-hydroxyprogesterone, androstenedione, 
plasma ACTH, plasma renin activity, plasma metanephrine and normetanephrine, 21-
hydroxylase antibodies, and overnight urinary steroids and metabolites. An ACTH-
stimulation test (250g ACTH1-24, with cortisol measured at 30 and 60min) was then 
performed starting between 08.30 and 09.00hrs. All cortisol results in the text and 
figures are the peak concentration of the 3 timepoints during each test. Two of the 
outcome assessments were delayed by 1 and 3 weeks, due to participants having 
forgotten to omit steroid medication and unforeseen travel commitments, respectively. 
For participants who achieved the primary end point (a peak cortisol >400 nmol/l), 
steroid replacement therapy was judiciously titrated down to produce maximal adrenal 
stimulation, without compromising patient wellbeing. Patients were reviewed every 4-6 
weeks for optimisation and down-titration of their steroid dosage. Synacthen treatment 
was also weaned off over 8 to 10 weeks once glucocorticoid replacement was stopped 
with regular review of participant wellbeing.  Throughout both phases of the study, 
patients were reviewed every 2 weeks to ensure their general wellbeing and tolerance to 
the treatment, including blood pressure and serum electrolytes measurements. 
Participants also have 24 hour access to the research team via mobile phone for advice 
or assessment in case of illness. 
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3.2.4 Methods for objective outcome measurements 
3.2.4.1 Hormonal and biochemical assessments 
Blood samples were taken and sent to the Biochemistry laboratories at the Royal 
Victoria Infirmary, Newcastle upon Tyne on the day of the assessment. Details of the 
assays used for each assessment were given by a biochemical scientist working at the 
laboratory. I entered the results into clinical record forms which were then verified by 
another clinical investigator. 
Serum cortisol measurements were made by a competitive chemoluminescent 
immunoassay on a Centaur platform (Siemens, UK), with a limit of detection (LD) of 
25nmol/l (0.91µg/dl). Serum aldosterone was measured using a solid-phase 
radioimmunoassay (DPC coat-a-count kit), with a limit of detection (LD) of 70 pmol/l. 
Serum DHEAS was assayed by solid-phase competitive chemoluminescence on an 
Immulite platform (Siemens) with a limit of detection (LD) of 0.1 µmol/l. 
Immunometric ‘sandwich’assay using chemiluminescent detection technique  (DPC 
Immulite) was used to measure ACTH. The normal reference range is 10-55 ng/L. 
Androstenedione was assayed by solid-phase competitive chemoluminescence on an 
DPC Immulite platform with a limit of detection (LD) of 1.05 nmol/L.  
On the other hand, plasma renin activity was measured indirectly using the DiaSorin 
assay.  This assay measured the rate of angiotensin-1 production from angiotensinogen 
by renin in patients’ samples. Angiotensin-1 levels were subsequently measured by 
radioimmunoassay with values expressed as the amount of angiotensin-1 produced per 
hour, which was inversely related to the amount of renin present in the sample.  
 Plasma metanephrines were first extracted using rapid, hydrophilic interaction liquid 
chromatography to isolate and concentrate the low femtomolar concentrations of free 
metanephrines in plasma into a purified low volume form.   
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Plasma metanephrine concentration was also measured as part of the biochemical 
assessment for adrenal steroidogenic function. Glucocorticoid is known to upregulate 
expression of the phenylethanolamine N-methyltransferase (PNMT) gene in adrenal 
chromaffin cells, which then catalyses the methylation of noradrenaline to adrenaline 
(Evinger et al. 1992). Hence, a patient with adrenal insufficiency usually has 
undetectable metanephrine level. In light of adrenal medulla being in close proximity to 
the adrenal cortex, which has a rich vascular supply, even a minimal rise in cortisol 
production could potentially result in a significant rise in plasma metanephrine levels. 
Hence, plasma metanephrine was measured as a potential marker to detect early 
steroidogenesis. The plasma metanephrine level was measured using a tandem 
quadrupole mass spectrometer with the limit of detection set at 40. 
 
3.2.4.2 Serum 21-hydroxylase autoantibodies 
Serum samples were saved and stored in a -80
o
C freezer at each outcome assessment. 
Aliquots of serum samples (5mls) were sent to the FIRS lab at Cardiff for assay of 21-
hydroxylase antibodies within 2 years of collection. Serum 21-hydroxylase antibodies 
were measured by immunoprecipitation of radiolabelled (
125
I) recombinant in vitro 
translated 21-hydroxylase protein (RSR ltd. Cardiff, UK), as described previously 
(Tanaka et al. 1997). The results are expressed as arbitrary units according to the kit 
manufacturer’s instructions. 
 
3.2.4.3 Urine metabolites 
Urine samples were collected for 16-24 hours at each outcome assessment, following 
36-42 hours of withdrawal from regular steroid replacement therapy. Urine samples 
were then stored at -80
o
C freezer before being sent to the Centre for Diabetes and 
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Metabolism (CEDAM) at Birmingham for analysis, which was carried out within 2 
years of collection. Measurement of urinary steroid metabolite excretion was carried out 
by using gas chromatography/mass spectrometry (GC/MS). A detailed description of 
this methodology has been published previously by Arlt and colleagues (Arlt et al.2011). 
In summary, free and conjugated steroids were extracted from 1 ml urine by solid-phase 
extraction. GC/MS was carried out on an Agilent 5973 instrument operating in selected-
ion-monitoring (SIM) mode to achieve sensitive and specific detection and 
quantification of steroid metabolites. There were 32 steroid metabolites selected by 
CEDAM, Birmingham to include important representatives of steroid groups such as 
androgen metabolites, glucocorticoid metabolites, mineralocorticoid metabolites, and 
3β-hydroxy-Δ5 steroid precursors, as shown in figure 3.2. 
 
 
 
 104 
 
 
 
 
 
 105 
 
Figure 3.2  Schematic representation of adrenal steroidogenesis and 24 hour 
urinary steroid metabolite excretion in healthy people 
 (Extracted from Arlt et al. 2011)  
A.  Schematic representation of  adrenal steroidogenesis depicting the major 
precursors of adrenocortical steroid synthesis, including  the mineralocorticoid 
aldosterone (dark green) and its precursors (light green);  glucocorticoid 
precursors (yellow), the active glucocorticoid cortisol (orange);  its metabolite 
cortisone  and the adrenal androgens and their precursors (light blue).  
B. Representative of the 24-h urinary steroid metabolite excretion in healthy 
controls (n = 88) (Arlt et al. 2011). Color coding of steroid metabolites mirrors 
that were used for depicting the major adrenal corticosteroid classes in A.  
[CYP, Cytochrome P450; HSD, hydroxysteroid dehydrogenase; DHT, 5α-
dihydrotestosterone] 
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3.2.5 Subjective outcome measures- Quality of Life assessments 
Subjective assessments of physical and emotional functioning were measured at 
baseline and at each outcome assessment. The short form 36 (SF-36) health survey 
questionnaire (version 2), the Addison’s disease specific quality-of-life questionnaire, 
(AddiQoL; version2 ) and a visual analogue scale wellbeing questionnaire were used.  
 
3.2.5.1  SF-36 health survey questionnaire (version 2)  
The SF-36 health survey questionnaire (Ware  & Sherbourne 1992) consists of eight 
domains: physical functioning, (PF), role functioning physical, (RP), bodily pain (BP), 
general health perception (GH), vitality (energy and fatigue, VT), social functioning, 
(SF), role functioning emotional (RE) and mental health (MH). Psychometrically based 
physical and mental health summary measures are also included in the analysis. The 
total domain scores range from 0 to 100, with higher values denoting better subjective 
health status. The scores were then converted using norm-based scoring, which employs 
a linear T-score transformation with mean = 50 and standard deviation = 10, to make it 
possible to meaningfully compare scores for the eight-scale profile and the physical and 
mental summary measures in the same graph.  
 
3.2.5.2  Addison’s disease specific quality-of-life questionnaire (AddiQoL) 
AddQoL(version 2) (Oksnes et al. 2012) is an Addison's disease-specific questionnaire 
comprising 30 questions that quantify altered functional and emotional status in 
Addison’s patients. The total score ranges from 30-120, with a higher score indicating 
better quality of life. The questionnaire is included in the appendices. 
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3.2.5.3 Visual analogue scale (VAS) 
In addition, a concise questionnaire comprising 10 visual analogue scales (VAS) was 
developed to assess changes in the subjective functional and emotional health of all 
AAD participants’ following treatment at each outcome assessments (figure 3.3). The 
VAS questionnaire was validated using the Pearson’s coefficient correlation to compare 
the correlation between VAS wellbeing test with SF-36 and AddiQoL assessments. 
 
3.2.6 Statistical analysis 
The differences between baseline and outcome assessments (10 or 20 weeks) with 
respect to participants’ quality-of-life and 21-hydroxylase antibody titre were assessed 
using paired-T test.  Wilcoxon ranked sign test was used if normality was not 
demonstrated. All probability values shown are two-sided, except where stated.  
One-tailed paired T test was used to examine the mean difference between stimulated 
and baseline serum cortisol concentration, performed at 30 and 60 minutes respectively 
following ACTH1-24 administration. The data was gathered from both week-10 and 
week-20 outcome assessments. One-tailed paired T test was also used to assess the 
ability of various biochemical markers in detecting adrenal steroidogenesis. Statistical 
analysis was performed using Minitab 6. 
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Figure 3.3 A representation of the visual analogue scale (VAS) wellbeing 
questionnaire used in this study 
VAS questionnaire comprises 10 questions testing the psychometric domains commonly 
affected in AAD. It is expressed on a linear scale with a horizontal line, 100mm in 
length and anchored by word descriptors at each end. The participants marked the point 
that they felt represented their perception of their current state. The score was then 
measured in centimetres from the left side of the line to the point that was marked by 
the patient. 
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3.3 Results 
3.3.1 Baseline characteristics 
Thirteen subjects (11 females and 2 males), with a mean age of 39 years (range 16-65) 
were enrolled in the study. Twelve participants completed part I of the study (to 10 
weeks), with 10 participants going on to complete the full protocol to 20 weeks. One 
male participant withdrew following the week 5 assessment owing to pain at injection 
sites. Baseline characteristics are shown in table 3.2 and the steroid replacement 
regimens of participants at study entry is depicted in table 3.3. 
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Table 3.2. Patient baseline characteristics 
P ID Sex; 
age (yr) 
Time since 
diagnosis of 
AAD (yr) 
Peak  serum 
cortisol 
(nmol/l)
a
 
Plasma 
ACTH 
(10-55 ng/L) 
21-Hydroxylase 
antibody  
(<1 U/mL) 
Associated 
autoimmunity 
Oral steroid 
regimen  
(dosage) 
Previous 
adrenal 
crisis 
01 F; 65 12 <24 828 3.1 HT HC,FC Yes 
02 F; 43 8 219 225 6.3 HT PD, FC No 
03 F; 44 6 <24 >1250 169.8 HT HC,FC Yes 
04 M; 46 19 <24 417 2.3 Nil HC,FC Yes 
05 F; 23 8 <24 752 0.3 HT HC,FC No 
06 F; 36 4 171 174 27.7 HT PD,FC No 
07 F; 16 2 <24 1080 5.1 Nil HC,FC Yes 
08 M; 45 3 <24 610 12.3 T1DM HC,FC No 
09 F; 54 1.5 30 >1250 617.3 Nil HC,FC Yes 
10 F; 24 6 <24 805 3072.7 T1DM HC,FC Yes 
11 F; 48 6 32 645 1607 HT HC,FC No 
12 F; 35 1 <24 550 73 Nil HC,FC Yes 
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13 F; 27 1 <24 1000 101 Nil HC,FC Yes 
 
Table 3.2  legend 
F, female; M, male; HC, hydrocortisone;  PD, prednisolone;  FC, fludrocortisone; HT, hypothyroidism; T1DM, type 1 diabetes mellitus 
a
Reference range for serum cortisol response after 250µg ACTH1-24 is greater than 550 nmol/L. To convert from nmol/L to µg/dL divide by 
27·6. 
b
Reference range for morning plasma ACTH is 10-55 ng/L. 
cReference range for serum 21-hydroxylase antibodies is less than 1·0 U/mL. 
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Table 3.3. Steroid replacement regimens of participants at study entry 
 
Participant Glucocorticoid  (daily dosage, 
mg) 
 Fludrocortisone (daily dosage, 
µg) 
01 Hydrocortisone (25) 100 
02 Prednisolone (5) 200 
03 Hydrocortisone (15) 100 
04 Hydrocortisone (17.5) 100 
05 Hydrocortisone (17.5) 150 
06 Prednisolone (6) 150 
07 Hydrocortisone (15) 100/200 alternate days 
08 Hydrocortisone (20) 100 
09 Hydrocortisone (17.5) 150 
10 Hydrocortisone (17.5) 150/100 alternate days 
11 Hydrocortisone (20) 100 
12 Hydrocortisone (20) 100 
13 Hydrocortisone (25) 150 
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3.3.2 Adrenal steroidogenic function  
During the screening visit, nine of the 13 participants had undetectable ACTH-
stimulated peak serum cortisol concentration. Four of them had detectable cortisol 
levels (≥25nmol/l) with 2 participants (subject 02 and 06) demonstrated 
concentrations of 219 nmol/l and 171 nmol/l, respectively (table 3.2). After 10 and 
20 weeks of treatment with synacthen, ten of the twelve participants had a peak 
serum cortisol concentration that remained below 100 nmol/l (figure 3.4A). Similarly, 
the same group of participants had serum aldosterone levels below the threshold for 
detection (figure 3.4B). In contrast, participants 02 and 06 showed an increase in 
serum cortisol concentration by week 5. Nevertheless, serum aldosterone only started 
to rise above the threshold for detection at week 20 and week 40 for patient 02 and 
06, respectively. 
The response of adrenal androgen towards synacthen therapy was quite variable. 
Serum 17-α hydroxyprogesterone (17-α OHP) was detectable in all male participants, 
ranging between 1.9-3.8 nmol/L (normal range: 1-14 nmol/L) but no significant 
changes were observed throughout the study. Four female patients (including one 
post-menopausal woman) had detectable 17-α OHP levels at baseline (range 1.1-
6.5nmol/L, mean 1.7). Two of them (02 & 06) demonstrated peak serum17-α OHP 
concentration at 1.3X above the upper limit of the normal range following synacthen 
therapy (figure 3.5A). However, no significant changes were seen in the remaining 
seven female participants who had serum 17-α OHP below the limit of detection (<1 
nmol/L). 
Another adrenal androgen precursor, serum androstenedione was detectable in six 
participants at baseline. These include 2 males and 3 female participants who had 
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detectable cortisol level at baseline assessment. The serum androstenedione level 
rose progressively in patients 02 and 06, with more than a threefold rise at week -20 
and week-60 respectively (figure 3.5B). Serum dehydroepiandrosterone sulphate 
(DHEAS) was detectable in the male participants but no significant changes were 
shown throughout the study. The rest of the participants had either undetectable 
DHEAS concentration or level below the reference range (1-7 µmol/l). However, the 
DHEAS concentration in participant 02 showed a gradual rise into the reference 
range (>1.0µmol/l) by week 104 (figure 3.6A). 
Interestingly, participants 02 and 06 showed a gradual rise in plasma metanephrine 
concentration and achieved a 5-fold and 3-fold rise in the peak plasma metanephrine 
levels respectively (figure 3.6B). However, it was found to be undetectable or below 
the normal reference (80-510 pmol/L) in 10 of the 13 participants at baseline 
(including subject 02). No sustainable increment was seen in the three remaining 
participants who had normal plasma metanephrine levels at baseline (range 86-129). 
Statistical analysis using a paired T-test (one-tailed test with mean difference >0) 
was carried out to compare the sensitivity of each hormonal and biochemical marker 
for adrenal steroidogenesis. A short synacthen test is the standard assessment for 
adrenal function and the study protocol measured serum cortisol concentration at 
both 30 and 60 minutes post ACTH1-24 stimulation. These results suggest that 
stimulated cortisol levels at 60 minutes is more sensitive (60 minutes vs 30 minutes: 
p-value 0.012 vs 0.018) in detecting a rise in serum cortisol concentration following 
250ug ACTH1-24 administration, compared to a 30-minute cortisol level (table 3.4). 
Using a similar analytical method, serum 17 α-OHP (p=0.03) was found to be a 
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better predictor for the recovery of adrenal function, as it is more sensitive in 
detecting small increments in adrenal androgen concentration (P<0.05) (table 3.4) . 
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Figure 3.4 Longitudinal course of serum cortisol and aldosterone 
concentrations in autoimmune Addison’s disease patients during and after 
tetracosactide (ACTH1-24) therapy. 
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Figure 3.4 Panel A.  Serum cortisol and all other steroid hormone measurements 
were made following 36 to 42 hours of withdrawal from regular glucocorticoid and 
fludrocortisone replacement therapy. For each timepoint we recorded the highest 
serum cortisol observed during a short tetracosactide test (250 µg i.m., with blood 
sampling at baseline, 30 and 60 min after injection). The normal response to this 
stimulus is a peak cortisol concentration over 550nmol/L. The limit of assay 
detection (LD) was 25nmol/L shown as the shaded horizontal area.  
Panel B.  Serum aldosterone concentrations. The reference range for recumbent 
serum aldosterone is 100-450 pmol/L, with a limit of detection (LD) of 70 pmol/l, 
shown as the shaded horizontal area. Several patients’ data are superimposed on this 
limit of detection line.  
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Figure 3.5 Longitudinal course of serum 17-α hydroxyprogesterone and 
androstenedione concentrations in autoimmune Addison’s disease patients 
during and after tetracosactide (ACTH1-24) therapy. 
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Figure 3.5 Panel A.  Serum 17-α hydroxyprogesterone (17-α OHP) concentrations. 
The reference range for recumbent serum aldosterone is 0-14nmol/L, with a limit of 
detection (LD) of 1 nmol/L, shown as the shaded horizontal area. Several patients’ 
data are superimposed on this limit of detection line.  
Panel B. Serum androstenedione concentrations. The female reference range is 1·2 
to 14·3 nmol/L and the male reference range is 1·4 to 9·1 nmol/L. The limit of 
detection (LD) of 1.05 nmol/L, shown as the shaded horizontal area. Several patients’ 
data are superimposed on this limit of detection line.  
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Figure 3.6 Longitudinal course of serum DHEAS and plasma metanephrine 
concentrations in autoimmune Addison’s disease patients during and after 
tetracosactide (ACTH1-24) therapy. 
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Figure 3.6. Panel A.   Serum dehydroepiandrosterone sulfate (DHEAS) 
concentrations. The female reference interval is 1·0 to 9·2 µmol/L and the male 
reference interval is 2·4 to 11·6 µmol/L, with a limit of detection (LD) of 0·1 
µmol/L (shown as the shaded horizontal area). Several patients’ data are 
superimposed on this limit of detection line.  
Panel B.  Plasma metanephrine concentrations. The reference range for plasma 
metanephrine is 80-510pmol/L, with a limit of detection (LD) of 40pmol/L, shown 
as the shaded horizontal area. Several patients’ data are superimposed on this limit of 
detection line.  
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Table 3.4. Serum cortisol concentrations at 30 and 60 minutes post ACTH 1-24 
(250µg/ml) stimulation. 
 
Changes in serum 
cortisol concentration 
(n=12) 
Mean difference 
(standard deviation)  
p-value (95% lower 
bound for mean 
difference) 
Serum cortisol (30-
minutes vs baseline) 
15.42  (22.40)      0.018  (3.80)  
Serum cortisol (60-
minutes vs baseline) 
22.33  (29.68)     0.012 (6.95)  
 
 
Positive changes (increment) in serum cortisol concentrations at 30 and 60 minutes 
during ACTH1-24 stimulation tests were examined using one-tailed paired t-test (µ 
>0). Short synacthen tests taking place at baseline, week-10 and week-20 for the 4 
participants with detectable serum cortisol concentrations in this study were included 
(n=12).  
*n= number of short synacthen tests 
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Table 3.5. Hormonal changes during synacthen treatment 
 Baseline vs. week-10 (n=12) Baseline vs. week-20 (n=10) 
 Mean 
difference 
(S.D) 
p-value (95% 
lower bound 
for mean 
difference) 
Mean 
difference 
(S.D) 
p-value (95% 
lower bound 
for mean 
difference) 
17-α OHP 1.73  (2.86)     0.030* (0.240) 2.56   (5.43)      0.066 (1.63) 
Androstendione 0.26  (0.51)     0.050  (0.003) 0.71  (1.46)     0.059 (0.04) 
DHEAS 0.042  (0.1) 0.088 (0.010) 0.00  (0.15)    0.500 (0.07) 
Plasma 
metanephrine 
10.90   (44.5) 0.207 (12.20) 47.8  (205.80)      0.219 (58.9) 
 
One-tailed paired-T test (to detect mean difference, µ >0) was used to examine the 
sensitivity of various hormonal tests in detecting adrenal steroidogenesis (increment 
in hormonal levels) during synacthen treatment at week 10 and week 20.   
*statistically significant 
 
 
 
 
 
 
 125 
 
3.3.3 Participant 02 and 06 
Two out of the 13 participants (participant 02 and 06) in this study achieved the 
primary endpoint during the study. The detailed clinical and biochemical 
characteristics when they were first diagnosed with AAD are summarised in Table 
3.6 3.6. At week 10, participant 02 achieved the primary endpoint. She had a peak 
serum cortisol concentration, which improved further to 506 nmol/L at week-20. Her 
oral steroid replacement was judiciously weaned down, with close monitoring to 
ensure well-being. Her oral prednisolone therapy was stopped at week 13, 
fludrocortisone at week 23 and synacthen injections at week 32 without any 
deleterious consequences. Since the cessation medication, she has experienced a few 
episodes of cold-like symptoms and one significant episode of viral gastroenteritis 
with diarrhoea, but has neither needed to take steroid medication nor hospital 
treatment during these illnesses. Both her peak serum cortisol and aldosterone 
concentrations were normal at 672 nmol/L and 273 pmol/L, seventy two weeks after 
weaning off all therapies other than levothyroxine. At present, she has remained well 
for 42 months without steroid replacement. 
At week 29, participant 06 achieved the primary endpoint of the study. She 
demonstrated biochemical evidence of steroidogenesis with peak serum cortisol 
concentration of 441nmol/L. Her oral steroid replacement therapy was then 
progressively reduced, ceasing oral prednisolone at week-36, synacthen injections at 
week-45 and fludrocortisone at week-57. She remained well with the staged 
reduction of steroid and synacthen therapy, but her peak serum cortisol 
concentrations decreased progressively once synacthen injection was stopped. Oral 
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steroid replacement therapy was restarted at week-64, when she became 
symptomatic with a peak cortisol level of 211 nmol/L. 
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Table 3.6. Biochemical and clinical characteristics for participant 02 & 06 at 
diagnosis 
Biochemical tests (reference range) 
 
Participant 02 Participant 06 
Sodium (133-146 mmol/L) 131 130 
Potassium (3.5-5.3 mmol/L) 5.7 4.7 
Urea (2.5-7.8 mmol/L) 9.4 5.7 
Creatinine (55-95 umol/L) 112 92 
Baseline cortisol 195 273 
Peak cortisol after stimulation with 
250µg ACTH1-24  (>550 nmol/L) 
 
212 279 
ACTH (10-55ng/L) 498 55 
Renin (0.5-2.1 pmol/L/h) 8.7 7.5 
Aldosterone (100-450 pmol/L)   72 <70 
Clinical symptoms  
 
Duration of symptoms before diagnosis 
(months) 
Pigmentation 5 12 
Weight loss 6 18 
Lethargy/fatigue 6 24 
Nausea/ vomiting 6 12 
Postural lightheadedness 6 12 
Salt craving 6 6 
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3.3.4   21-hydroxylase antibodies  
All patients except participant 05 had positive 21-hydroxylase antibody titre (>1.0 
U/ml) at baseline. None of them demonstrated significant changes in the 21-
hydroxylase antibody titre at either 10 or 20 weeks of the study (p>0.05, paired t-
test). Similarly, participants 02 and 06 who were followed up for 65 and 80 weeks 
respectively did not show any significant increment in the antibody concentration 
(figure 3.7). 
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Figure 3.7  Serum 21-hydroxylase autoantibodies 
 
 
 
 
 
 
 
 
 
The concentration of serum 21-hydroxylase autoantibodies over time is shown (note 
the logarithmic Y-axis). The reference range is <1·0 U/ml. Measurements were made 
in duplicate by immunoprecipitation of radiolabelled recombinant 21-hydroxylase 
expressed in yeast (S. cerevisiae) (RSR ltd. Cardiff, UK) (Tanaka et al.1997). 
Samples from participants 02 and 06 were run in two separate batches (weeks 1-40 
and weeks 40 onwards) and measurements corrected using duplicate samples run in 
both assays. 
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3.3.5 Urine steroid metabolites 
Urinary glucocorticoid and glucocorticoid metabolite excretion increased in patients 
02 and 06 from below the 5
th
 centile to above the median of healthy female controls 
over 10 and 40 weeks, respectively (figure 3.8). This was paralleled by increases in 
urinary mineralocorticoid. However androgen precursor and androgen excretion 
were slower to increase into the reference range. Urinary steroid metabolites 
remained under the normal reference range for all male participants (n=2) (figure 
3.9). 
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Figure 3.8 Longitudinal course of urinary steroid metabolite excretion in female participants during and after tetracosactide (ACTH1-
24) therapy 
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Error! Reference source not found.. Data from the 11 female participants are presented in comparison to results obtained in 55 healthy women 
ith the median of the normal cohort indicated as a dotted line and the shaded area representing the 5
th
-95
th
 centile range.  
Panel A: The sum of the metabolites of the glucocorticoid precursors 17-hydroxyprogesterone (17-hydroxy-pregnanolone, pregnanetriol) and 
11-deoxycortisol (tetrahydro-11-deoxycortisol) are plotted against time (reference range median 493 [5
th
-95
th
 centile 167-821] µg/24h).  
Panel B: The sum of the active glucocorticoid metabolites (cortisol, tetrahydrocortisol, 5α- tetrahydrocortisol, α-cortol, β-cortol, cortisone, 
tetrahydrocortisone, α-cortolone, and β-cortolone) are plotted against time (reference range 5867 [2935-9632] µg/24h).  
Panel C: The sum of the mineralocorticoid metabolites (3α,5β-tetrahydroaldosterone, tetrahydrocorticosterone, 5α-tetrahydrocorticosterone, 
tetrahydrodeoxycorticosterone, 5α-tetrahydrodeoxycorticosterone, tetrahydro-11-dehydrocorticosterone, and 5α-tetrahydro-11-
dehydrocorticosterone) are plotted against time (reference range 432 [167-821] µg/24h).  
Panel D: The sum of the androgen precursor metabolites dehydroepiandrosterone, 16α- dehydroepiandrosterone, 5-pregnanediol and 5-
pregnanetriol are plotted against time (reference range 1003 [177-3897] µg/24h).  
Panel E: The sum of the major active androgen metabolites androsterone and etiocholanolone are plotted against time (reference range 2139 
[484-4790] µg/24h).  
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Figure 3.9 Longitudinal measurements of 24-h urinary steroid excretion (µg/24h) in the two male participants (patients 4 and 8) at study 
baseline, during tetracosactide treatment, and after tetracosactide (ACTH1-24) therapy 
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Figure 3.9. Normal reference ranges derived from healthy male controls (n=27; 20-60 years) are represented by the median (indicated by the 
dotted line) and the 5
th
 to 95
th
 centile range (represented by the shaded areas). 
Panel A: The sum of the metabolites of the glucocorticoid precursors 17-hydroxyprogesterone (17-hydroxy-pregnanolone, pregnanetriol) and 
11-deoxycortisol (tetrahydro-11-deoxycortisol) are plotted against time (normal range median 1007 [5
th
-95
th
 centile 405-2196] µg/24h).  
Panel B: The sum of the active glucocorticoid metabolites (cortisol, tetrahydrocortisol, 5α- tetrahydrocortisol, α-cortol, β-cortol, cortisone, 
tetrahydrocortisone, α-cortolone, β-cortolone) are plotted against time (normal range 10329 [4447-18496] µg/24h).  
Panel C: The sum of mineralocorticoid metabolites (3α,5β-tetrahydroaldosterone, tetrahydrocorticosterone, 5α-tetrahydrocorticosterone, 
tetrahydrodeoxycorticosterone, 5α-tetrahydrodeoxycorticosterone, tetrahydro-11-dehydrocorticosterone, 5α-tetrahydro-11-
dehydrocorticosterone) are plotted against time (normal range 628 [279-1631] µg/24h).  
Panel D: The sum of the androgen precursor metabolites, dehydroepiandrosterone, 16α- dehydroepiandrosterone, 5-pregnanediol and 5-
pregnanetriol are plotted against time (normal range 2262 [237-10548] µg/24h).  
Panel E: The sum of the major androgen metabolites, androsterone and etiocholanolone, are plotted against time (normal range 4067 [1660-
12017] µg/24)
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3.3.6  Quality of life assessments  
Subjective assessment of patient’s wellbeing was performed using 3 sets of 
questionnaires (SF-36, AddiQoL and wellbeing visual analogue score). These 
questionnaires were completed by all participants at baseline, week 10 and week 20. 
However, one patient did not complete the SF-36 questionnaires at week 10. 
In the SF-36 test, participants showed significant improvements in mental health at 
both week-10 and week-20 (p<0.01). Subjective improvement was also 
demonstrated in social functioning, vitality and general health, although they were 
not statistically significant, except in the vitality domain (table 3.7).  
Similarly, participants showed significant increases in AddiQoL scores with a mean 
of 84.1 +/-10.2 at baseline that increased to 93.0 +/-11.6 and 94 +/-13.7 at week-10 
and week-20 respectively (p<0.05) (table 3.8).  
For the Addison wellbeing visual analogue scale (VAS), participants achieved a 
significantly higher score at the end of week 10 (p=0.038) and week 20 (p= 0.008 
(table 3.9).  The construct validity of wellbeing VAS compared to AddiQoL 
questionnaire is good, with a Pearson’s r varying between 0.82 to 0.97 (P<0.001). 
All domains in SF36 were also correlated strongly with the VAS wellbeing score, 
except bodily-pain and physical functioning, as shown in table 3.10. 
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Table 3.7. SF-36 scores at week-10 and week-20 assessment, in comparison with baseline score.  The scores are expressed in mean 
(standard deviation) 
SF36 domains Baseline 
(n=11) 
Week-10 
(=11) 
P-value Baseline 
(n=10) 
Week-20 
(n=10) 
P-value 
Mental Health 46.11 (9.46) 52.51 (8.04) 0.003* 47.04 (8.86) 52.73 (9.82) 0.013* 
Role-Emotional 49.56(10.9) 47.65 (11.61) 0.593 52.15 (7.09) 50.04 (11.37) 1 
Social Functioning 41.83 (13.47) 48.25 (9.77) 0.106 44.64 (10.24) 48.43 (13.04) 0.365 
Vitality 42.19 (10.72) 52.06 (10.81) 0.004* 43.39 (10.06) 51.19 (13.77) 0.091 
Role-Physical 51.97 (7.59) 51.71 (10.11) 0.371 51.97 (7.59) 50.56 (11.89) 0.593 
General Health 39.85 (9.97) 42.31 (10.71) 0.265 40.39 (8.61) 44.19 (9.45) 0.137 
Bodily Pain 53.95 (8.26) 53.66 (11.96) 0.941 52.08  (8.37) 52.99 (7.6) 0.576 
Physical Functioning 51.80 (3.87) 51.60 (5.77) 0.889 52.10 (3.94) 52.30 (3.92) 0.854 
PCS 48.23 (5.60) 48.65 (9.49) 0.863 48.06 (4.83) 48.28 (5.03) 0.865 
MCS 43.63 (11.46) 49.79 (9.86) 0.021* 46.02 (7.97) 50.73 (12.47) 0.083 
*Statistically significant  
PCS- Physical component summary 
MCS- Mental component summary     
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Table 3.7  Short –form 36 (SF36) comprise 8 physical and mental health variances that form 2 distinct higher-ordered components. Physical 
functioning (PF), bodily-pain (BP) and role-physical (RF) correlate most highly with the physical component and contribute to the scoring of 
the Physical Component Summary (PCS) measure (Ware et al., 1994). Mental health (MH), role-emotional (RE), and social functioning (SF) 
scales contribute most to the scoring of the Mental Component Summary (MCS) measure. Vitality (VT) and general health (GH) have 
correlations with both components.  
The total domain scores from 0 to 100, with higher values denoting better subjective health status. The scores were then converted using 
norm-based scoring, which employs a linear T-score transformation with mean = 50 and standard deviation = 10, to make it possible to 
meaningfully compare scores for the eight-scale profile and the physical and mental summary measures in the same graph. The final MCS and 
PCS were calculated using an SF-36 heath survey scoring as published in the SF-36 physical and mental health summary scales. A manual for 
users of the second edition can be found on their website (http://www.sf-36.org).  
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Table 3.8. AddiQoL scores (means and standard deviations) for week-10 and week-20 in comparison with the baseline assessment 
 Baseline  
(n=12) 
Week-10 
(=12) 
 
P-value Baseline 
(n=10) 
Week-20 
(n=10) 
P-value 
AddiQoL score 84.08 (10.18) 93.00 (11.62) 0.030* 84.50 (6.72) 94.00 (13.66) 0.022* 
 
AddQoL(version 2) (Oksnes et al 2012) is an Addison's disease-specific questionnaire comprising 30 questions that quantify the altered 
functional and emotional status in Addison’s patients. The total score ranges from 30-120 and the higher score indicates a better quality of 
life. A paired t-test was used to calculate the p-value. 
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Table 3.9. VAS for Addison wellbeing assessment (means and standard deviations) for week-10 and week-20 in comparison with the 
baseline assessment 
 
 Baseline  
(n=12) 
mean (S.D) 
Week-10 
(=12) 
mean (S.D) 
P-value Baseline 
(n=10) 
mean (S.D) 
Week-20 
(n=10) 
mean (S.D) 
P-value 
VAS Wellbeing score 72.89 (15.25) 80.96 (17.92) 0.038* 74.11 (9.29) 88.92 (11.56) 0.008* 
 
A 10-question visual analogue scale (VAS) was developed to assess the changes perceived by participants in terms of functional and 
emotional health. It is expressed on a linear scale with a horizontal line, 10cm in length and anchored by word descriptors at each end. The 
measurements in centimetres were converted to the same number of points ranging between 0 and 10 for each quetion, summed up to give a 
total score out of 100cm. The participants marked on the line the point that they felt represented their perception of their current state. The 
scores were then measured in millimetres from the left hand end of the line to the point where the patients marked. Pearson’s coefficient 
correlation was used to validate the questionnaire. 
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Table 3.10. Correlation between Addison VAS vs. AddiQoL and SF 36 
 Baseline Week-20 
Pearson’s r p-value Pearson’s r p-value 
AddiQoL 0.82 0.001 0.97 <0.0001 
SF 36 
Mental health 0.68 0.015 0.97 <0.0001 
Role-emotional 0.88 <0.0001 0.91 <0.0001 
Social functioning 0.69 0.013 0.73 0.017 
Vitality 0.54 0.072 0.95 <0.0001 
Role-physical 0.82 0.001 0.93 <0.0001 
General Health 0.58 0.050 0.89 <0.0011 
Bodily-pain 0.162 0.615^ 0.249 0.487^ 
Physical functioning 0.50 0.098^ 0.50 0.14^ 
Physical component score 0.52 0.084^ 0.82 0.004 
Mental component score 0.83 0.001 0.97 <0.0001 
 
^ Statistically non-significant 
Construct validity of the wellbeing VAS was carried out by comparison with SF-36 and 
AddiQoL by means of Pearson’s correlation analysis. 
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3.3.7  Safety and tolerability  
The synacthen therapy was well tolerated by the large majority of participants, with 
only one participant withdrawing from the study due to pain at injection sites. The 
common side-effects from synacthen that were observed include the development of 
transient redness, itches and swelling at the injection sites. Areas of erythema and 
swelling of up to 4 cm in diameter were reported and resolved over a 48-72hr period 
following each injection. The size of the lump tended to be smaller with synacthen 
infusion, which has a lower cumulative dose compared to the alternate day injection. 
The adverse events reported by participants during the study are summarised in table 
3.11. 
Four of the eleven female participants developed menstrual disturbance, with 
disruptions to a previously regular menstrual cycle and lower abdominal cramps at 
some point during the study. In addition, one participant developed inter-menstrual spot 
bleeding for 24 hours after ACTH-stimulation test at week-20. One participant felt 
unwell at week-25 during an assessment, around 30 minutes after 250µg synacthen 
intramuscular injection. She experienced generalised weakness, heavy legs, nausea and 
abdominopelvic cramps, like menstrual pain. There was a drop in blood pressure to 
76/50mmHg accompanied by sinus tachycardia (104bpm, regular) at the height of 
discomfort. There was complete resolution 70 minutes after the onset of the event. 
Two participants developed allergy-like reactions during major outcome assessments at 
week-15 and week-20. They both developed wheals at previous abdominal synacthen 
infusion sites 5 to 10 minutes after 250µg synacthen had been administered 
intramuscularly. They also reported itchiness and redness over their palms and soles. 
One of them developed lower abdominal cramps and vomiting which were resolved 
within 30 minutes. They remained haemodynamically stable throughout the events, 
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which were resolved after an hour. The potential investigational medicinal product 
(IMP)-related adverse events are summarised in table 3.12. 
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Table 3.11. Adverse events reported by participants during the study (unlikely 
casuality to IMP) 
Adverse events Severity 
grade* 
Actions Outcome Number of 
participant
s affected 
Cough, sore throat, 
feverish 
1-2 Doubling 
steroid dose 
Full 
recovery 
10 
Generally unwell, flu-
like symptoms 
1-2 Doubling 
steroid dose 
5 
Vaginal candidiasis 2 150mg oral 
fluconazole 
(single dose) 
1 
Migraine 1-2 Simple 
analgesics 
5 
Nausea/poor appetite 1 None 2 
Acute tonsilitis 2 Penicillin V 
500mg qds 
for 10 days 
1 
Diarrhoea and vomiting 2 Two patients 
doubled the 
steroid doses 
and 1 patient 
required IM 
steroid 
injection (not 
in crisis and 
no hospital 
admission 
required 
 3 
*Severity Grade according to the Common Terminology Criteria for Adverse 
Events (CTCAE) 
 Grade 1:  mild effect; asymptomatic or mild symptoms with clinical or 
diagnostic observations only; intervention not indicated. 
 Grade 2:  moderate effect; minimal, local or non-invasive intervention indicated 
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Table 3.12. Potential adverse drug reactions (IMP-related) reported by 
participants during ACTH1-24 therapy 
Adverse events Severit
y 
grade* 
Actions Outcome Number of 
participant
s affected 
Menstrual 
irregularity with 
menstrual-like 
abdominal cramps 
1 None Full 
recovery 
4 
Generally unwell 
with transient 
hypotension, 
tachycardia and 
lower abdominal 
cramps following 
short synacthen test 
at week-25. Normal 
tryptase level 
2 100mg 
intravenous 
hydrocortisone, 
200mg 
ibuprofen and 
10mg buscopan 
1 
Wheal developed at 
previous synacthen 
injection sites 
following short 
synacthen test.  
Associated with 
itchiness and 
redness over palms 
and soles. 
1 Piriton 4mg and 
ice packs 
applied over the 
wheals 
2 
Lower abdominal 
cramps and 
vomiting (one 
episode) following 
short synacthen test 
and spot 
intermenstrual 
bleeding 
2 Cyclizine and 
ibuprofen 
1 
*Severity Grade according to the Common Terminology Criteria for Adverse 
Events (CTCAE) 
 Grade 1: mild effect; asymptomatic or mild symptoms with clinical or diagnostic 
observations only; intervention not indicated. 
 Grade 2: moderate effect; minimal, local or non-invasive intervention indicated 
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3.4 Discussion: 
Autoimmune Addison’s disease (AAD) has long been perceived as a chronic and 
incurable condition. Patients with AAD rely on lifelong steroid replacement therapy for 
survival. However, exogenous steroids failed to mimic physiological corticosteroid 
secretion and many patients have impaired quality of life or recurrent Addison crisis. I 
sought to find out if adrenal steroidogenic function is salvageable in established AAD 
by using the synthetic analogue of adrenocortical trophic hormone (synacthen, ACTH1-
24). Four out of the thirteen participants had detectable serum cortisol at baseline testing, 
despite having established AAD for periods ranging from 1.5 to 8 years. Two of them 
had progressive improvements in adrenal steroidogenic function during treatment with 
synacthen. In both of these patients, improvements in serum cortisol level were detected 
as early as 5 weeks following synacthen therapy. Daily steroid replacement medication 
was able to be withdrawn with maintenance of good health in both cases. However, one 
participant only achieved transient improvement with a progressive decrease in 
stimulated serum cortisol once synacthen injections stopped. A glucocorticoid 
replacement-free period of 28 weeks was achieved in this case. In the other participant, 
the treatment has led to a prolonged improvement in adrenal steroidogenesis, such that 
she has remained well and without steroid replacement medication for 42 months at the 
time of writing. She encountered a few acute illnesses such as gastroenteritis and cold-
like symptoms but no steroid therapy was required. Nevertheless, despite a peak cortisol 
level of 672 nmol/l during stimulation testing, she does not currently have normal 
adrenal function, as her plasma ACTH (159ng/l, reference range 10-55) and renin 
(14pmol/l/h; reference range 1-5.5) remain elevated. Synacthen therapy has produced 
clinical remission in 2 AAD patients although one was transient. This is a paradigm 
shift for AAD from a chronic treatable condition to a potentially curable disease. 
Although clinical remission happened following boluses of 1mg synthetic ACTH1-24 
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injections in an alternate day pattern, other regimens of subcutaneous synacthen therapy 
(continuous infusion or pulses via pump) were not tested in these 2 patients. The dosage 
of synacthen used is also supra-physiological and further studies are required to 
establish the best regimen and the optimal dosage required to stimulate endogenous 
adrenal steroidogenesis.   
In terms of subjective assessment of general wellbeing, it is interesting to note that the 
majority of participants (mostly female) reported better quality of life following 
synacthen therapy, despite not having significant changes in serum cortisol 
concentration. The perceived improvement in mental health and social functioning 
remained statistically significant at both week-10 and week-20. It is well known that 
female patients with AAD suffer from severe androgen deficiency as adrenal 
dihyroepiandrosterone (DHEA) is the most important androgen source for them. 
Considering that most participants demonstrated significant fluctuation in serum 
androstenedione and 17-α hydroxyprogesterone concentration, with many showing 
short-lived increments in these adrenal androgen precursors following synacthen 
therapy, this potentially accounts for the improvement in quality of life. Indeed, a few 
studies have demonstrated improvements in mood and wellbeing following DHEA 
replacement in patients with primary adrenal insufficiency (Arlt W et al.1999, Gurnell 
et al.2008). Nevertheless, this positive effect could well be due to a placebo effect, as no 
control group was involved in this study. 
Although synacthen therapy was tolerated well by the majority of participants, a few of 
them developed allergic cutaneous reaction, with 1 patient developing more severe side 
effects of transient hypotension and near-syncope. In light of these reactions occurring 
within minutes of ACTH1-24 administration, an immune-mediated response involving 
antibody-antigen reaction might have taken place. Hence, I proceeded to investigate this 
relationship, with the next chapter explaining the details of my findings. 
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This study demonstrates that AAD is a heterogeneous condition, with 2 of the 13 
participants having useful residual adrenal steroidogenic function, and a third patient 
having a small rise in serum cortisol. Contrary to expectations, these patients with 
residual adrenal functions were not those with the most recently diagnosed disease. 
Indeed, the two patients exhibiting signs of recovery had been treated for AAD for 4 
and 8 years prior to the study respectively. In contrast, 4 participants who were 
diagnosed with AAD within two years before the baseline visit exhibited no signs of 
residual steroidogenesis. This suggests that certain AAD patients may have residual 
steroidogenic function that is durable over long periods of time. One previous study of 
AAD patients showed increases in serum cortisol in 10 of 27 patients during synacthen 
testing, despite prior dexamethasone administration (Smans & Zelissen 2011). Along 
with the data from this study, residual steroidogenic function may be present in around 
30% of AAD patients. There are only three reports in the medical literature of 
spontaneous partial recovery from established Addison’s disease (Smans &  Zelissen 
2008; Chakera & Vaidya  2012, Bater et al.2013). These cases showed partial and 
intermittent remission with peak cortisol concentrations above 200 nmol/l following 
ACTH1-24 stimulation test, having have AAD diagnosed between 7 to 37 years. 
Nevertheless, their plasma ACTH and renin levels remained elevated. In light of the 
data from this study, these 3 patients are likely to have residual steroidogenic function 
that improved owing to endogenous ACTH stimulation, once the patients had decided to 
reduce or stop their steroid medication.  
Residual islet beta-cell function (marked biochemically by C-peptide ‘positivity’) is 
well described in about 20% of patients with autoimmune type 1 diabetes, and the 
findings from this study could represent a parallel state of partial destruction of the 
target organ in an autoimmune disease process. In C-peptide positive type 1 diabetes 
patients, the residual insulin secretion is significant, and has been correlated with 
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improved glycaemic control and fewer microvascular complications (The DCCT group 
1987 & 1998, Panero et al. 2009). In AAD, around 40% of patients have never been 
hospitalised with an adrenal crisis (White & Arlt  2010, Hahner et al. 2010), and this 
was the case for our 2 participants who exhibited ACTH-responsiveness with useful 
residual adrenal function. It is possible that long-term freedom from adrenal crises could 
be due to residual adrenal function in certain AAD patients.  
In contrary to the conventional concept of the natural history of AAD, this study 
provides new and valuable information about the heterogeneity of the natural history of 
the disease, by demonstrating that certain AAD patients have residual steroidogenic 
function several years after diagnosis. The residual adrenal function is clinically 
important as it can be exploited to ameliorate the condition. This study has clearly 
demonstrated that clinical remission is achievable following administration of 
exogenous trophic ACTH stimulation in patients with useful residual adrenal function. 
An important ramification of our study is that at the time of the first treatment of AAD 
using standard replacement therapy, it was unknown as to whether the exogenous 
glucocorticoid and mineralocorticoid treatment which decreases trophic ACTH drive 
would compound the functional adrenal failure by producing an additional degree of 
steroid-induced adrenal suppression/atrophy.  
In light of the curable potential for AAD patient with residual adrenal function, it is 
paramount to identify sensitive markers of residual adrenal function at the time of 
diagnosis to enable this patient group to be distinguished. Measurement of peak serum 
cortisol level following ACTH 1-24 stimulation testing has been the gold-standard 
dynamic assessment of adrenal function. However, residual adrenal function could be 
well below the conventional lower limit of assay detection. A more sensitive 
biochemical marker should be established to detect residual adrenal function in AAD. 
Interestingly, a few participants demonstrated improvements in serum 17-α 
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hydroxyprogesterone, androstenedione, urinary corticosteroid metabolites and plasma 
metadrenaline levels, without changes in basal or stimulated serum cortisol. Hence, 
these markers could be a highly sensitive indicator of endogenous adrenocortical 
cortisol production and a large population-based study is required to verify this 
hypothesis.  
Despite a concern over the potential for reactivation of the autoimmune response, there 
has been no worsening of humoral anti-adrenal autoimmunity over time in patients 02 & 
06, as judged by 21-hydroxylase antibody concentrations. This is consistent with the 
hypothesis that adrenocortical steroidogenesis may protect the adrenal against immune 
attacks because the high local glucocorticoid concentrations impair the functions of 
antigen-presenting dendritic cells and several other immune cells (Betterle et al 2002, 
Mitchell & Pearce 2012). Nevertheless, T lymphocyte reactivity against adrenal 
antigens was not studied and an ongoing or renewed T cell attack could have 
contributed to the early decline in steroidogenic function in participant 06.  
This study established an important proof of principle that ACTH stimulation by means 
of synacthen therapy can lead to recovery of adrenal function following long-term 
adrenal insufficiency in AAD. The approach described in this study needs further 
exploration, including the optimal treatment duration and dosage regimen. However, it 
is likely that a proportion of AAD patients could have similar long-term benefits from 
such therapy, particularly those with useful residual adrenal function. Hence, 
identification of this group of AAD patients is crucial as they might benefit from 
lowered doses of exogenous steroid replacement and a trial of synacthen therapy. Future 
studies are also required to investigate if a second morphogenic signal is required to 
work synergistically with ACTH to promote adrenal steroidogenesis in AAD. 
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Chapter 4. Spontaneous and 
tetracosactide-induced anti-
ACTH antibodies 
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4.1 Background 
As previously discussed, four of the 13 patients with autoimmune Addison’s disease 
(AAD) developed allergic cutaneous reactions immediately after ACTH1-24 (synacthen; 
tetracosactide) injections during short synacthen tests. This happened following a 
prolonged duration of high-dose synthetic adrenocorticotropic hormone (zinc 
tetracosactide; depot synacthen) therapy, in an attempt to stimulate adrenal regeneration 
(RoSA study). One participant (06) whose adrenal function initially improved during 
ACTH1-24 therapy failed to sustain the clinical improvement. Despite ACTH being an 
endogenous peptide to which immune tolerance should be established, these phenomena 
made me wonder if there was an immunogical reaction generated against the depot 
synacthen therapy. 
The immune system is programmed to discriminate between self and non-self peptides, 
with the aim of eliminating foreign organisms and proteins that are harmful, but without 
generating an immune response to endogenous self-peptides. Nevertheless, tolerance to 
endogenous self-proteins does break down to produce autoimmune disorders, in which 
immune responses may be directed against many different proteins, most typically 
enzymes (eg. thyroid peroxidase, steroid 21-hydroxylase, glutamic acid decarboxylase) 
or cell-surface receptors (eg. TSH-receptor, acetyl choline receptor, calcium-sensing 
receptor) (Kaufman & Tobin 1993, Song et al. 1996, Merbl et al. 2007, Li et al.1996, 
Gavalas et al. 2007). In addition, a small number of conditions are characterised by 
antibodies against secreted peptide hormones, the most common of which is type 1 
diabetes in which anti-insulin antibodies are highly prevalent (Palmer et al. 1983, 
McEvoy et al.1986).  
ACTH is a polypeptide composed of 39 amino acids and is produced from 
proopiomelanocortin (POMC), by endopeptidase activity yielding ACTH and other 
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peptide products, including β-melanocyte stimulating hormone (MSH) and β-endorphin 
(Lee et al. 1961). ACTH exerts its effects on the adrenal cortex by binding to a member 
of the melanocortin receptor family, melanocortin-2 receptor (MC2R). The amino N-
terminal segment of the peptide (residues 1-24) is the biologically active region of 
ACTH and is highly conserved across vertebrate species whereas the carboxyl terminal 
is considered to be more antigenic (Costa et al. 2004). Tetracosactide, also known as 
cosyntropin or synacthen, is a synthetic polypeptide identical in structure to the amino-
terminal 24 amino acids of the naturally existing self-peptide, corticotroph (ACTH 1-39) , 
and contains the biological activity to stimulate adrenal steroidogenesis. 
 
Depot tetracosactide used in the RoSA study has prolonged duration of action compared 
to soluble, unconjugated tetracosactide, as the peptides are absorbed onto a zinc 
phosphate substrate, delaying its absorption from the site of injection. The structural 
differences between depot synacthen and un-conjugated ACTH1-24, as well as full length 
ACTH is depicted in figure 4.1. 
In this study, I investigated the possibility that immunoreactivity towards synacthen 
therapy had developed in these trial patients. I extended the study to additional 
autoimmune patient cohorts, including unrelated AAD and Graves’ disease patients 
with no history of prolonged exposure to synathen therapy. In view of a significant 
proportion of individuals with isolated ACTH deficiency having coexisting autoimmune 
diseases and the target autoantigen has yet to be defined, I also investigated the potential 
role of anti-ACTH autoantibodies in isolated ACTH deficiency. 
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Name ACTH1-39 ACTH1-24 ; 
tetracosactide; 
synacthen 
Depot synacthen; 
ACTH1-24 mixed with 
zinc phosphate( 3:2) 
Molecular 
formula 
C207H308N56O58S  C136H210N40O31S C272H422N80O70P2S2Zn3
+2
 
Molecular 
weight 
4541.06582   2933.437   6254.972604 
Figure 4.1 Schematic representative of the 2-dimension structure of full length 
ACTH1-39, ACTH1-24 (synacthen or tetracosactide) and depot synacthen 
(tetracosactide mixed with zinc phosphate (3:2). 
Synacthen is a synthetic peptide that is identical to the 24-amino acid segment at the N-
terminal of (ACTH1-39) and is similar among all species. (resource: PubChem Substance; 
http://www.ncbi.nlm.nih.gov). 
C-terminal 
N-terminal 
Zn 
ACTH1-39 
Depot synacthen 
ACTH1-24 
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4.2 Patients and methods 
4.2.1 Patients 
Thirteen Caucasian patients with established AAD were recruited for the RoSA study 
(revival of steroidogenic function in AAD study; NCT01371526), either from the 
endocrine clinics of the Newcastle upon Tyne NHS hospitals (n=12), or self-referred 
following an ethics committee agreed advertisement in the national Addison’s disease 
self-help group (ADSHG) quarterly newsletter (n=1). Clinical details of these patients 
are provided in chapter 3. 
The sera from 131 AAD and 92 Graves’ disease patients were obtained via recruitment 
since 1996 through outpatient endocrinology services in the North East of England and 
the UK Addison’s disease self-help group. Sera from 102 patients with negative 
autoimmune screening (rheumatoid factor, anti-nuclear antibody, anti-mitochondrial 
antibody, anti-gastric cell antibody) were obtained from the Clinical Pathology 
department at the Newcastle upon Tyne NHS hospitals trust. These sera were used as 
“non-autoimmune” controls. The thyroid and adrenal autoantibody status of the control 
group is unknown. Fifteen Caucasian patients with isolated ACTH deficiency were 
recruited either from the John Hunter Children's Hospital, Newcastle Australia (n=11) 
or Newcastle upon Tyne NHS hospitals (n=4). This study was carried out with the 
approval of the North East-Sunderland Research Ethics Committee, UK (ref. 
12/NE/0101) and the Hunter New England Human Research Ethics Committee, 
Australia.  
4.2.2 Methods 
4.2.2.1 Tricine-SDS-PAGE 
In this study, Tricine- sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoretic (PAGE) technique was used to separate proteins. SDS is an anionic 
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detergent that denatures the secondary and tertiary structures and imparts an even 
distribution of negative charge per unit mass. This results in the separation of protein by 
their approximate size during electrophoresis. Tricine-SDS PAGE is useful in 
separating low molecular mass protein (1-30kDa). Both ACTH1-24   (~3kDa) and ACTH 
1-39 (~ 5kDa) have molecular weight <30kDa.   
Having reviewed the protocol published by Schägger H, a three-gel technique 
comprising stacking, spacer and separating gels was used to increase the resolution of 
the separating bands (Schägger 2006).  A 16% acrylamide separating gel was selected 
as it covers protein with 1-70 kDa. In order to enhance the resolution for proteins <5 
kDa, acrylamide-bisacrylamide(AB)-6 stock solution (49.5% T, 6% C mixture) that 
contains a higher percentage of crosslinker bisacrylamide (C) was used in the separating 
gel. A 10% ‘spacer gel’ inserted between the 4% stacking and 16% separating gels, 
considerably sharpens the bands for proteins of 1-5 kDa.  
The following reagents were used for gel preparation and SDS-PAGE. The detailed 
protocols of making each solution were provided in the supplementary section. 
 AB-3 stock solution (49.5% T, 3% C mixture) 
 AB-6 stock solution (49.5% T, 6% C mixture) 
 3x Gel Buffer 
 10% Ammonium Persulphate (APS) 
 Glycerol 
 Tetramethylethylenediamine (TEMED) 
 Loading buffer 
 1x Cathode Buffer  
 5x Anode Buffer  
 1x Transfer Buffer 
 1x TBST (Tris buffered saline with  1% Tween 20) 
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4.2.2.2 Acrylamide gel preparation 
The three-layered acrylamide gels were prepared as following: 
16% separating gel: 
 16% 
Gel 
Acrylamide-bisacrylamide 
(AB)-6 
10ml 
Gel buffer (3x) 10ml 
Glycerol 3g 
Add water to final volume 30ml 
Polymerise by adding:  
APS (10%) 100ul 
TEMED 10ul 
 
10% Spacer Gel: 
 10% Gel 
AB-3 6ml 
Gel buffer (3x) 10ml 
Add water to final volume 30ml 
Polymerise by adding:  
APS (10%) 150ul 
TEMED 15ul 
 
4% Stacking Gel: 
 4% Gel 
AB-3 1ml 
Gel buffer (3x) 3ml 
Add water to final volume 12ml 
Polymerise by adding:  
APS (10%) 90ul 
TEMED 9ul 
 
 
The plates and combs were cleaned with 70% ethanol and all dust or left-over 
acrylamide gel were removed. The plates were locked with a holder and set up on the 
rack. The bottom edges of the 2 plates were flushed to ensure that there was no leakage. 
The 16% separating gel solution was then pipetted carefully onto the plates, to avoid 
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generation of bubbles which could inhibit polymerisation. Once the gel was formed, 10% 
spacer and 4% stacking gel solutions were pipetted in sequence.  
 
4.2.2.3 SDS-PAGE Electrophoresis  
Tetracosactide (synacthen) or full length ACTH1-39 was mixed with 1x SDS loading 
buffer and boiled at 95
o
C for 5 minutes. Samples were immediately loaded onto the16% 
polyacrylamide tricine gel (2.5μg of tetracosactide or ACTH1-39 per well) and run at 
90V for an hour, with a pre-chilled running buffer (1x cathode and 1x anode buffers). 
The synacthen or ACTH1-39 polypeptide was then electroblotted onto Hybond C 
membrane (Amersham), with ice-cold transfer buffer at 350mA for 45 minutes. 
Ponceau stain was used to locate the transferred protein. Ponceau stain has no 
deleterious effect on the blotted polypeptides and is easily reversible with water washes 
to facilitate subsequent immunoblotting. 
4.2.2.4 Detection of anti-synacthen antibodies by immunoblotting 
The blotted synacthen membranes were incubated with patient and control sera (1:250 
dilution) for 75 min at room temperature, following blocking with 5% non-fat milk 
powder. Following washing with TBST (3 x 5 minutes), goat anti-human IgGγ-chain-
horseradish peroxidase (HRP)(A6029, Sigma-Aldrich) was used to oxidise 
diaminobenzidine (DAB) substrate (Sigma-Aldrich, Poole, Dorset). Additional blots 
made using full length ACTH1-39 (Sigma-Aldrich, UK) were probed and a monoclonal 
antiACTH1-24 antibody (1B55, Santa Cruz, CA) was used as a positive control (detected 
with goat antimouse IgG (A4416, Sigma-Aldrich).   
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4.2.2.5 Detection of anti-tetracosactide antibodies by enzyme-linked 
immunosorbent assay (ELISA)(figure 4.2) 
 
Tetracosactide (ACTH1-24) was bound to the solid phase of ELISA plates (NUNC 
maxisorp) in a concentration of 1μg/ml overnight at 4oC in 1x carbonate coating buffer. 
Plates were washed three times in phosphate-buffered saline tween 20 (PBST; PBS, 1% 
tween 20) and blocked with 2% bovine serum albumin (BSA) for 1 hour at room 
temperature. Serum diluted to 1:250 in 2mg/ml BSA were incubated in plates at room 
temp for 75 min, followed by washing and secondary antibody (goat anti-human IgG γ-
chain-HRP) diluted 1:500 in 2mg/ml BSA for 1 hour at room temperature. Following 
washing and detection with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Sigma-
Aldrich, Poole, Dorset T0440) for 3 minutes, reactions were stopped by 1M 
hydrochloric acid, and absorbance measured at A450 on an Ascent Multiskan (Thermo). 
The anti-tetracosactide binding activity was measured in triplicates for each participant 
sera, and each result reproduced on at least 2 different days. Results are expressed as 
arbitrary units of absorbance, having subtracted the background absorbance (mean of 3 
wells without serum). A positive control was run on each occasion to check for 
interassay variation, which was within 10% on successive days. To check for non-
specific serum binding to peptides, all positive samples were run with an identical 
ELISA protocol, with plates coated with octreotide (somatostatin 1-8) 1μg/ml instead of 
tetracosactide. 
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Figure 4.2 Schematic of direct binding ELISA to detect anti-syacnthen activity 
 
A. Synacthen is bound to solid phase 
B. Anti-synacthen antibody from patient’s sera recognise and binds to synacthen 
C. Bound sera are detected with anti-human IgG γ-chain-conjugated to horseradish 
peroxidase (HRP) 
D. HRP catalyses the oxidation of TMB (3,3’,5,5’-tetramethylbenzidine) 
chromogen, results in a blue colour change. The colour then changes to yellow 
with the addition of sulphuric acid with maximum absorbance at 450nm. 
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4.2.2.6 Immunohistochemistry study of pituitary tissues  
Sections of human pituitary tissue were kindly provided by the Cellular Pathology 
department at the Royal Victoria Infirmary, Newcastle upon Tyne. These tissue sections 
were embedded in paraffin wax blocks and then sectioned at a thickness of 4µm by the 
department. I carried out immunohistochemistry study on these pituitary tissue sections, 
using the indirect HRP-labelled antibody method. Sections underwent deparaffinization 
and rehydration as delineated in table 4.1. Antigens were retrieved by boiling the 
sections in Tris-EDTA buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 
20, pH 9.0) for 10 minutes in a microwave (850W). The sections were allowed to cool 
for 20 minutes followed by 2 washes with PBS plus 0.025% Triton X-100. The sections 
were then blocked with 10% goat serum in 1% BSA for an hour.  This was followed by 
4
o
C overnight incubation with pooled patient sera (from 3 positive subjects) diluted 
1:100. Following 2 washes with PBS plus 0.025% Triton X-100, sections were 
incubated in 1% hydrogen peroxide for 15 minutes to block peroxidase activity. The 
slides were then washed twice prior to incubation with HRP conjugated goat anti-
human IgGγ-chain antibodies (A6029, Sigma-Aldrich) for 1 hour. Following 3 washes 
with PBS, Antibody-binding was visualised with the chromogen diaminobenzidine 
(DAB) (Sigma-Aldrich, Poole, Dorset) and counterstained with haematoxylin. The 
slides then underwent the rehydration protocol using Histoclear and ethanol as stated in 
table 1. Monoclonal anti ACTH1-24 antibody (1B55, Santa Cruz, CA) was used as a 
positive control (detected with goat antimouse IgG (A4416, Sigma-Aldrich).  The slides 
were mounted with DPX (Sigma Aldrich) and glass-coverslip added. Microscopy was 
performed using Axioplan 2 widefield microscope with Axiovision software (Carl Zeiss) 
The immunocytochemistry staining was optimised by different antibody (primary and 
secondary) dilution and blocking system. The antibody concentration titration was 
 161 
 
carried out using positive controls (monoclonal antibody towards ACTH). A 4-point 
scoring system was employed to assess the intensity of staining (Adams et al. 1999):  
- (no stain); + (weak staining); ++(moderate staining); +++ (strong staining), with the 
positive control slide taken as  +++.  
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Deparaffinise and rehydrate Dehydrate and clear 
Histoclear 2x 3min 50% ethanol 3 min 
Histoclear:100% ethanol  
(1:1) 
3 min 70% ethanol 3 min 
100% ethanol 2x3 min 95% ethanol 3 min 
95% ethanol 3 min 100% ethanol 3 min 
70% ethanol 3 min Histoclear:100% ethanol  
(1:1) 
3 min 
50% ethanol 3 min Histoclear 2x 3min 
Running cold tap water to rinse Clear and mount 
Table 4.1 Protocols for depraffinisation/rehydration and dehydration in 
immunocytochemistry study 
Paraffin embedded sections require thorough depraffinisation and rehydration as 
incomplete removal of paraffin will result in poor staining of the section. The slides are 
to be kept in the tap water following the deparaffinasation steps to avoid dehydration, 
that could cause non-specific binding and high background staining. 
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4.3 Results 
4.3.1 Anti-tetracosactide immunoreactivity among patients receiving 
high-dose depot tetracosactide 
Using immunoblotting of immobilised ACTH1-24 , protein bands with an apparent 
weight of 3-4kDa were recognised in patients’ sera. Sera from all of the patients who 
had an adverse reaction to tetracosactide identified a ~4kDa band on immunoblotting 
against the tetracosactide (ACTH1-24) peptide (figure 4.3 panel A). This band was found 
in 10/13 (77%) of patients who had received multiple doses of tetracosactide depot as 
part of the clinical study. In eight patients, the immunoreactivity was absent in baseline 
samples but noted to develop over time during exposure to ACTH1-24. However, there 
was similar immunoreactivity in 2 participants at baseline, before sustained peptide 
exposure.  
Immunoblotting against full-length ACTH1-39 peptide showed that all of the patient sera 
which reacted with the tetracosactide (ACTH1-24) peptide, also showed specific 
reactivity at ~6kDa with full-length ACTH peptide (figure 4.3 panel B). This is in 
contrast to results from 3 healthy control sera, which showed no binding to either the 
ACTH1-24 or ACTH1-39 peptides. A commercial anti-ACTH amino-terminal 
(corresponding to the tetracosactide peptide) monoclonal antibody was used to probe 
blots and showed bands corresponding to the expected size with both the tetracosactide 
and the full-length ACTH peptides (figure 4.3 panel B). An ELISA was then designed, 
using tetracosactide peptide captured onto solid phase, to quantify the anti-synacthen 
binding activity. The ascertainment of a threshold for normality was carried out using a 
larger sample cohort as stated in the next section. Sera from five of the 13 patients (38%; 
all female) demonstrated relative absorbance above 0.21 units at baseline (the threshold 
for positivity; see below) with 2 of them having relative absorbance of more than 2 units 
(figure 4.3 panel C). Upon completion of either 10 or 20 weeks of tetracosactide therapy, 
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11/13 (84.6%) patients showed immunoreactivity towards tetracosactide, with relative 
absorbance scores above 0.21 units. Nine of the 11 female participants demonstrated a 
1.5 to 12-fold increase in the ELISA absorbance score following tetracosactide peptide 
treatment but sera from both male patients were negative throughout the study. 
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Figure 4.3 Anti-tetracosactide immunoreactivity detected with immunoblotting & 
ELISA. 
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Figure legend (4.3) 
Panel A: Detection of serum binding activity to immunoblotted ACTH1-24 , at baseline 
and week 20 for participants 1, 6, 7 and 10, as assessed by the band of ~4kDa, the 
expected molecular weight of ACTH1-24. Sera from healthy subjects were used as a 
negative control.  
Panel B: Immunoblotting was performed with blots made using both tetracosactide 
(ACTH1-24) peptide and full-length human ACTH1-39, both 2.5μg per well. 
Representative positive sera from 2 participants (sera A & B), a monoclonal anti-
ACTH1-24 antibody (C) and serum from a healthy control (serum D) are shown. The 
monoclonal anti-ACTH antibody recognizes bands of the same molecular mass as the 
positive participant sera for both ACTH1-24 and ACTH1-39 peptides, which was not seen 
with control sera. 
Panel C. Anti-tetracosactide binding activity on immunoblotting from all the patients of 
RoSA study was quantified using ELISA. Results (±SEM) are expressed as arbitrary 
units of absorbance at 450nM, having subtracted the background absorbance (mean of 3 
wells without serum). All except 5 patients had relative absorbance units of less than 
0.21 at baseline. A positive control was run on each occasion to check for interassay 
variation, which was within 10% on successive plates.  
 
 
 
 
 
 
 167 
 
4.3.2 Anti- tetracosactide immunoreactivity among controls vs. patients 
with autoimmune diseases (autoimmune Addison’s disease, Graves’ 
disease and isolated ACTH deficiency) 
 
The study of autoimmunity towards ACTH1-24 peptide was extended to larger groups 
involving healthy controls, patients with Graves’ disease, autoimmune Addison’s 
disease and isolated ACTH deficiency. Initially, 102 control sera from anonymous 
hospital attendees with negative autoantibody status were investigated, along with a 
patient serum that had proven positive on immunoblotting. Only one of the 102 control 
sera exceeded 0.21 absorbance units in the ELISA (figure 4.4). This value was then 
taken as an arbitrary threshold of positivity. Of the sera from 131 patients with 
autoimmune Addison’s disease, 28 (21%) were positive (>0.21 U) for anti-
tetracosactide binding on the ELISA assay. Similarly, sera from 92 patients with Graves’ 
disease and 15 with isolated ACTH deficiency were run: 13 (14%) and 1 (7%) were 
positive, respectively. 
To investigate whether the anti-synacthen peptide binding in the ELISA could be owing 
to non-specific binding, all positive sera were tested in an identical assay, except that 
the plates were coated with octreotide (somatostatin octapeptide) instead of 
tetracosactide. None of the sera gave a positive signal in the assay with octreotide 
(figure 4.5, panel A). Similarly, all positive patient sera in the ELISA were tested 
against the tetracosactide peptide on immunoblotting, and all 41 showed specific 4kDa 
binding (figure 4.5, panel B).  
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Figure 4.4  Anti-synacthen binding activity detected by ELISA 
Relative quantitation of anti-tetracosactide binding activity using ELISA with sera from 
102 controls, 131 unrelated patients with AAD, 92 patients with Graves’ disease and 15 
patients with isolated ACTH deficiency. Tetracosactide (ACTH1-24) 1μg/ml was bound 
to solid phase ELISA plates (NUNC maxisorp). Results (±SEM) are expressed as 
arbitrary units of absorbance at 450nM, having subtracted the background absorbance 
(mean of 3 wells without serum). A positive control was run on each occasion to check 
for interassay variation, which was within 10% on successive plates. ELISA of the 102 
control sera (from anonymous hospital attendees with negative autoantibody status) 
showed absorbance readings of ≤0.2 units in 101 sera, with 1 serum showing an 
absorbance of 0.6 units.  
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Figure 4.5 Verification of ACTH immunoreactivity in samples’ sera 
Panel A. All positive samples were run against an identical ELISA protocol, with plates 
coated with octreotide (somatostatin1-8) 1μg/ml. None of the sera gave a positive signal 
in the assay with octreotide.  
Panel B. All positive patient sera in the ELISA were tested against the tetracosactide 
peptide on immunoblotting, and all 41 showed specific 4kDa binding. Representative 
positive sera from 6 patients (A-F) are shown. 
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4.3.3 Immunohistochemistry study 
Lastly, I examined normal human pituitary sections by immunohistochemistry to 
determine whether the patient sera with anti-synacthen binding activity would recognise 
native ACTH in tissue sections. Figure 4.6 shows that these positive sera produce 
moderate (++) cytoplasmic staining in a similar pattern to that of a commercial anti-
ACTH antibody (+++).  
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Figure 4.6 Immunohistochemistry results 
Immunohistochemistry was performed to identify whether sera with anti-tetracosactide 
binding activity would recognise native ACTH in contiguous tissue sections. 
Representative positive patient sera (panel A) and negative patient sera (panel C) were 
used. Monoclonal antiACTH1-24 antibody (1B55, Santa Cruz, CA) was used as positive 
control (panel B). The positive sera produced a cytoplasmic staining in a similar pattern 
to that of the commercial anti-ACTH antibody. (Magnification x100) 
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4.4 Discussion 
The development of serum anti-ACTH antibodies following long-term porcine or 
synthetic full-length ACTH peptide therapies was reported in the 1960s &70s (Felber et 
al. 1966, Glass et al. 1971). Glass and colleagues detected anti-ACTH antibodies using 
haemagglutination and antigen displacement methods in 32% of 38 rheumatoid arthritis 
subjects treated with long-term depot tetracosactide (zinc tetraocosactide)( Glass & 
Daly 1971). In line with these early observations, this study demonstrated the 
development of anti-tetracosactide and full-length ACTH binding activities using 
immunoblotting among 77% of 13 patients with autoimmune Addison’s disease, 
following multiple doses of depot tetracosactide therapy.  
Although antibodies to self-peptide should not generally occur, the development of 
antibodies to various peptide therapies has been extensively reported. Anti-insulin 
antibodies were observed in patients with diabetes treated with exogenous insulin 
leading to immunological resistance and poor glycemic control (Berson et al. 1956, 
Berson &Yalow 1959). A similar experience was shared among patients treated with 
growth hormone therapy, and to enzyme replacement in Gaucher’s disease (Okada et al. 
1987, Ponce et al. 1997, Ahangari et al. 2004). Hence, my findings are consistent with 
this phenomenon and may explain some of the side effects seen in the RoSA study. In 
addition, modification of circulating tetracosactide concentrations by sequestering or 
increased clearance mediated by circulating anti-ACTH antibody could account for 
treatment failure in some of the patients and ‘treatment resistance’ observed in one 
participant (patient 06), who lacked a sustained improvement during tetracosactide 
therapy. Indeed, Felber and colleagues described inactivation of corticotropin following 
formation of antibody towards porcine ACTH, using a radioimmunoassay assay (Felber 
et al. 1966). It was also demonstrated that antibodies generated in guinea pigs 
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immunised with synthetic full-length ACTH were responsible for a loss of ACTH 
bioactivity in vitro. Furthermore, as antibodies against tetracosactide would be directed 
against the biologically active amino acid sequence of ACTH, the 1-24 segment, this 
clearly has the potential to reduce the therapeutic potency and effectiveness of depot 
tetracosactide therapy. This might also explain the well described phenomena of 
acquired resistance to chronic adrenocorticotropic hormone (ACTH) therapy (Goslings 
et al. 1951, West 1962).  
Interestingly, the same autoreactivity has not been reported with soluble synthetic 
tetracosactide. Indeed, animal studies showed that conjugates of the ACTH1-24 peptide 
were antigenic, but that unconjugated ACTH1-24 peptide failed to induce an antibody 
response in rabbits or guinea pigs (Felber et al.1966, Gelzer 1968). The N-terminal 
segment (1-24) of ACTH peptide is highly conserved among all species and is believed 
to have low antigenicity (Lee et al. 1961, Kertesz  et al. 1998, Costa et al. 2004). Hence, 
it seems likely that the complex of ACTH1-24 and zinc in the depot tetracosactide 
formulation preparation may be important in the generation of the humoral immune 
response. However, I was intrigued to find out that five of the 13 participants from the 
RoSA study, who were never exposed to depot tetracosactide, demonstrated positive 
serum anti-ACTH binding activity at baseline. Similar findings were made in the larger 
cohort of Addison’s patients. These latter patients had all received one or two soluble 
ACTH1-24 peptide injections during diagnostic testing for Addison’s disease. Hence, I 
speculate that the anti-ACTH antibody response could potentially have been generated 
either from previous exposure to soluble tetracosactide, or more likely towards native, 
full-length endogenous corticotropin. This group of patients may be more susceptible to 
the breakdown of immune self-tolerance, by dint of their autoimmune Addison’s 
disease, but may also be susceptible owing to the very high levels of endogenous 
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plasma ACTH circulating in the months before their diagnosis of AAD. Indeed, several 
previous studies have revealed activity in the sera of AAD patients that appeared to 
attenuate the in vitro steroidogenic response of cultured adrenal tissue to ACTH 
(Wulffraat et al. 1989, Wardle et al. 1993, Kendall-Taylor et al. 1988). Although this 
was believed to be due to patient immunoglobulins that bound to and blocked 
stimulation of the ACTH receptor, several of the effects described would be consistent 
with antibodies that neutralized ACTH action in vitro. With this in mind, could these 
ACTH antibodies that were found in 21% of the unrelated AAD patients in our cohort 
contribute to the pathogenesis of autoimmune Addison’s disease? If these antibodies 
had functional consequences in terms of binding or clearing endogenous ACTH, then a 
state of relative “corticotropin resistance” could potentially lead to an accelerated 
decline in adrenal function during the natural history of evolving Addison’s disease. 
Plasma ACTH may be elevated for many years prior to the diagnosis of Addison’s 
disease (Torrejón et al. 2007) and this ACTH drives small islands of adrenal hyperplasia 
and regeneration (Guttman 1930, Saphir & Binswanger 1930), slowing the ultimate 
onset of adrenal steroidogenic failure. Thus early adrenal unresponsiveness to ACTH 
stimulation in evolving Addison’s disease may have the potential to tilt the balance 
from subclinical or partial adrenal insufficiency to clinically apparent adrenal 
insufficiency. This hypothesis would need to be confirmed in a future study. 
The significance of anti-ACTH antibodies in a small number of patients with Graves’ 
disease is also unknown, especially in the absence of clinically apparent adrenal 
insufficiency. Nevertheless, several studies have documented a blunted cortisol 
response to tetracosactide in hyperthyroid Graves’ disease, which would be consistent 
with the effects of anti-ACTH antibodies in these patients (Karl et al. 2007, Price et al. 
2012). It is also well known that patients suffering from one autoimmune disease are 
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susceptible to development of a second autoimmune condition, either manifesting as an 
overt disease following pathological destruction of self-tissue, or as the presence of 
circulating autoantibodies alone. Outside the context of autoimmune conditions, ACTH 
autoantibodies have been detected in patients suffering from anorexia nervosa and 
bulimia nervosa (Fetissov et al.2002). Patients suffered from major depression were also 
found to have impaired hypothalamic-pituitary-adrenal axis (Demitrack et al.1991, Scott 
et al.1998). Hence,it has been suggested that the presence of ACTH antibodies could 
potentially lead to a subclinical hypocortisolemia state or subnormal ultradian/circadian 
rhythm of ACTH secretion. This might result in chronic lethargy, anorexia, depression 
and even maladaptive behaviour due to poor stress response (Wheatland et al. 2005). 
The origin of these autoantibodies is unknown although some suggested that past or 
persistent infection could bring on this autoreactivity, potentially from molecular 
mimicry where some microorganism share common sequence fragment with ACTH, 
such as H.pylori and staph aureus infections (Oldstone et al. 1998).  Hence, the 
significance of auto-ACTH antihbody in human health warrants further investigation. 
With the demonstration that sera with anti-ACTH antibodies recognise native ACTH in 
human pituitary sections, I also wondered whether anti-ACTH antibodies could have a 
role in isolated ACTH deficiency. I was able to obtain sera from just a small number of 
individuals due to the rarity of this condition, and only one serum showed the anti-
ACTH binding activity. While isolated ACTH deficiency is a heterogeneous condition, 
a significant proportion of individuals have coexisting autoimmune thyroid disease or 
manifest other features of autoimmunity, and the target autoantigen has yet to be 
defined. Nevertheless, the presence of anti-ACTH antibodies in just one (7%) of these 
patient groups suggests that although these antibodies would be a logical mediator of 
isolated ACTH-deficiency, they are not a major cause of this condition. Larger patient 
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cohorts of this rare condition would needed to be examined in the future to confirm our 
preliminary findings.  
In summary, this study demonstrates that repeated administration of depot tetracosactide 
can lead to anti-ACTH autoreactivity. In addition, a significant number of untreated 
AAD and GD patients also had similar autoreactivity (P<0.001 vs controls). It is 
possible that these anti-ACTH antibodies mediated some of the adverse effects seen in 
participants of the RoSA study and that their propagation in individuals following 
multiple ACTH injections could explain the well-described phenomenon of resistance 
to chronic ACTH therapy. In future, further investigation is necessary to better define 
the role of these anti-ACTH antibodies in the pathogenesis of autoimmune Addison’s 
disease, isolated ACTH deficiency and other autoimmune conditions. 
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Chapter 5. Characterisation of 
adrenocortical stem cell 
phenotype: Isolation of 
mesenchymal stem cell-like cell 
populations from human adrenal 
cortex 
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5.1 Background 
The plasticity of the adrenal cortex suggests the presence of adrenocortical stem cells 
(ACSC) but the exact in vivo identity of ACSC remains elusive. In the past few decades, 
mesenchymal stromal or stem cells (MSCs) has emerged as a popular topic of interest in 
the field of research, owing to their multipotent differentiation capacity, low 
tumorigenicity and low immunogenic nature. They were initially isolated from the adult 
bone marrow and have subsequently been harvested from several other tissues, 
including the adipose tissue (Zuk et al. 2001), pancreas (Hu et al. 2003), umbilical cord 
(Wang et al. 2004), synovium (De Bari et al. 2001), dental pulp (Pierdomenico et al. 
2005), trabeculae bone (Tuli et al. 2003) and skeletal muscle (Young et al. 1995). MSCs 
are conceptually the postnatal progenitor cells of most derivatives of mesoderm (Bianco 
et al. 2008). The adrenal gland is thought to have originated from the intermediate 
mesoderm embryonically and hence MSC could potentially be the progenitor/stem cell 
source. In recent years, it has been shown that mouse and human MSC (adipose tissue 
or bone marrow-derived) could be induced to steroidogenic cells that produce a variety 
of steroids, via steroidogenic factor 1  (Gondo et al.2004, Yazawa et al. 2006, Tanaka et 
al. 2007, Gondo et al. 2008, Yazawa et al. 2011). With this in mind, I investigated the 
direct isolation of MSC from human adrenal cortex. 
 
MSCs lack a unique surface antigen that could be used for positive selection. However, 
they are characterised by their ability to be enriched and adhered to plastic dishes in a 
low-serum medium, growing as a homogenous population of adherent cells and express 
a set of marker proteins on their surface, including CD44, CD90, 105 and CD166 
(Pittenger et al. 1999, Dominici et al. 2006).  However, these markers are not specific to 
MSCs and they are mainly characterized by their capacity to differentiate along 
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mesodermal lineages into osteocytes, chondrocytes, adipocytes, and skeletal muscle 
cells (Pittenger et al. 1999).  The in vitro culture condition for the multilineage 
differentiation of human MSCs is driven by signalling cues directed by both cell density 
and supplementation with exogenous soluble factor (Barbero et al. 2003). 
On the other hand, studies attempting to define adrenocortical stem cells with murine 
models have suggested that adrenocortical progenitor cells reside at the capsule or 
subcapsular region of the adrenal cortex. The adrenal cells residing at the subcapsular 
region were found to co-express SF1 and DAX, with SHH responsive cells localized to 
the capsular region. Interestingly, DAX1 expression was found to be limited to the 
subcapsular region of the adrenal cortex and inhibits the ability of SF1 to transactivate 
steroidogenic enzymes. This prevents the differentiation of adrenal cells into the 3-zonal 
adrenocortical lineages. Hence, it has been postulated that subcapsular adrenal cell 
population that express SF1, SHH and DAX1 is a good candidate for adrenocortical 
progenitor cells.  
The aim of this study was to investigate if the human adrenal cortex harbours 
multipotent MSCs which were capable of differentiation into multiple mesodermal 
lineages, as well as their role as adrenocortical progenitor cells. This was carried out via 
cell culture, immunocytochemistry and flow cytometry studies. 
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5.2 Methods 
5.2.1 Preparation of transport medium, growth medium and digestion 
solution 
The following transport and growth media were prepared: 
 Transport medium comprising Dulbecco’s Modified Eagle Medium/Nutrient 
mixture F-12 (DMEM: Ham F12) medium (Invitrogen) with 1% 
penicillin/streptomycin (Invitrogen). 
 Complete growth medium (CM) comprising DMEM: Ham F12 medium with 
supplement mix as stated in table 5.1 and 1% penicillin/streptomycin. 
 Mesenchymal stem cell growth promotion medium (MGPM) comprising alpha 
modified Eagle’s medium (alpha MEM) (Invitrogen), 10% (vol/vol) fetal bovine 
serum and 5ng/ml fibroblast growth factor 2 (FGF2) (Sigma Aldrich). 
 Enzymatic digestion solution comprising 0.2% collagenase (2mg/ml) (Sigma 
Aldrich) and 0.01% deoxyribonuclease I (DNAse I) (Sigma Aldrich) (0.1mg/ml) 
dissolved in 30mls DMEM:Ham F12 medium. 
Table 5.1 Components of complete growth medium (CM) 
Component Concentration 
Insulin-Transferrin-Selenium (ITS) (Invitrogen) 0.5% 
Ascorbic acid (Sigma Aldrich) 0.25% 
Horse serum (Invitrogen) 5% 
Fetal bovine serum (FBS) (Invitrogen) 10% 
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5.2.2 Preparation of adrenal tissue and cell culture 
Full ethical approval was obtained from the local ethics committee (12/NE/0101). 
Adrenal tissue was obtained from consented patients undergoing either radical 
nephrectomy or partial nephrectomy for upper pole tumours, whereby their adrenal 
glands would be removed at the same time. The removed adrenal tissue was transferred 
within 24 hours to the laboratory on ice in a transport medium. A small part of the 
adrenal tissue was sliced sagittally to 3mm width and fixed in 4% paraformaldehyde 
solution overnight at room temperature, before being subjected to a further histological 
process as described in the next section. The remaining adrenal tissue was dissected and 
separated from fat and the adrenal medulla by removing tissue adjacent to the central 
vein. Instruments used include a round tipped pair of sterile scissors, forceps and blades. 
All dissection work was carried out in a sterile laminar flow hood and tissues were 
placed in a 10cm diameter Petri dish containing 10mls growth medium. The remaining 
adrenal cortex with capsule attached was then minced with scissors into approximately 
1mm
3
 and washed 3 times with DMEM/Ham 12 (1:1) medium, before being 
enzymatically dispersed in a digestive solution for 30 minutes at 37
o
C in a shaker table.  
Small tissue pieces are essential for a better final cell yield. 
The digested tissues were then disaggregated by gentle aspiration through a sterile 18 
gauge cannula before being filtered through a 70 µm nylon cell strainer (BD Falcon) 
into a 50ml centrifuge tube. The undigested tissue fragments were resubmitted to the 
same digestion procedure until all tissues were fully digested. The filtered cells were 
centrifuged at 437x g (Heraeus Labofuge 400R) for 5 minutes. The supernatant was 
carefully removed leaving approximately 0.5 ml liquid and the cell pellet at the bottom 
of the tube. The cell pellet was then resuspended gently in 2ml of growth medium to 
avoid bubble generation. 1ml of the cells were seeded in a complete growth medium 
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(CM) at a density of 1.0 x10
6
 per T-75 cell culture flask. The remaining 1ml of the cells 
were seeded in mesenchymal stem cell growth promotion medium (MGPM) at a density 
of 1.0 x10
6
 per T-75 cell culture flask. Cells grown under complete growth medium 
were incubated at 37
o
C  under an atmospheric oxygen tension of 20% and 5% CO2, 
whereas cells seeded in MGPM were incubated at a low oxygen tension of 5% O2, using 
a hypoxia incubator. Non-adherent cells were removed after 48 hours and monolayer 
cells were washed twice with 1% phosphate buffered saline (PBS) (Invitrogen) before 
being replaced with a new medium. Medium changes were carried out every 3 days 
thereafter. Colony forming units-fibroblasts (CFU-Fs) were counted in each culture 
every 2 days. All cell culture work was carried out under sterile condition in a class II 
laminar flow hood.  
 
5.2.3 Maintenance of adrenocortical cell culture 
Established cultures of adrenal cells seeded in either complete medium or MGPM were 
passaged when 80-90%% confluent by enzymatic detachment using TrpLE
TM
 Express 
(Invitrogen) and seeded at a density of 1x10
6
 /flask density. TrpLE
TM
 Express is a 
recombinant fungal trypsin-like protease with similar dissociation kinetics to trypsin but 
exhibits lower cellular toxicity. The medium was changed every 3 days. 
 
5.2.4 Detachment of monolayer cells from tissue culture plastics 
Monolayer cells were washed twice with 1% PBS before incubating with 3ml of 
TrpLE
TM
 Express at 37
 o
C for 5 minutes. When adequate cellular detachment was 
achieved, as visualised under a light-phase microscope, the cells were pipetted up and 
down gently to form single cell suspension and transferred to a sterile polypropylene 
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conical tube (BD Falcon). The cell suspension was then centrifuged at 437 x g for 5 
minutes. The cell pellet was resuspended carefully in 3ml of growth medium. 
 
5.2.5 Cell count 
Detached cells were resuspended in 3mls of complete medium. Cell count was 
performed by placing 10µl of fluid on a cell counter slide (haemocytometer) and 
counting the number of cells visible in 1 big square. The average count between the 3 
large squares was made and the total number of cells within the cell suspension was 
calculated. 
Viable cell counts were carried out with trypan blue (an acid dye which binds to 
intracellular proteins and would have only taken up when membrane integrity is lost), 
an exclusion dye that is only taken up by dead cells (Strober 2001). 90µl of cell 
suspension following detachment of monolayer cells was mixed with 10µl of 0.4% (v/v) 
trypan blue. 10µl of this mixture was then transferred to each chamber of a cell counter 
slide (haemocytometer) and viable cells were counted. The average cell count between 
the 3 chambers was made and the total number of cells within the cell suspension was 
calculated with the following formula: 
Total number of cells = Total cell counted x Dilution factor x 10
4 
cells/ ml 
 
5.2.6 Population doubling time 
Following primary cell culture, adrenal cortex-derived cells from passage 1 were plated 
in a 6-well culture plate at 10x10
4
 cells/well. They were cultured in both complete 
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growth medium and MGPM, respectively. The cells from each well were detached with 
TrpLE
TM
 Express and counted in triplicate with a hemocytometer every day until day 6.  
The population doubling time, or the time required for a culture to double in number, 
was calculated  with the formula previously described (Xu et al. 2010). 
Doubling Time = T x log2/ log(Nt/N0)  
T =  time interval in any units 
N0  = cell count at the beginning of the incubation 
Nt = cell number at the end of the incubation time 
 
5.2.7 Freezing and thawing of cells 
Monolayer of cells were detached with TrpLE
TM
 Express and resuspended in a freezing 
medium (Gibco) at 1x10
6
 cells/ml. The cells were frozen down in 1 ml aliquots in 
cryogenic vials at the rate of a 1
o
C decrease in temperature per minute using 
isopropanol chamber and stored at -80
 o
C in a freezer. 
 
5.2.8 Osteogenic, chondrogenic and adipogenic differentiation of human 
adrenocortical cells 
The monolayer adrenal cells grew in MGPM and complete media were detached with 
TrpLE
TM
 Express. The adrenal cells were then centrifuged at 630 x g for 4 minutes at 
room temperature. The supernatant was removed and the adrenal cells were resuspended 
in 4 ml of DMEM:Ham F12 medium with 10% FBS. Cells were then counted and 
collected as per the optimal quantity required for adipogenenic, osteogenic and 
chondrogenic differentiation, as stated below. 
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Chondrogenesis 500,000 cells/pellet 
Adipogenesis 100,000 cells/ml 
Osteogenesis 25,000 cells/ml 
 
5.2.8.1 Chondrogenic differentiation of human adrenocortical cells 
2 x 10
6
 adrenocortical cells were resuspended in 4 ml of StemPro chondrogenic 
differentiation medium (Invitrogen) to a final cell density of 500000 cells/pellet/ml. 1ml 
aliquots were transferred to sterile 15ml polypropylene conical tubes. The cells were 
then centrifuged at 630 x g for 4 minutes at room temperature to the bottom. The tubes 
were loosely capped to allow for gas exchange. The cell pellets were incubated in a low 
oxygen tension of 5% O2, hypoxia incubator. The chondrogenic medium was changed 
once every 3 days. 
 
5.2.8.2 Osteogenic differentiation of human adrenocortical cells 
The counted cells (100,000 cells) were resuspended in 4 ml DMEM:Ham F12 medium 
enriched with 10% FBS and seeded in a 12-well dish to a final cell density of 25,000 
cells/ml/well. The cells were incubated overnight until settled. Twenty-four hours post 
seeding, the DMEM +10% FBS medium were replaced with StemPro osteogenesis 
differentiation medium (Invitrogen). The medium was changed once every 3 days. 
 
5.2.8.3 Adipogenic differentiation of human adrenocortical cells 
The counted cells (400,000 cells) were resuspended in 4 ml DMEM:Ham F12 medium 
enriched with 10% FBS and seeded in a 12-well dish to a final cell density of 100,000 
cells/ml/well. The cells were incubated overnight until settled. The DMEM +10% FBS 
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medium was then replaced with StemPro adipogenesis differentiation medium 
(Invitrogen) the next day. The medium was changed once every 3 days. 
 
5.2.9 Histological examination of differentiated osteogenic, chondrogenic 
and adipogenic cells from human adrenocortical cells 
Safranin O staining 
Safranin O staining was used to characterise the formation or deposition of 
glycoaminoglycans (GAG) within cell pellet (Rosenberg 1971). The cell pellet was first 
processed and dehydrated through the machine processor and embedded in wax as 
described in the section below. Cell pellet sections were then deparaffinised through 
Histoclear (4x10 minutes), rehydrated through 100% ethanol (4x10 minutes) and rinsed 
in deionised water. The sections were then stained in Harris’haematoxylin for 4 minutes, 
destained in acidic alcohol for 10 seconds and rinsed in deionised water. This was 
followed by staining with 0.02% aqueous fast green (FCF) (Sigma Aldrich) for 3 
minutes, rinsing in 1% acetic acid for 30 seconds then staining with 0.1% aqueous 
Safranin O (Sigma Aldrich) for 5 minutes. The slides were rinsed thoroughly in 
deionised water and dehydrated with 100% ethanol (4x 30seconds) and Histoclear (4x1 
minutes) before being mounted using DePEX mouting medium (Leica Biosystem) and 
visualised using a phase contrast microscope. 
Alizarin Red S staining  
Alizarin Red S (ARS) is an anthraquinone derivative and was used to characterise 
calcium-rich deposits by cells in culture, in which calcium will form a complex with 
ARS in the chelation process (Lievremont et al. 1982, Gregory et al. 2004). Alizarin 
Red working solution (40µM ARS, pH 4.2) was prepared by dissolving 0.7g of Alizarin 
 187 
 
Red S (Sigma Aldrich) in 25mls double distilled water (ddH2O). The pH of the solution 
was adjusted to 4.2 with 0.5% ammonium hydroxide. DdH2O was added to bring the 
final volume to 50ml. The final solution was then filtered through a 100µm cell strainer. 
The monolayer of adrenal cells were washed with 1x PBS and fixed in 2% (v/v) 
paraformaldehyde (Santa Cruz) for 10 minutes at room temperature. Paraformaldehyde 
was removed and the monolayers were washed twice with ddH2O. 1ml of 40µM ARS 
was then added to each well and incubated at room temperature for 30 minutes with 
gentle shaking. The dye solution was then pipetted out carefully and wells were washed 
4 times (4x5 minutes) with 3 ml of ddH2O. The plate was then left at an angle for 2 
minutes to facilitate removal of excess water. The stained monolayer cells were then 
examined under a phase contrast microscope. 
 
Oil Red O staining  
Oil Red O comprised of lysochrome (fat soluble dye) used to demonstrate the presence 
of triglyceride deposition. The monolayer of adrenal cells were washed with 1x PBS 
and fixed in 2% (v/v) paraformaldehyde (Santa Cruz) at room temperature for 10 
minutes. Paraformaldehyde was removed and the monolayers were washed twice with 
ddH2O. The cells were then washed with 2ml of 60% isopropanol for 5 minutes at room 
temperature before letting them dry completely at room temperature. 1ml of Oil Red O 
(Sigma Aldrich) solution was added to each well and incubated at room temperature for 
15 minutes. The dye solution was then pipetted out carefully and ddH2O was added 
immediately to the wells. The cells were washed 4 times (4x5 minutes) with 3 ml of 
ddH2O. The plate was kept wet to keep the lipid vacuoles from disrupting. The stained 
monolayer cells were then examined under a phase contrast microscope. 
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5.2.10 Immunocytochemistry study of adrenal cells 
5.2.10.1 Fixation of monolayer cells 
Cells were harvested in either coverslips (sterilised with 70% ethanol) which had been 
plated in 12-well dishes or Lab-Tek
TM
II chamber slides (BD Bioscience), at cell 
densities between 10 x10
4
 to 30 x10
4
 cells per wells. Cells were cultured for 24-48 
hours. 
5.2.10.2 Immunofluorescent staining  
Cell culture media was removed and the monolayer cells were washed twice with 
1%PBS. The cells were then fixed in 2% paraformaldehyde for 10 minutes at room 
temperature and rinsed with 1%PBS (2x5 minutes). Autofluorescence quenching was 
enhanced by incubation with 1M ammonia chloride diluted with 1% PBS for 5 minutes 
followed by 2 washes (2x 5 minutes) with 1% PBS. Antigen retrieval was carried out 
where appropriate by incubating the cells in 0.1% triton X-100 for 3 minutes at room 
temperature followed by 3 washes with PBS (3x5 minutes). The cells were blocked with 
1% bovine serum albumin (BSA) and 5% goat serum for 30 minutes at room 
temperature. This was followed by incubation with the primary antibodies which were 
diluted with 1% BSA, either in a humidified chamber overnight at 4°C or at room 
temperature for 1 hour. One well was incubated with only 1% BSA, to use as a negative 
control. The isotype-matched species antibodies (Santa Cruz Biotechnology) were also 
used as IgG controls (with the same protein concentration as the primary antibodies 
used). Following on from primary antibody incubation, the cells were washed with 1% 
PBS (3X5 minutes). The appropriate secondary antibodies were then added for 1 hour at 
room temperature in the dark. Cells were then washed with 1% PBS (3X 5 minutes) and 
mounted with Vectashield containing 4’, 6-diamidino-2-pheny-lindole (DAPI) (Vector 
Laboratories), an anti-fade water-based mounting agent with integral nuclear stain and 
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coverslips. Slides were kept at 4°C in the dark for up to one week. The slides were 
visualised using AxioImager Z1 microscope (Zeiss fluorescent microscope with 
Apotome attachment). The dilution and manufacture of the primary and secondary 
antibodies used are detailed below (table 5.2 & table 5.3). 
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Table 5.2. Primary antibodies used for immunofluorescence 
Primary antibody 
 
Source Dilution (final 
concentration) 
Catalogue 
number 
SHH goat IgG Santa Cruz 
Biotechnology 
1:100 
(2µg/ml) 
SC1194 
GLI rabbit IgG Santa Cruz 
Biotechnology 
1:100 
(2µg/ml) 
SC20687 
SF1 goat IgG Santa Cruz 
Biotechnology 
1:100 
(2µg/ml) 
SC10976 
DAX1 rabbit IgG 
 
Abcam 1:200 
(2µg/ml) 
Ab97369 
MSC antibody panel 
including CD19, 
CD44, CD45, CD90, 
CD105, CD106, 
CD146, CD166  
R&D system 1:40 
(2.5µg/ml) 
 
SC017 
 
Table 5.3. Secondary antibodies used for immunofluorescence 
Secondary antibody Source/manufacture Dilution Catalogue 
number 
Bovine anti-goat IgG-
FITC  
Santa Cruz 
Biotechnology 
1:1000 
(0.4 µg/ml) 
S2348 
Sheep anti-rabbit 
IgG- Texas Red  
Abcam 1:2000 
(1 µg/ml) 
Ab6793 
Goat anti-mouse IgG- 
AF488  
Invitrogen 1:2000 
(1 µg/ml) 
A-10667 
Donkey anti-mouse 
IgG-AF 594 
Invitrogen 1:2000 
(1 µg/ml) 
A-21203 
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5.2.11 Flow cytometry analysis 
Flow cytometry was used to assess the immunophenotype and MSC immunoprofile of 
adrenal cells, as described by the position paper of the International Society for Cellular 
Therapy (ISCT) (Dominici et al 2006). Human adrenal cells were detached with 
TriplExpress and washed once in PBS followed by centrifugation at 1750 x g for 3 
minutes. The cell pellet was resuspended in fluorescence-activated cell sorting (FACS) 
buffer (1%PBS with 0.1% BSA) at a concentration of 5 × 10
5
 cells per 100 µL. These 
cells were filtered through a 100 µm nylon cell strainer (Falcon BD) and transferred to 
sterile 1.5ml microfuge tubes (1x10
6
 cells/ 200µl/tube). For indirect flow cytometry, the 
single-cell suspensions were incubated at 4°C for 1 hour with appropriate unconjugated 
primary antibodies or isotype-match control antibodies (Santa Cruz Biotechnology), as 
shown in table 5.4.  The cells were washed once and centrifuged at 1750 x g for 3 
minutes. The supernatant was aspirated and the cell pellets were resuspended in a 200µl 
cold FACS buffer. The cells were incubated with appropriate secondary antibodies on 
ice in the dark for 40 minutes. They were then washed twice with cold PBS and 
resuspended in 700ml 1% PBS for immediate analysis. For direct flow cytometry, 
single-cell suspensions were incubated with fluorochrome-conjugated primary 
antibodies (table 5.4), on ice and in the dark for 40 minutes. They were washed with 
cold 1%PBS twice and resuspended in 700ml of 1% PBS for flow cytometry analysis. 
For intracellular staining, 100µl of fixation medium (reagent A) from the Fix and Perm 
cell permeabilization kit (Invitrogen) were added to 100µl of single cell suspension 
following detachment of monolayer cells. These cells were incubated at room 
temperature for 15 minutes and washed once with 1ml of PBS. The supernatant was 
aspirated and cell pellets were resuspended in 100µl of FACS buffer. 100µl of reagent 
B (permeabilization medium) and the appropriate unconjugated antibody or the 
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corresponding isotype control were added. Cells were incubated for 20 minutes at room 
temperature and washed once with 1ml PBS. The cell suspensions were incubated with 
secondary antibodies on ice and in the dark for 40 minutes. Cells were then washed 
twice and resuspended in 1% PBS for immediate analysis. The controls comprised 
unstained cells, cells incubated with secondary antibodies only and isotype-matched 
species antibodies as IgG control (same protein concentration as primary antibodies 
used). The dilution and manufacture of the antibodies and fluorochromes used are 
detailed in table 5.5. I used mesenchymal progenitor/stromal cells harvested from knee 
aspirate as the positive control.  These knee-aspirate derived MSCs were a gift from the 
musculoskeletal stem cell group at the Institute of Cellular Medicine, Newcastle 
University. 
Flow cytometry analysis was carried out using FACS Canto II Colour flow cytometer 
(BD Biosciences) with the following parameters (table 5.6). Electronic gating on the 
basis of forward scatter (FCS) and side scatter (SSC) was used to eliminate cell debris 
and non-viable cells. Data was analysed using FACS Diva version 8 and Venturi One 
version 2 softwares. Figure 5.1 and figure 5.2 depicted the details of FACS analysis; 
20,000 events were recorded for each sample.  
The flow cytometry analysis was performed at passage 1, 3, 5, and 7 for MPGM and 
passage 1, 2 and 3 for cells harvested in CM. 
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Table 5.4. Unconjugated and conjugated primary antibodies used in flow 
cytometry 
Primary antibody Source Dilution Catalogue 
number 
Unconjugated primary antibody 
 
DAX1 rabbit IgG 
 
Abcam 1:10 
(40 µg/ml) 
Ab97369 
GLI rabbit IgG Santa Cruz 
Biotechnology 
1:10 
(20 µg/ml) 
SC20687 
MSC antibody panel 
(mouse antibodies) 
R&D system 1:1 
(100 µg/ml) 
SC017 
Conjugated primary antibody 
 
MHC I HLA-ABC 
Antibody, FITC 
conjugate  
Thermo Scientific 1:1 
(100ug/ml) 
MA1-80454 
MHC II HLA-DR 
Antibody, FITC 
conjugate 
Thermo Scientific 1:1 
(100ug/ml) 
MA1-19620 
 
Table 5.5. Secondary antibodies and fluorochrome used in flow cytometry 
Secondary antibody Source/manufacture Dilution Catalogue 
number 
APC-conjugated goat 
anti-rabbit IgG (400 
µg/ml) 
Santa Cruz 
Biotechnology 
1:100 
 
SC3846 
FITC-conjufated goat 
anti-mouse IgG  
Sigma Aldrich 1:100 
 
F2653 
 
Table 5.6.  Flow cytometry set up and parameters 
Parameters/fluorochrome Emission filters Voltage 
FSC - 280 
SCC - 300 
FITC 488/530/30 310 
APC 633/660/20 420 
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B  
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D 
 
Figure 5.1An example of a FACS analysis with one of the MSC marker–CD44 
(FITC labelled) and DAX1 marker (APC-labelled) in the study 
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Figure legend 5.1 
A. The negative control graph for FITC labelled antibodies as shown by the 488/530/30 
band pass filter (X-axis) against cell counts (Y-axis). The histogram is shifted to the left 
as the sample was not incubated with primary antibodies but only FITC-conjugated 
anti-mouse antibodies. The P2 section was configured in a way that allowed 98% of the 
negative control counts to fall outside this area.  
B. Histogram for sample labelled with primary antibody (CD44) and FITC-conjugated 
secondary antibody, showing nearly 100% cell counts falling in the P2 section, 
suggesting positivity of CD44 in the sample.  
C. The IgG isotype control graph for APC labelled antibody as shown by 633/660/20 
band pass filter (X-axis) against cell counts (Y-axis). The P4 section is set so that 98% 
of the isotype control counts fall outside this area.  
D. Histogram for sample labelled with primary antibody (DAX1) and APC-conjugated 
secondary antibody, showing nearly 100% cell counts falling in the P4 section with 
strong positive staining of DAX1 marker. 
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A              B 
     
 
C            D 
   
Figure 5.2 A-D demonstrated the dot-plot for the double-immunostaining with 
CD90 (FITC labelled- 488/530/30) and GLI (APC-633/660/20) markers in the study 
APC-labelled GLI1+ count (X-axis) was plotted against the FITC labelled CD90+ count 
(Y-axis). Positivity with dual-staining was indicated by the Q2 region, in which >98% 
of the control and species-specific isotype controls fall outside this area. 
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5.2.12  Tissue embedding and paraffin wax blocks. 
A small section of adrenal tissue (cut sagittally) or cell pellet from chondrogenic culture 
medium was washed in 1% PBS before being fixed in 4% paraformaldehyde for at least 
3 hours at room temperature. The tissue was then transferred to a machine processor 
programmed to carry out the following dehydration steps. The tissue was first 
dehydrated in 50% ethanol for a minimum of 2 hours at room temperautre in the shaker 
and then overnight in 70% ethanol. Dehydration was completed in 3 changes of 100% 
ethanol (total 6 hours) at room temperature. Tissue was then cleared overnight in a glass 
container in Histoclear (National Diagnostics) and stored in a fume hood before being 
equilibrated in 3 changes of paraffin over 6 hours at 60°C. The glass tube was swirled 
occasionally to ensure adequate penetration of the wax. The adrenal tissue or cell pellet 
was then orientated in a plastic mould so that the cut surface accurately represented the 
tissue. The block was then left to set at room temperature for at least 1 hour and cooled 
on ice before removing the paraffin block from the mould. 
 
5.2.13 Microtome sectioning 
Paraffin blocks of adrenal tissues or cell pellets were sectioned at a thickness of 4 µm 
using a Leica RM2135 rotary microtome with disposable microtome blades. The cut 
sections were floated onto a water bath at 37°C. This allowed the sections to expand and 
removed any creases. The sections were then floated onto Superfrost slides (Thermo 
Scientific). The slides were dried for 1 hour on a heating plate (37°C), to promote 
adhesion of the section onto the glass slides, followed by heating in an oven at 60°C for 
1 hour. These slides were then stored in plastic slide boxes at room temperature until 
staining was required. 
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5.3  Statistical analysis 
To ascertain if the mean values of a measurement on one sample was significantly 
different from another un-paired sample, the two sample Student’s T test was carried 
out on experimental data which was normally distributed. For experimental data that 
could not be transformed to exhibit a normal distribution, either due to out-lying data 
points or if the distributions curve of the data was skewed, the Kruskal-Wallis H test 
was carried out as a non-parametric equivalent to the student’s T test. Data was 
analysed using Microsoft Excel, GraphPad version 6 and Minitab version 16. All the 
data was expressed as mean±SEM (standard error of the mean). 
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5.4 Results 
In order to determine if mesenchymal stem cells could be isolated from human adrenal 
cortex, I performed cell culture using 3 independent adrenal tissues and performed the 
experiments in triplicates of the same culture condition, using normal human adrenal 
tissues obtained from nephrectomy for upper pole tumours. For each culture, 
adrenocortical cells were seeded in a complete medium (CM) and mesenchymal stem 
cell growth promotion medium (MGPM). 
 
5.4.1 Morphological characterisation of monolayer adrenocytes in the CM 
vs MGPM  
The initial cultures of both CM and MGPM were relatively similar, demonstrating a 
highly heterogenous population of cells, which are sparsely distributed (figure 5.3 & 
5.4A). The cultures were predominantly comprised of larger adrenocotical cells, with a 
polygonal appearance and a lipid core. Within the same culture, a number of smaller 
cells that had a long, thin and spindle-like shape appearance were observed. There are 
characteristics of the bone-marrow derived mesenchymal stem cell (MSC) fibroblasts 
(Friedenstein et al. 1976, Pittenger et al. 1999).  With increasing passage numbers, 
morphological differences were observed between the CM versus MGPM treated 
adrenal cell populations (figure 5.3 & 5.4E). The control adrenal cells grown in CM 
continued to exhibit a morphologically heterogenous cell population which were more 
spread out. On the contrary, the adrenal cells grown in MPGM became more 
homogenous by demonstrating a uniform population of spindle-shape cells, consistent 
with MSC-like cell population. These cells were smaller, elongated and aligned in 
parallel to each other. 
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The colony forming-unit (CFU) fibroblast-like cells were seen in as early as day 5 and 
day 2 of seeding in CM and MGPM respectively. Cells seeded in MGPM exhibited a 
higher number of CFUs. Another distinctive feature was the presence of a number of 
phase-bright specks (indicated by black open-head arrows) in MGPM that are largely 
absent from the complete medium. These are thought to represent mitotic bodies, 
indicating increased proliferative ability caused by fibroblast growth factor 2 (FGF2) in 
MSC-promoting medium. The differences between cells seeded in CM and MGPM are 
summarised in table 5.7. 
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Table 5.7. Differences between adrenal cortex-derived cells harvested in CM vs. 
MGPM 
Differences CM MGPM 
Cell population Heterogeneous Homogenous 
Morphology Large polygonal Elongated spindle-shape 
Lipid core/secretion Yes None of first passage 
Number of CFUs/T-75 
flask (prior first passage) 
2-3 8-10 
Presence of mitotic bodies Few Abundant 
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Figure 5.3. Morphological characterisation of monolayer adrenocortical cells in complete growth medium (CM). 
Human adrenal cells isolated from patients undergoing nephrectomy for upper pole tumours were expanded by plastic adherence in T-75 flasks. 
Representative images were taken of culture at day 3(A), day 5(B), day 7(C), day 10(D), passage 1 (E), passage 3(F). Most of the cells are comprised 
of adrenocortical cells that are larger with polygonal appearance and light refractive lipid (steroid) core. Black closed-head arrows indicate colony-
forming units with fibroblast-like cells (B&C). White closed-head arrow show lipid fragments protruded or elongated from steroid-producing 
adrenocortical cells (A,D&E). Black open-head arrows indicate long, thin, spindle-shape fibroblast-like cells (E). (Magnification x100) 
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Figure 5.4. Morphological characterisation of monolayer adrenal cells in mesenchymal stem cell growth promotion medium (MGPM) 
 
Human adrenal cells isolated from patients undergoing nephrectomy for upper pole tumour were expanded by plastic adherence. Representative images 
were taken of culture on day 2(A), day 3(B), day 4(C), day 5(D), day 6(E) and passage 1(F). Cells on day 2 largely comprised of adrenocortical cells 
that were larger with polygonal appearance and light refractive lipid (steroid) core, similar to those seeded in CM. However, cells seeded in MGPM 
were gradually replaced by spindle-shape fibroblast-like cells. Black closed-head arrows indicate colony-forming unit fibroblast-like cells (A&B). 
White closed-head arrow show lipid fragments protruded or elongated from steroid-producing adrenocortical cells (A). Black open-head arrows 
indicate the presence of phase-bright mitotic bodies (F). (Magnification x100)
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5.4.2 The proliferative capacity of monolayer adrenal cells in CM vs 
MPGM 
Adrenal cortex-derived cells isolated and expanded in MSC promoting media were 
noted to have an increased proliferative capacity compared to those cultured in normal 
media (figure 5.5). The doubling time for cells cultured in MGPM and CM was 38 and 
69 hours respectively. The adrenal cells harvested and maintained in MGPM had been 
maintained for up to 10 passages without changing their morphology and might be 
capable of long-term culture. In contrast, adrenal cells cultured in CM showed 
replicative senescence following passage 3, as suggested by growth arrest despite 
renewal of the culture medium and sub-culturing. For adrenal cells maintained in 
MGPM but switched to CM at passage 5 and 7, replicative senescence was observed in 
the same passage when the medium was changed. The cells in CM were grown to 
confluence approximately once every 10-14 days whereas cells in MGPM had reached 
confluence by day 5. Adrenal cells cultured in both CM and MGPM achieved more than 
90% viability upon each passage of cell culture, as determined by the trypan blue dye. 
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Figure 5.5. Comparison proliferation rate in MGPM vs. CM 
 
Adrenal cortex-derived from passage 1 showed a higher growth rate in medium 
with mesenchymal stem cell growth promotion medium (MGPM) as compared to 
the proliferation rate observed in complete growth medium (CM). The values are 
expressed as means ± SD of 3 independent measurements.
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5.4.3 In-vitro differentiation capacity of adrenal cortex-derived MSCs-like 
cells 
I evaluated the mesenchymal lineage differentiation potential of adrenal cortex-derived 
cells, which is the hallmark of MSCs. Cells from passage 2 (CM) and passage 3 
(MGPM) were cultured under conditions favourable for osteogenic, adipogenic and 
chondrogenic differentiation, as detailed in the method section. 
Osteogenic differentiation was induced in cells cultured in both CM and MGPM 
although the staining for Alizarin red S was significantly weaker in cells harvested in 
CM (figure 5.6). In contrast, cells harvested from CM failed to survive both 
chondrogenic and adipogenic medium. 
For adrenal cells cultured in MGPM, morphologic changes consistent with adipogenesis 
were observed as early as day-14 (figure 5.7A). Maximal lipid accumulation was seen 
in week-3 with lipid droplets being observed floating in the medium prior to staining. 
The lipid vacuoles were visualised with Oil-red O staining (figure 5.7B). Adrenal cells 
harvested in MGPM managed to form cell pellets but no staining was detected with 
safranin O suggesting lack of glycosaminoglycans (GAG) formation (figure 5.8). 
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Figure 5.6. Osteogenic differentiation capacity of adrenal cortex-derived cells 
 
Adrenal cells cultured in MGPM (1) and CM (2) were exposed to osteogenic 
differentiation medium. Cells from both media were shown to differentiate into 
osteogenic lineage at day-21 with enhancement of alkaline phosphatase activity as 
shown with the positive staining for Alizarin S (A). Figure B showed negative staining 
for non-induced controls. (Magnification x100) 
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Figure 5.7. Adipogenic differentiation capacity of adrenal cortex-derived cells 
 
Cells cultured in MGPM were exposed to adipogenic differentiation medium. Cells 
from MPGM were induced into adipogenic lineage, as shown by the cellular 
accumulation of lipid-rich vacuoles (A), which stained with Oil-red O (B). Figure C 
showed negative staining for non-induced controls (Magnification x100) 
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Figure 5.8. Chondrogenic differentiation capacity 
 
Adrenal cells cultured in MGPM were processed into cell pellets and exposed to 
chondrogenic differentiation medium for 21 days. This figure showed 50x (A) and 100x 
(B) magnification of cell pellet following safranin O staining. The pellet had negative 
staining signifying a lack of GAG accumulation within the cell region. Adrenal cortex-
derived cells cultured in either CM or MGPM were lacking in chondrogenic 
differentiation capacity under these conditions. 
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5.4.4 Flowcytometric analysis 
I performed immunophenotyping using flow cytometer to characterise the antigens 
expressed by adrenal-cortex derived cells. The cell surface and intracellular marker 
evaluations were carried out at various stages of cultures. Adrenal cortex-derived cells 
are heterogeneous in their composition and hence no cell subset can be clearly 
discriminated on light scatter grounds. Nevertheless, adrenal cells harvested from 
MGPM have low side angle scatter (low cytoplasmic granularity) and forward angle 
scatter (smaller cell size) (figure 5.9). Neither the cells from CM or MGPM were 
positive for haematopoietic (CD45) or lymphocytic markers (CD19). Similar to the 
mesenchymal stromal cells (MSC) isolated from knee aspirate, which I used as a 
positive control, adrenal cortex-derived cells were strongly positive for MSC markers- 
CD44, CD90, CD105 and CD166. All these cells were also positive for MHC class I but 
negative for MHC class II markers (figure 5.9).  The average percentage of cells 
positive for MSC markers was significantly less among those harvested from CM, in 
comparison to those from MGPM (CM vs MGPM (mean± S.D: 57.7±24.6% vs. 83.9± 
14.5% ; p=0.006). The frequency or percentage of cells positive for each MSC marker 
cultured in CM and MGPM is summarised in table 5.8. 
In addition, it was noted that the intensity of MSC marker expression was higher among 
cells from MGPM compared to those from CM, although this difference was not 
statistically significant (fluorescence intensity for CM vs. MGPM: 2639±611 vs.3194± 
902; NS). When the cells harvested in MGPM were cultured in CM following the 5
th
 
and 7
th
 passage, there was a reduction in the intensity of MSC surface marker 
expression (figure 5.10), but this was not statistically significant. The average frequency 
of cells positive for MSC markers was also decreased (90.5± 3.11% vs 78.0±9.62%, 
p=0.255,NS). There was no significant difference observed with respect to the intensity 
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of antigen expression or frequency of MSC marker-positive cells, between the various 
passages for both CM and MGPM-cultured cells. 
Immunophenotyping using DAX1 and GLI1 intracellular markers was also carried out 
(figure 5.11). A significantly higher percentage of adrenal cortex-derived cells cultured 
in MGPM expressed GLI1 marker, compared to those harvested from CM (MGPM: 
92.7±2.75% vs. CM:22.8±2.7; p=0.035).  Cells from MGPM also showed stronger 
signals towards the GLI antibody, although this was not statistically significant (figure 
5.12). GLI expression was significantly decreased following incubation with a synthetic 
adrenocorticotropic hormone (ACTH1-24 ; synacthen) among MGPM-cultured cells 
(antigen expression: 31.6± 0.8%; P=0.03). A similar observation was noted when cells 
changed from MGPM to CM at passages 5 and 7 (antigen expression: 37.3± 9.8%; NS). 
Interestingly, DAX1 was highly expressed in cells cultured in MGPM but negligible in 
those harvested from CM, as the count was similar to those from controls (CM:3.95 
±1.05 vs MGPM: 94.9± 0.7% ; p=0.009). Double-immunnostaining of adrenal cells also 
revealed that MSC markers co-localized with GLI and DAX1staining (figure 5.13 & 
5.14) 
I attempted to study the expression of SHH and SF1 in adrenal cells using flow 
cytometry but failed. The anti-SHH and anti-SF1 antibodies purchased were probably 
not suitable for flow cytometry. Nevertheless, these antibodies showed good results in 
immunocytochemistry, as depicted in the next section. 
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Table 5.8. Immunophenotyping of MSC markers 
MSC markers Percentage of positive cells (%+SEM) 
MGPM (first passage) CM (first passage) 
CD44 89.7 ± 2.52 61.2 ±7.34 
CD90 80.4 ± 14.4 44.6± 14.6 
CD105 91.6 ± 0.9 83.7 ±.1.65 
CD166 73.9 ± 8.12 41.4± 16.8 
 
The differences between the frequency of positivity towards each MSC markers, 
cultured in CM and MGPM respectively, were non-significant (p>0.05). 
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Figure 5.9. Representative MSC immunophenotype profile of adrenal cortex-
derived cells cultured in CM and MGPM. 
 
Graph A&B represent the scatter plot (side scatter vs. forward scatter FSC/SCC) for 
cells from MGPM and CM respectively.  FSC/SCC represents the distribution of cells 
in the light scatter based on size and intracellular composition. More cells harvested 
from MGPM seem to have lower side angle scatter (low cytoplasmic granularity) and 
forward angle scatter (smaller cell size). The SSC/FCS gating of the total adrenal cells 
analysed was to exclude non-viable elements and debris.  
The panel of histograms represent MSC immunophenotypes of adrenal cells. The 
adrenocortical cells displayed strong signals with CD44, CD90, CD105 and CD166 
markers (as demonstrated by a shift to a higher fluorescent intensity from controls), but 
negative for haematopoitic and lymphocytic markers (CD19 and CD45).  X-axes 
display signal (fluorescent) intensity and y-axes represent cell count. 
(Red histogram: unstained cells; blue histogram: negative control with fluorochrome 
conjugated secondary antibodies only; green histogram: species-specific isotype contro; 
yellow histogram: The staining of cells with relevant antibody).  The colour codes are 
applicable to all histograms except graph on MHC class I & II, where blue histogram 
indicates negative control,  yellow and green histograms represent MHC class I (HLA-
ABC) and MHC class II (HLA-DR), respectively. 
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Figure 5.10. Effects of CM on MGPM-cultured cells with respect to MSC marker 
expression 
 
The bar chart demonstrates reduced MSC marker expression among adrenal cells when 
they were switched from MGPM to CM (at passage 5 and 7). Y axes represent the 
signal intensity (mean with SEM) (All differences were statistically non-significant, 
p>0.05). 
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Figure 5.11. Representative FACS analyses of DAX1 and GLI1 immunophenotype 
of adrenal cortex-derived cells cultured in MGPM 
 
The cells displayed positive signals with DAX1and GLI. The X-axes display signal 
intensity. (Red histogram: unstained cells; green histogram: negative control with 
fluorochrome conjugated secondary antibodies only; blue histogram: species-specific 
isotype control; yellow histogram: The staining of MGPM-cultured cells with relevant 
antibody) 
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Figure 5.12. depicting the fluorescent intensity of GLI1 and DAX2 expression 
among adrenal cortex-derived cells. 
 
 GLI was richly expressed both in MGPM and CM, without significant difference 
(p=0.83). DAX1 signal was only expressed in cells from MGPM (P=0.08). GLI1 
expression was reduced following incubation with ACTH at either 0.05µg/ml or 
250ng/ml concentration (NS). 
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Figure 5.13.  Dot plot for cells from 7th passage in MGPM, following dual staining 
with MSC (FITC labelled- 488/530/30) and DAX1/GLI markers (APC-633/660/20) 
as indicated. 
Positivity with dual-staining was indicated by the Q2 region, in which >98% of the 
control and species-specific isotype controls fall outside this area. Approximately 46.8% 
of the cells co-expressed CD44 and DAX1, whereas 23.8% of cells co-expressed CD90 
and GLI1. 
46.8% 
23.8% 
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Figure 5.14. Dot plot for cells from first passage in CM, following dual staining 
with MSC (FITC labelled- 488/530/30) and DAX1/GLI1 markers (APC-633/660/20) 
as indicated. 
Positivity with dual-staining was indicated by the Q2 region, in which >98% of the 
control and species-specific isotype controls fall outside this area. Approximately 1.3% 
of the cells co-expressed CD105 and DAX1, whereas 4.1% of cells co-expressed CD90 
and GLI1. 
0.8% 
3.4% 
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5.4.5 Immunocytochemistry study 
In order to verify the immunophenotyping results from FACS, I performed 
immunocytochemistry studies on cultured cells harvested from CM or MGPM. Adrenal 
cortex-derived cells cultured in either medium showed strong membranous staining 
towards CD44, CD90, CD105 and CD166 markers but negative for CD19 and CD45 
antigens, as shown in  figures 5.15 to 5.18. This was consistent with the results 
generated from FACS. Nevertheless, cells harvested from CM lost their positive 
staining towards CD 105/CD166 with only weak CD44/CD90 staining following 
second and third passages. In contrast, adrenal cells cultured in MGPM showed 
persistent positive staining towards all MSC markers used in this study despite repeated 
passaging. 
I then examined the presence of adrenal/gonadal-specific markers (SF1, DAX1) and 
morphogenic signalling antigens (SHH and GLI1), among the cultured adrenal cells.  
Adrenal cells harvested from CM showed strong nucleus staining towards SF1 and 
GLI1 markers, with negative DAX1 and SHH staining (figure 5.20 to 5.22). In contrast, 
DAX1 and SHH were expressed among MGPM-cultured cells, as demonstrated by 
positive nucleus and cytoplasmic staining, respectively (figure 5.21 & 5.22). Strong 
GLI1 and SF1 staining was also observed among cells harvested from MGPM (figure 
5.20 & 5.22).  GLI1 was observed to be more widely expressed among the cell 
population from MGPM compared to those from CM. 
Double-immunostaining revealed that MSC markers co-localised with SF1, SHH and 
GLI1 antigens (figure 5.23 and 5.24). However, I failed to demonstrate co-expression of 
DAX1 and MSC markers in either CM or MGPM- cultured cells. 
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Figure 5.15. Immunolabelling of adrenal cells for MSC surface markers  
Cells were cultured and maintained in CM and MGPM. Immunolabelling of MSC surface markers were carried out after passage 1 (day 10 in CM) and 
passage 3 (day 18 in MGPM) respectively. Negative controls were carried out in parallel to each immunolabelling reaction. The details of negative 
controls are depicted in figure 5.19. Cells from CM were larger and more sparsely distributed, compared to the smaller and more elongated cells from 
MGPM. Cells from both mediums stained positive for CD44, CD90, CD105 (Magnification x100). Pictures with higher magnification are depicted in 
figure 5.17 and figure 5.18.  
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Figure 5.16. Immunolabelling of adrenal cells for MSC surface markers  
Cells were cultured and maintained in CM and MGPM. Immunolabelling of MSC surface markers were carried out after passage 1 (day 10 in CM) and 
passage 3 (day 18 in MGPM) respectively. Cells from both mediums showed positive staining for CD166 but negative staining for CD19 and CD45 
markers (Magnification x100). Pictures with higher magnification are depicted in figure 5.16.
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Figure 5.17. Immunolabelling of adrenal cells for MSC markers (CD44 & CD90), visualised at higher magnification, x200. 
Complete medium (CM) MGPM 
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Figure 5.18. Immunophenotyping of adrenal cells for MSC markers (CD105,CD166), visualised at higher magnification, x200.
Complete medium (CM) 
MGPM 
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Figure 5.19. A representation of the negative controls used in this 
immunofluorescence study. 
The top panel represents incubation with the second antibody without the primary 
antibody. To confirm the specificity of each antibody used in the immunochemical 
reactions, control immunolabelling reactions were carried out in parallel using species-
specific pre-immune antibodies with the appropriate secondary antibodies, derived from 
mice, rabbits and goats (Santa Cruz Biotechnology). All isotype IgG controls were used 
in the same protein concentration as the relevant primary antibodies. 
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Figure 5.20. Immunolabelling of intracellular markers SF1  
Immunolabelling of intracellular markers SF1 (Santa Cruz Biotechnology) were carried out after passage 1 (day 10) and passage 3 (day 18) for cells 
cultured in CM and MGPM respectively. Immunolabelling with SF1 revealed strong nuclear with weak cytoplasmic staining in >95% of the cells 
cultured in either CM or MGPM. (Magnification x200) 
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Figure 5.21. Immunolabelling of intracellular markers DAX1  
Immunolabelling of intracellular markers DAX1 (Abcam) were carried out after passage 1 (day 10) and passage 3 (day 18) for cells cultured in CM 
and MGPM respectively. Positive DAX1 labelling was only found in cells harvested in MGPM, as demonstrated by the moderate degree of positive 
nuclear staining. (Magnification x200) 
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Figure 5.22.  Immunolabelling of intracellular markers for SHH and GLI1 
Cells were cultured and maintained in CM and MGPM. Immunolabelling of intracellular markers for SHH (Santa Cruz Biotechnology) and GLI1 
(Santa Cruz Biotechnology) were performed after passage 1 (day 10) and passage 3 (day 18), in CM and MGPM respectively. Immunolabelling with 
SHH revealed strong cytoplasmic staining for cells cultured in MGPM only.  GLI1 positivity was demonstrated among cells harvested from both 
cultures, as shown by strong nuclear staining.
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Figure 5.23. Double immunostaining of cells cultured in MGPM.  
Cells cultured in MGPM co-expressed CD44 (membrane/cytoplasmic staining), GLI1 (nuclear staining) and SHH (cytoplasmic staining) markers. 
(Magnification x200) 
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Figure 5.24. Double immunostaining of cells cultured in CM and MGPM as indicated. 
MSC marker (CD44 or CD90) co-localised with steroidogenic factor 1 (SF1) in cells harvested from both CM and MGPM, as indicated by the uptake 
of membranous staining (MSC) and nuclear/cytoplasmic staining (SF1). (Magnification x200) 
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5.5 Discussion: 
I have identified a cell population that exhibits marker signatures for both mesenchymal 
stem cells (MSCs) and adrenocortical cells. This group of cells could potentially be the 
previously uncharacterized multipotent human adrenocortical progenitor cells. 
According to the International Society of Cellular Therapy (ISCT), the minimal criteria 
for defining MSCs includes adherence to plastic under standard culture conditions, 
expression of cell surface markers such as CD90, CD105 and the lack of expression of 
CD45, CD19 and HLA-DR (MHC class II). They also have the capacity to differentiate 
into osteocytes, adipocytes, and chondrocytes (Dominici et al. 2006). However, other 
markers have also been associated with MSCs in previous years, including CD44, 
CD166 and HLA ABC (MHC class I) (Schaffler & Buchler C 2007). 
For the first time, it has been demonstrated that the human adrenal cortex harbours a cell 
population with properties consistent with MSCs that sustain long term culture. This 
MSC-like population is characterised by a low forward angle scatter (smaller cell size), 
and low side angle scatter (low cytoplasmic granularity). When plated onto a plastic 
vessel in the mesenchymal stem cell growth promotion medium (MGPM) under 
hypoxic condition, a homogenous cell population developed. They were 
morphologically fibroblast-like MSCs that were characterized by their ability to form 
colony-forming unit-fibroblast (CFU-F). They also had high proliferative capacity and 
exhibited multipotent potential towards osteogenic and adipogenic cell lineages. 
However, these cells failed to differentiate into the chondrogenic lineage. The exact 
reason for this is not clear but distinct features have been observed among MSCs 
isolated from different organs, with respect to their immunophenotype and secreted 
cytokines profile (Mitchell et al. 2006, Kilroy et al. 2007). Hence, the failure of 
induced-chondrogenesis among these adrenal-derived cells could be due to the lack of 
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innate chondrogenic differentiation potential or related to the in vitro cell expansion 
techniques.  
Adrenal cells cultured in a complete medium were noted to have died following 
incubation with chondrogenic or adipogenic medium. This is likely due to the lack of 
MSC-like cells in the CM following incubation under normal oxygen tension (21%), 
resulting in failure to withstand high glucose and dexamethasone concentration in the 
differentiation medium. Indeed, a study has shown that MSCs usually present in stem 
cell niche under hypoxic condition and in vivo primary culture in normal atmospheric 
tension may exert oxidative stress on MSCs leading to apoptosis, as well as limit their 
proliferation and cell fate commitment (Mohyeldin et al. 2010). 
As discussed in chapter 1, it has been postulated that adrenocortical progenitor cells 
reside at the subcapsular region of the adrenal cortex and co-express SF1 and SHH 
markers. This group of cells is essential for adrenal proliferation and to prevent cellular 
differentiation. DAX1 is the transcription factor for maintaining the ‘stemness’ of 
stem/progenitor cells, by turning off the cellular differentiation capacity. In this study, I 
found strong expression of SHH, GLI1 and SF1 among adrenal cells cultured in MGPM. 
SHH is the main initiator of the SHH-GLI pathway and GLI1 is the associated 
transcription factor. These markers were found to co-localize with SF1, the adrenal 
specific marker. This finding suggests that the MSC-like population expanded in vitro 
were predominantly adrenal progenitor cells, isolated from the subcapsular region of 
adrenal cortex and proliferated in MGPM. Furthermore, DAX1 expression was only 
observed among MGPM-cultured cell, indicating that ‘stemness’ was enhanced among 
an MSC-enriched medium. This accounts for the shorter doubling time, higher 
proliferative capacity and potential for long term culture.  
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This study has a few limitations. Firstly, it is difficult to isolate or sort the MSCs from 
the culture as the adrenal cortex-derived cells were comprised of a heterogeneous 
population of cells. This resulted in difficulties in quantifying and defining other 
molecular characteristics of this unique group of cells. Since this is the first study 
demonstrating isolation of MSC-like cells from the adrenal cortex, there is no previous 
published protocol with respect to the isolation and maintenance methods. Different 
isolation techniques, particularly the use of a digestive enzyme such as the recombinant 
fungal trypsin-like protease used in this study, might affect MSC function or 
differentiation capacity by non-specific degradation. Hence, future studies should 
attempt to explant the culture of MSC from adrenal cortex pieces.  
MSCs have great potential in tissue engineering as they provide an autologous source of 
cells, without the issues of tissue construct rejection or immunosuppressive therapy. 
MSCs also lack HLA-DR antigens and the co-stimulatory B71 and B72 (Devine and 
Hoffman 2000, Majumdar  et al. 2003), giving it great potential in allogenic 
applications. There is also increasing evidence that MSCs have the ability to migrate to 
the site of injury with anti-inflammatory and immunomodulatory properties ( Griffin et 
al. 2013, Le Blanc et al. 2012,Prockop et al. 2012). For instance, T-cell lymphocyte 
proliferation was shown to be inhibited during co-culture with MSC, but the reversal of 
this inhibition was seen following removal of MSC (Di Nicola et al. 2002). They had 
also been shown to inhibit auto-reactive T and B cells (Deng et al. 2005) and promote 
production of CD4+CD25+ regulatory T cells in the peripheral blood of the patients 
with multiple sclerosis (Karussis et al. 2010).  Hence, there has been increased interest 
in broadening the application of MSC to anti-inflammatory and immunomodulatory 
therapy, with some success already witnessed in conditions like diabetic foot ulcer 
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(Dash et al. 2009), Crohns’ disease and graft vs. host disease (Le Blanc et al. 2008, 
Duijvestein et al. 2010).  
MSC therapy certainly appears to have attractive therapeutic potential in autoimmune 
diseases. Experimental treatments of type 1 diabetes using MSC therapy in murine 
models have already shown some promising results. These studies demonstrated an 
increment in the number of pancreatic insulin-producing beta-cells with suppression of 
auto-reacitve T lymphocytes and inflammatory dendritic cells, leading to long term 
reversal of hyperglycaemia ( Lee et al. 2006, Fiorina et al. 2009, Jurewicz et al. 2010). 
With this in mind, an understanding of the cell biology of adrenal-derived MSCs will be 
essential to regenerative medicine approach in AAD. 
Further studies are required to confirm that this population of MSC-like cells consists of 
MSCs residing in the adrenal cortex. The location of adrenal-MSCs at the tissue level, 
as well as the genomic and proteomic properties of these cells, also warrants detailed 
investigations, potentially by qPCR or ELISA. A comprehensive high-throughput 
screening of the actions of various morphologic and transcription factors during 
differentiation of MSC to steroidogenic cells will also help identify the agents or factors 
essential for adrenal self-renewal or steroidogenesis. Finally, developing a method for 
differentiating MSCs into steroidogenic cells, in which the bone marrow or adipose 
tissues are a rich source for MSCs, could potentially lead to curative cell therapy for 
AAD. 
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Chapter 6. Final discussion 
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Genetics studies on autoimmune Addison’s disease (AAD) remain challenging due to 
the disease’s complex genetic traits and rarity. Similar to most of the susceptibility 
alleles identified thus far, the common CD226 variant (CD266 307*Ser) identified in 
this thesis showed only modest disease effects in AAD. Most of the known 
susceptibility genes are downstream effectors of the immune system and are likely to 
have roles in the etiological pathway of AAD. However, these individual susceptibility 
variants are neither necessary nor sufficient to cause the disease. The other common 
problem encountered in genetic studies of AAD is the small collection of patient cohorts 
due to the disease’s rarity, resulting in underpowered studies for detecting significant 
effects. Hence, future studies using either a candidate gene or linkage analysis approach 
will require more extensive international collaboration, perhaps cross-continent 
collaboration, to clarify the causal pathway involved in the development and 
progression of this condition. 
Genetic studies in the last few decades have been focused on common genetic variants, 
detected either via a candidate gene study approach or genome wide association studies. 
However, HLA variants in chromosome 6 are thus far the only gene variants identified 
as having a strong impact on the pathogenesis of AAD. Although the SIAE rare variants 
that I found among the AAD cohorts are not statistically significant, the association 
analysis was calculated using the statistical method conventionally used for common 
gene variants, which might not be powerful enough for detecting significant effects. 
Hence, a more accurate and powerful statistical method should be developed for 
multiple rare variant models. A greater emphasis should be placed on the investigation 
of the association between rare gene variants and autoimmune susceptibility, even if this 
means labour-intensive deep genome sequencing and functional testing of each rare 
variant. On the other hand, AAD is caused by a complex interplay between genetics and 
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external factors. Future studies should also look into the role of epigenetics in the 
pathophysiology of AAD, as environment, lifestyle and cultural variances could have an 
impact on gene expression. 
The work undertaken for this study has contributed to the advancement of knowledge 
that is relevant to the pathophysiology and treatment approach in AAD. The 
experimental medicine study using ACTH1-24 (synacthen) therapy in AAD has made a 
critical conceptual advance in the treatment of this chronic disease. This study showed 
that established AAD could be ameliorated by treatment other than the conventional 
steroid replacement therapy. However, this therapeutic approach requires further 
exploration, especially with regards to treatment duration, patient selection, dosage 
regimen and long term side effect profile. Of particular interest is the benefit of 
synacthen therapy other than adrenal steroidogenesis. The majority of the participants 
reported significant improvement in quality of life following synacthen therapy, despite 
not having obvious increments in serum cortisol concentration. Although the ACTH 
receptor, melanocortin type -2 receptor (MC2R) is expressed predominantly in the 
adrenal cortex, it has also been found in human bone (Zhong et al. 2005) and skin 
(Slominski et al. 1996, Guo et al. 2005). In addition, the co-expression of MRAP1 
(MC2R accessary protein 1) is essential in ACTH responsiveness (Metherell et al. 2005, 
Roy et al. 2007). Hence, it will be interesting to look for other tissues that express 
MC2R and MRAP, as well as the role of ACTH on these tissues. For instance, a study 
demonstrated that ACTH promotes osteoblast differentiation into mature osteoblast and 
counteracts dexamethasone-induced osteoblast apoptosis by stimulating the MC2R 
receptor on osteoblast with subsequent elevation of vascular endothelial growth factor 
(VEGF) (Isales et al. 2010). The observation of ACTH as the regulator of bone mass 
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showed the potential additive benefits of ACTH therapy in addition to re-establishing 
adrenal steroidogenesis in AAD. 
On the other hand, the discovery of residual adrenal function in some patients years 
after diagnosis and treatment of AAD has opened up a new therapeutic window for this 
condition. New information from this thesis suggests that AAD is a heterogeneous 
disorder. Patients who have residual adrenal function were observed to be less likely to 
suffer from adrenal crisis and responded better to the synthetic ACTH treatment. This 
has made a paradigm shift in the understanding of the pathophysiology of AAD, from a 
chronic disease with lifelong dependency on steroid replacement to a potentially 
reversible and treatable condition for some patients. Future studies should be carried out 
to ascertain the prevalence of residual adrenal function in patients with AAD, as well as 
to establish the most sensitive biochemical markers for detecting this state, which could 
be well below the conventional lower limit of assay detection. The stratification of 
AAD patients based on their residual adrenal function will have an impact on both the 
treatment approach as well as in advancing the study of disease pathophysiology and 
genetics. 
Although synacthen therapy has shown promising results, regular high-dose ACTH1-24 
therapy was not without adverse effects. The most significant of which were allergic 
cutaneous reactions and menstrual disturbance, which has been well described in the 
literature (Treadwell et al. 1964). Although anti-ACTH1-24 antibodies developed during 
the course of the study might explain some of the side effects, they could not account 
for the menstrual-related symptoms. Melanocortin receptors (MC3R and MC5R) are 
expressed in the placenta and ovary (Wikberg et al. 2000) but little is known about the 
role of ACTH and melanocortin receptors in uterine function, which clearly warrants 
further investigation. Besides, the discovery of spontaneous anti-ACTH1-24 antibodies 
 250 
 
among patients with AAD and Graves’ disease also raises the question of their role in 
endocrine autoimmunity, as well as other conditions typically attributed to steroid 
dysregulation. 
The finding of mesenchymal stem cell (MSC)-like population in the adrenal cortex has 
contributed towards the understanding of adrenal plasticity. Although these adrenal 
cortex-derived MSC-like cells have yet to be proven as the adrenocortical stem cells, 
they have been found to exhibit features consistent with progenitor cells. Similar to non-
bone marrow derived- MSC isolated from other tissues, the exact location of these 
MSC-like cells remains elusive. Many studies suggest that this group of cells resides on 
the luminal surface of endothelial cells in the perivascular niche, namely pericytes or 
adventitial cells (Crisan 2008, Corselli et al. 2012). They have also been shown to home 
in on injured or inflamed tissues, with anti-inflammatory and immmuno-modulatory 
properties. They promote tissue repair through the production of trophic factors which 
reduce inflammation and facilitate functional recovery of the damaged cells (Chopp & 
Li 2002, Lee et al. 2006, González et al. 2009).   
Promising results have been demonstrated in experimental murine models of acute 
tissue injury and autoimmunity, such as autoimmune encephalomyelitis,  
glomerulonephritis and acute fulminant liver failure (Zappia et al. 2005, Kunter et al. 
2006, Parekkadan et al. 2007).  A few phase I clinical trials have also demonstrated 
clinical safety and the feasibility of MSC therapy in inflammatory bowel disease 
(Ciccocioppo et al. 2011), liver cirrhosis (Kharaziha et al. 2009) and myocardial 
infarction (Hare et al. 2009). In view of these encouraging preliminary results, the 
discovery of MSC-like cells in the adrenal cortex should prompt further investigation 
with respect to their true in-situ properties and biological function, to form a potentially 
efficacious tool that could serve as a long term cure for AAD.  
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The restoration of adrenal function in some but not all Addison’s patients using 
synthetic ACTH suggests that ACTH may be necessary but not sufficient to induce 
adrenocortical stem/progenitor cell proliferation in all patients. Therefore, uncovering 
the interaction between ACTH and other endocrine and paracrine signals in the stem 
cell niche will be critical to the success of future regenerative medicine approaches in 
adrenal insufficiency. Key details, such as whether ACTH acts directly on ACSC, or 
whether an angiotensin-II signal is necessary for the transition from progenitor daughter 
cell to aldosterone-secreting zona glomerulosa cell, are unknown. Hence, a better 
understanding of the various molecular mediators and trophic factors involved in the 
regenerative and immunomodulatary process of adrenal-derived MSC-like cells is of 
paramount significance to bringing a therapeutic revolution in Addison’s disease a step 
closer to reality.  
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Appendix A 
 
AddiQoL (Health-related quality of life in Addison’s disease) 
 
 
The following questions ask for your views about your health over the last 4 weeks 
and how you feel about life in general. Do not spend too much time answering, as your 
immediate response is likely to be the most accurate. Please answer every question. 
 
 None of 
the time 
A little 
of the 
time 
Some 
of the 
time 
 
A good 
bit of 
the time 
 
 
Most of 
the time 
 
 
 
All of 
the time 
 
 
I feel good about my health       
I can keep going during the day without 
feeling tired 
      
Normal daily activities make me tired       
I have to struggle to finish jobs       
I have to push myself to do things       
I lose track of what I want to say       
I sleep well       
I feel rested when I wake up in the 
morning 
      
I feel unwell first thing in the morning       
I am satisfied with my sex life       
I am relaxed       
I feel low or depressed       
I am irritable       
I find it difficult to think clearly       
I feel lightheaded       
I sweat for no particular reason       
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 None of 
the time 
A little 
of the 
time 
Some 
of the 
time 
 
A good 
bit of 
the time 
 
 
Most of 
the time 
 
 
 
All of 
the time 
 
 
I get headaches       
I get nauseous       
My joints and/or muscles ache       
I have back pain       
My legs feel weak       
I worry about my health       
My ability to work is limited       
I can concentrate well       
I am happy       
I feel full of energy       
 
 
 
 
Strongl
y dis-
agree 
Dis-
agree 
Slightly 
disagre
e 
 
Slightly 
agree 
 
 
 
Agree 
 
 
 
 
Strongl
y agree 
 
 
I feel physically fit       
I get ill more easily than others       
I take a long time to recover from 
illnesses 
      
I cope well in emotional situations       
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Appendix B 
 
Protocols for making relevant solutions for SDS-PAGE 
 
3x Gel Buffer: 
 Dissolve 182g tris base in 300ml ddH2O. 
 Adjust to pH8.45 with HCl.  
 Add H2O to 500ml total volume.  
 Add 1.5g SDS and store at 4°C. 
 
AB-3 stock solution 
 Dissolve 48g acrylamide and 1.5g bisacrylamide in 100ml water. 
 Keep solutions at 7 – 10°C, crystallisation occurs at 4°C. 
 
AB-6 stock solution 
 Dissolve 46.5g acrylamide and 3g bisacrylamide in 100ml water. 
 Keep solutions at 7 – 10°C, crystallisation occurs at 4°C.  
 
10% APS 
 0.5g APS in 5ml SDW. 
 
1x Cathode Buffer (load on top into wells) 
 12.11g Tris base 
 17.92g tricine 
 1g SDS 
 Dilute to 1 litre with ddH2O 
 Do not adjust pH 
 Store at 4°C. 
 
5x Anode Buffer (load bottom w/ 1x, gel apparatus tray) 
 121.1g Tris base 
 500ml H2O 
 Adjust to pH 8.9 with conc HCl 
 Dilute to 1 litre with ddH2O 
 Store at 4°C. 
 
10x Transfer Buffer 
 30.3g Tris base 
 144g glycine 
 Add 800ml ddH2O, when dissolved make up to 1litre. Do not autoclave. 
 
10x TBST 
 87.7g NaCl, dissolve in 500ml water. 
 Add 250ml 2M Tris pH7.5 
 Make up to 1 litre and add 5ml Tween 20. 
 Do not autoclave. 
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Loading buffer 
 1x buffer (10 ml) Final concentration 
Glycerol (100%) 4ml 40% 
Tris/HCl (1mM; pH6.8) 2.4 ml 240mM 
SDS 0.8g 8% 
Bromophenol Blue 4mg 0.04% 
Beta-mercaptoethanol 0.5ml 5% 
DDH20 3.1ml - 
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